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The hypothalamic-pituitary-adrenal (HPA) axis is a pivotal neuroendocrine system in 
mammals and the end product, glucocorticoids (GCs), are steroid hormones involved in 
several essential processes including cognitive functions, metabolic processes, and regulation 
of the inflammatory response. Glucocorticoids are secreted from the adrenal gland in 
response to stimulation by adrenocorticotropic hormone (ACTH), which in turn is secreted 
from the anterior pituitary gland following stimulation by corticotropin-releasing hormone 
(CRH).  
The HPA axis is activated as part of the stress response and following circadian cues, 
and the overall GC secretion occurs in a circadian manner, with higher GC concentrations 
during the active phase (daytime in humans and nighttime in rodents). Moreover, this 
circadian variation is made up of high-frequency ultradian pulses, which have an important 
role in regulating gene expression in GC target tissues. Corticosterone (CORT) is the main GC 
in rodents, and studies in rats have shown approximately hourly pulses of CORT, which are 
preceded by pulses of ACTH. 
Importantly, in humans, altered HPA axis activity is seen in various stress-related 
disorders including depression and anxiety.  
Hypothalamic-pituitary-adrenal axis activity is regulated by a negative feedback loop 
that involves activation of the glucocorticoid receptor (GR). The GR, in turn, is regulated by its 
chaperone protein, FKBP51. Clinical studies have shown an association between FKBP51 
polymorphism and the instances of depression. Thus, the general hypothesis is that increased 
FKBP51 expression can cause a hyperactive HPA axis and GC resistance. 
To further investigate the role of FKBP51 in the regulation of HPA axis activity, two 
FKBP51-specific inhibitors were used to investigate their effects on the HPA axis in male and 
female rats.  Serial automated blood sampling (ABS) procedures were performed in basal and 
stress-induced conditions following both acute, and sub-chronic (5-days) treatment with 
either a central and peripheral FKBP51-inhibitor (SAFit2), or a peripheral-only inhibitor 
(SAFit1). Furthermore, at what level of the HPA axis the SAFit compounds had their effects 
were investigated, by stimulating ACTH, and CORT secretion with CRH and ACTH, respectively, 




minutes post-noise stress in the hypothalamus and anterior pituitary gland following SAFit2, 
SAFit1, or vehicle administration were compared.  
Acute treatment with SAFit2 in male rats resulted in lower maximum CORT, and lower 
stress-induced CORT compared to vehicle-treated rats. Similar results were observed 
following sub-chronic SAFit2 treatment, with lower mean, maximum, and basal CORT, and 
lower stress-induced CORT compared to vehicle-treated rats. Acute SAFit1 treatment had no 
effect in male rats, however shorter CORT pulses under basal conditions were observed, and 
a lower stress-induced CORT was observed following sub-chronic SAFit1 treatment in male 
rats compared to vehicle-treated rats.  
In females, acute SAFit2 treatment had no effect, whilst acute SAFit1 treatment result 
in lower mean CORT, and lower stress-induced CORT compared to vehicle-treated rats. Sub-
chronic treatment with SAFit2 in female rats caused lower mean, maximum, and basal CORT 
concentrations, but did not affect the stress-induced CORT.  
Moreover, reduced CRH-induced ACTH secretion from the anterior pituitary gland was 
found in male rats treated for one day with either SAFit2 or SAFit1, suggesting a potential 
decrease in GR-mediated GC negative feedback.  
These findings suggest a sexual dimorphism in the processes regulating GC-mediated 
negative feedback during basal conditions and following stress. Moreover, the sub-
chronicSAFit1 treatment in male rats changes the pulsatility of ultradian pulses. This work has 
made important steps to further unravel the complexity of the HPA axis negative feedback 
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MpFC  Medial prefrontal cortex 
MR  Mineralocorticoid receptor  
mRNA  Messenger ribonucleic acid 
mTOR  Mammalian target of rapamycin 
NEB  Nuclear extraction buffer  
Neuro D1 Neurogenic differentiation 1 
nGRE  Negative Glucocorticoid response element  
NMDA  N-Methyl-D-aspartic acid 




NTS  Nucleus tractus solitarii 
Nurr1  Nuclear receptor related 1 protein 
Nur 77  Nuclear receptor related 77 protein 
NurRE  Nuclear receptor response element  
OVX  Ovariectomised 
PCR  Polymerase chain reaction 
pCREB  Phosphorylated cAMP response element binding protein 
PER1  Period circadian protein homolog 1 
PFC  Prefrontal cortex 
PKA  Protein kinase A 
PL  Prelimbic  
POMC  Pro-opiomelanocortin 
PPIase  Peptidyl-prolyl isomerase  
PR  Progesterone receptor 
PVDF  Polyvinylidene fluoride  
PVN  Paraventricular nucleus  
PVT  Paraventricular thalamic nucleus  
RCF  Relative centrifugal force 
REM  Rapid eye movement  
RIA  Radioimmunoassay 
RNA   Ribonucleic acid 
RT-qPCR Real-time quantitative polymerase chain reaction 
SAFit  Selective antagonist of FKBP51 by induced fit 
S.C.   Subcutaneous  
SCN  Suprachiasmatic nucleus 
SD  Standard deviation  
SDS  Sodium dodecyl sulphate  
SF-1  Steroidogenic factor 1 
SGK1  Serine/threonine-protein kinase 
SHR  Steroid hormone receptor  




SNP  Single nucleotide polymorphism  
SSC  Standard saline citrate  
StAR  Steroidogenic acute regulatory protein 
STUB1  STIP1 homology and U-Box containing protein 1 
TBST  Tris buffer saline with 0.05% Tween 20  
TEBP  Telomere End Binding Protein 
TPR  Tetratricopeptide repeat  
TSST  Trier social stress test 
TULP1  Tubby-related protein 1 
VPG  Vesicular phospholipid gel 
vSUB  Ventral subiculum 
V1BR  Vasopressin receptor 1 B 
WT  Wild type  






Chapter 1 – Introduction 
 
1.1. The hypothalamic-pituitary-adrenal axis and glucocorticoids 
Glucocorticoids (GCs) are steroid hormones produced in vertebrate species in 
response to circadian cues and stress. When an organism (animal or human) is exposed to a 
physiological or psychological stressor, the subsequent increase in GCs enhances the chances 
of survival by preparing the body to cope with the stressor. The stress response is initiated by 
the activation of various afferent neuronal pathways, including those originating from the 
limbic structures of the brain (1). This response is very rapid, and GCs are synthesised and 
secreted from the adrenal gland within minutes upon exposure to a stressor. The activation 
of the hypothalamic-pituitary-adrenal (HPA) axis following stress results in increased 
attention, cognitive functions, and arousal, improved motor reflexes, a decrease in sexual 
arousal and appetite, and increased pain tolerance. The HPA axis activation also changes 
cardiovascular output, metabolism, and immune system regulation (2, 3). The main active GC 
in humans is cortisol, and in most rodents, including rats and mice, it is corticosterone (from 
here on referred to as CORT).  
Glucocorticoids have a wide range of effects in the body and their signalling is essential 
for survival, with mutations in the glucocorticoid receptor (GR) in mice resulting in death 
within hours of birth (4). Glucocorticoids are perhaps most known for their anti-inflammatory 
properties and this has led to the development of several synthetic GCs currently used in the 
clinic. Further, GCs are involved in metabolic processes (5, 6) and cortisol is elevated in 
patients with insulin resistance, associated with hyperglycaemia and fatty liver (7, 8). 
Although some effects of synthetic GCs are widely characterised, the potential to provide 
therapeutics targeting a distinct mechanism of the HPA axis could minimise side effects, 
provide a disease-specific therapy, and more effective treatment.  
 
1.1.1. HPA axis activity 
Glucocorticoids are synthesised from cholesterol in the adrenal glands following the 




dorsal hypothalamus, the anterior pituitary gland, and the zona fasciculata of the adrenal 
cortex. The PVN is activated by other brain areas, both by circadian input from the retina via 
the suprachiasmatic nucleus (SCN) and by physiological and psychological stressors via limbic 
areas, the brain stem, and the frontal cortex. The PVN contains three major types of neurones, 
dorsomedial parvocellular neurones, dorsolateral magnocellular neurones, and autonomic 
parvocellular neurones. The dorsomedial parvocellular neurones comprise mainly 
corticotrophin-releasing hormone (CRH) expressing neurones, but also arginine vasopressin 
(AVP) expressing neurones and CRH and AVP are co-expressed in some. When the 
parvocellular neurons of the PVN are stimulated by neuronal input, they release CRH and AVP 
(9-11)(figure 1.1 A). Corticotrophin-releasing hormone is produced in these neurones and 
stored in vesicles in the axon terminals projecting into the median eminence. Afferent 
activation of CRH neurones causes depolarization and subsequent calcium influx which 
ultimately results in the fusion of CRH vesicles with the cell membrane and exocytotic release 
of CRH proximal to the pituitary gland portal vessels (12). Activation of CRH neurones also 
initiates the transcription of CRH, with increased messenger RNA (mRNA), followed by de 
novo synthesis of the CRH peptide. This process is initiated by an intracellular increase in cyclic 
adenosine monophosphate (cAMP), which is induced by PKA activation. Cyclic AMP enhances 
the binding of phosphorylated CREB (pCREB) to the cAMP response element (CRE) on the CRH 
promoter and ultimately results in enhanced transcription of the CRH gene (13).  
The CRH and AVP travel via the portal vessels to the corticotropic cells in the anterior 
pituitary gland where they bind CRH receptor1 (CRHR1) and AVP receptor 1B (V1BR), 
respectively (14, 15). This induces enhanced transcription of pro-opiomelanocortin (POMC), 
which is further cleaved to produce to adrenocorticotropin-releasing hormone (ACTH) and 
ACTH is then stored in vesicles (12, 16). The binding of CRH to corticotropic cells also triggers 
the activation of PKA and cAMP which results in the phosphorylation of ion-channels and 
subsequent calcium influx and ACTH release by vesicular exocytosis (17). ACTH is secreted in 
the systemic circulation and reaches the adrenal glands where it binds its cognate receptor, 
the MC2R on zona fasciculata cells in the adrenal cortex (figure 1.1. A). The binding initiates a 
series of genomic and non-genomic events that ultimately results in the production of CORT. 
As CORT is lipophilic it cannot be stored in vesicles and has to be synthesised de novo and this 







Figure 1.1. The HPA axis. (A) The HPA axis is initiated by circadian cues and stress and 
activates CRH release from the PVN, which acts on the corticotrophs in the anterior pituitary 
gland to secrete ACTH. ACTH, in turn, activates GC synthesis and release from the adrenal 
glands. (B) A CORT profile from a male rat demonstrates the circadian pattern of CORT 
secretion, with increased levels before the onset of the dark (active) phase in the rat. From 
(20).  
 
1.2. Neuronal inputs to the HPA axis 
The activity of the HPA axis is initiated and regulated by excitatory and inhibitory 
neuronal input to the PVN. This occurs via input from other brain areas following circadian 
stimulation or a stressor. These areas involve the SCN (discussed below), limbic areas such as 
the hippocampus and amygdala and other areas such as the prefrontal cortex (PFC) (21), and 









The hippocampus projects to the PVN via the dorsal hippocampus, the lateral fornix, 
and the bed nucleus of stria terminalis (BNST), and exerts mainly inhibitory actions on the 
PVN (34). In rats, hippocampal ablation results in both elevated basal CORT concentrations 
and elevated CORT concentrations following some stressors, including restraint stress and the 
open field test (25-28). Further, lesion of the dorsal hippocampus or the lateral fornix results 
in dysregulation of the diurnal CORT rhythm and increases basal CORT concentrations (29, 
30), whilst ablations of the whole hippocampus are required to observe an effect on stress-
induced CORT secretion (31), suggesting a role for the hippocampus in regulating both basal 
GC secretion and following certain stressors.  
In contrast to the dorsal hippocampus, the ventral hippocampus and the ventral 
subiculum (vSUB) are largely involved in the regulation of the CORT response following a 
stressor, and specific activation of the ventral hippocampus causes an increase in CORT 
concentrations (32). Lesions of the vSUB results in increased c-Fos and CRH peptide in the 
PVN in response to restraint stress, indicating activation of the HPA axis but does not affect 
basal CORT either in the morning or in the evening. Conclusively, the vSUB has an inhibitory 
effect on CORT secretions following physiological and cognitive stressors (28, 30, 33). The 
vSUB is an important region of the hippocampus as it is the point of output from the 
hippocampus to the PVN. Glutamatergic neurons in the vSUB project mainly to the BNST, 
medial preoptic area and dorsomedial hypothalamus, all areas that are rich in GABA-ergic 
neurons projecting directly to the PVN and exerting inhibitory actions (34). 
 
1.2.2. Amygdala  
The amygdala has an excitatory effect on the HPA axis activity and electrical 
stimulation of the amygdala results in elevated CORT secretion in rats (35), monkeys (36), and 
humans (37). Ablation of the amygdala causes reduced stress-induced CORT in response to 
odour stress (27) but not to ether (38). There are strong differences in the CORT response to 
certain stressors in the sub-regions of the amygdala and their functions. For example, the 
central amygdala (CeA) is sensitive to systemic stressors such as inflammatory stressors (39, 




(41-43). In contrast, the medial amygdaloid nucleus (MeA) is sensitive to physical and 
psychological stressors such as noise, restraint and forced swim (39, 40, 44), and lesions of 
the MeA results in decreased CORT responses to restraint stress but not to an immune 
stressor (41).  The CeA and the MeA project to the PVN indirectly via GABAergic input to the 
BNST (45), which in turn has GABAergic input to the PVN, suggesting that activation of the 
amygdala causes an activation of the PVN by a disinhibitory process. Moreover, the MeA 
projects to the preoptic area, which is highly expressing GABAergic neurons involved in 
inhibiting the HPA axis (46).  
In addition, the basolateral amygdala (BLA) is involved in the response to psychogenic 
stressors, including forced swim and foot shock, but it is not activated following an immune 
stressor (39). Some studies have implicated the BLA in the role of chronic stress, and increased 
CRH mRNA in the CeA has been observed following synthetic GCs treatment and exposure to 
chronic stressors (47, 48). It has been suggested that the BLA is not involved in the regulation 
of acute stress, however, it is important in chronic stress. Indeed, chronically stressed animals 
with inactivated BLA showed increased HPA axis activity only in response to a novel stressor 
and not a familiar stressor (49).  
 
1.2.3. Prefrontal cortex  
Numerous studies have implicated the medial prefrontal cortex (MpFC) in the 
regulation of the stress response. Increased c-Fos and glucose utilisation in the MpFC is 
observed following numerous stressors (50-52). Indeed, lesion of the prelimbic (PL) area of 
the MpFC results in increased c-Fos expression in the PVN, as well as increased ACTH and 
CORT concentrations in response to restraint stress, but not a systemic stressor (53-55). The 
infralimbic (IL) region of the MpFC is involved in the regulation of immune stressors and other 
systemic stressors (56), and lesions of this region enhance the ACTH and CORT response to 
these stressors. Interestingly, ablation of the dorsal or ventral MpFC does not affect basal 
ACTH or CORT secretion (54, 55), suggesting that the MpFC is specifically involved in the 
stress-induced activation of the HPA axis (57). The PL and the IL cortex projects to several 
regions known to affect PVN activity, for example, the PL projects to the dorsal raphe involved 




BLA and the vSUB (58, 59). In addition, the IL projects to the BNST, CeA and the nucleus tractus 
solitarii (NTS), all of which in turn project to the PVN to regulate HPA axis activity. The IL also 
projects to the dorsomedial and lateral hypothalamus, inhibiting HPA axis activity (59-61). 
 In addition to areas described in detail above several other areas are also involved in 
the direct or indirect activation of HPA axis activity, including  BNST, other nuclei within the 
hypothalamus itself, intra-PVN neurons, brain stem nuclei, and more (21). Thus, a wide range 
of brain areas are involved in regulating the PVN output and hence HPA axis activity. 
Interventions to try and alter GC secretion can potentially, therefore, target various brain 
areas.   
 
1.3. Glucocorticoid and Mineralocorticoid Receptors  
The various effects elicited by GCs occur by binding their cognate receptors, the 
glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). These receptors 
belong to the nuclear receptor superfamily (62, 63). When inactive, both the GR and MR 
reside in the cytoplasm where they are associated in a complex with various chaperone 
proteins including the heat shock proteins hsp90, hsp70, and hsp23, and the two closely 
related immunophilins from the FK506-binding protein family, FKBP51 and FKBP52 (64, 65).  
Studies in the rat in the 1980s revealed a difference in distribution between the GR 
and the MR (66, 67). The GR is widely expressed throughout the body and is involved in 
inducing CORT-mediated regulation of metabolic events and immune system functions, whilst 
peripherally the MR is expressed mainly in the kidney (68) and the heart (69). In the rat brain, 
MR is mainly expressed in the limbic system with high expression in the hippocampus and low 
expression in the amygdala. The GR is expressed in most brain areas, highly expressed and 
co-localized with MR in the hippocampus, and amygdala, and highly expressed in frontal brain 
regions and the pituitary gland (62, 66, 67).  
Further, the MR has an approximately 10 fold higher affinity for CORT than do GR  (66) 
and is therefore occupied when CORT concentrations are low; in the morning in rats and the 




therefore only occupied when CORT levels are high such as during the circadian peak, and 
after a stressor, when the CORT concentrations increase rapidly (66). 
Due to their difference in distribution and occupancy, the MR and GR exert different 
effects on the body. In the periphery, MR in the kidney regulates water and salt balance. In 
the brain, tonic activation of MR, mainly in the hippocampus, is involved in the regulation of 
cognitive functions, mood and affect (62); it also relays sensory information to ensure an 
appropriate neuroendocrine and behavioural response. Concerning the role of MR in 
regulating HPA axis activity, intra-hippocampal injection of the MR antagonist RU28318 
increases basal HPA axis activity both in the morning and evening and results in higher CORT 
concentrations compared to the vehicle-treated animals, following exposure to a novel 
environment. The increase in basal CORT following an MR antagonist demonstrates the effect 
of MR on tonic inhibition of the HPA axis, whereas the increase in CORT after a stressor is 
believed to be due to inhibited MRs in the limbic areas and hence leads to increased stress 
response (70). In addition to its peripheral effects on metabolism and immune system 
function, centrally active GR initiates the stress-mediated process and, in the PVN and the 
pituitary gland, the GR mediates the negative feedback mechanism of GCs.  This negative 
feedback response is important in regulating CORT concentrations, and altered GR activity 
and subsequent changes in the GC negative feedback is implicated in psychiatric disorders 
(71).  
Glucocorticoids are lipophilic and hence readily cross the plasma membrane. In the 
cytoplasm, free CORT can bind the GR and MR and subsequently causes the receptors to 
translocate to the nucleus where they regulate gene transcription of various target genes. 
Nuclear translocation of GR and MR is regulated by the binding of the receptor to the FK506-
binding protein 51 and 52 (FKPB51 and FKBP52) (65, 72). The role of FKBP51 and 52 in 








1.4. HPA axis rhythms  
1.4.1. HPA axis Circadian rhythm 
The circadian rhythm in an organism refers to the daily biological variations over 24 
hours. Circadian rhythms are conserved in organisms ranging from bacteria to mammals and 
are characterised by several processes including biochemical, physiological, endocrine, and 
behavioural, functioning to prepare the organism for changes in the environment in the 
light/dark cycle. In mammals, GCs synthesis and release are synchronised in a circadian 
pattern with the highest levels upon awakening, to prepare the organism for energy 
expenditure and to synchronise physiological processes in a daily rhythmical manner. In 
diurnal mammals such as humans, the highest levels of GCs occur in the morning, and in 
nocturnal mammals, including the rat and the mouse, this occurs in the evening. These 
circadian rhythms are synchronised by a master clock in the ventral hypothalamic SCN (73-
75). The central regulation by the SCN is entrained by light exposure, which is perceived by 
the retina and relayed to the SCN via the retino-hypothalamic tract (76, 77).  
Several ‘clock genes’ in the SCN form an oscillating system, including the circadian 
locomotor output cycles kaput (CLOCK), brain and muscle aryl hydrocarbon receptor nuclear 
translocator-like (BMAL1), period 1-3 (PER1-3), and cryptochrome 1-2 (CRY1-2) (78-80). These 
genes are transcribed in a rhythmic fashion resulting in a rhythmic oscillation of the proteins, 
controlled by negative and positive transcriptional and translational feedback mechanisms 
(81). In rodents, lesion of the SCN produces a disruption in circadian rhythms in body 
temperature, locomotor activity, and endocrine activity (82-85). Peripheral tissues, including 
the liver, kidney, lung, skeletal muscle, and the adrenal, also express clock genes with 
circadian variation in their activation, (75, 86-88). The SCN sustains its rhythm but the 
peripheral clocks are dependent on the circadian drive from the SCN to maintain their 
light/dark synchronisation (89, 90).  
 
1.4.2. Regulation of HPA axis circadian rhythm 
The PVN receives direct input from the SCN via the dorsomedial hypothalamus (DMH) 
(91, 92) and results in an overall circadian rhythm of CRH synthesis and secretion. This is turn 




cortex, most of the steroidogenic proteins, for example, steroidogenic acute regulatory 
protein (StAR), are also expressed in a circadian manner, shown by variations in both mRNA 
and protein levels during the 24 hours (94-96). Circadian variations in both ACTH and adrenal 
steroidogenic proteins work synergistically to produce circadian rhythms of CORT secretion 
from the adrenal cortex.  
The SCN contains AVP-expressing neurons that project to the PVN and are involved in 
regulating SCN output and hence important in regulating HPA axis circadian rhythms (97). 
Studies using micro-infusions of AVP or an AVP antagonist, in the DMH or PVN directly have 
shown an inhibitory effect of AVP on CORT secretion in the rat (98). This is further 
demonstrated by a decrease in AVP in the SCN neuron terminals in the DMH before the dark 
phase in the rat, and this is necessary for the circadian peak of CORT (99). Hence in nocturnal 
mammals such as the rat, the light entrains AVP release from the SCN to ensure low CORT 
levels during the circadian nadir (day time) (99). By contrast, in diurnal species such as 
humans, the light also induces AVP release from the SCN, however, in diurnal species, this 
AVP release has a stimulatory effect on the HPA axis. Hence, AVP can both stimulate or inhibit 
CRH release from the PVN, and this depends on activation of excitatory or inhibitory neuronal 
projections to the PVN which in turn regulate the CRH release (91, 92). However, there is as 
yet no evidence for direct connections between AVP-containing neurones in the SCN and the 
CRH-expressing neurons in the PVN (100, 101).  
 
1.4.3. HPA axis Ultradian Rhythms  
In addition to the rapid increase in CORT following an acute stressor, basal HPA axis 
activity exhibits high-frequency pulsatile dynamics, which make up the circadian rhythm of 
GC secretion. This circadian rhythm is characterised by a peak of GC secretion before the 
active phase, comprising the night in nocturnal animals such as rats and mice, and the 
morning in diurnal mammals such as humans (102, 103). The high-frequency pulsatile 
dynamics, so-called ultradian rhythms, have a variable amplitude of the GC pulses throughout 
the 24 hours and result in the overall circadian variations in GC concentrations (104, 105). The 
discovery of this ultradian rhythm in the rat was achieved with the help of an intra-adrenal 




system have been used allowing plasma CORT to be measured in frequent intervals during 
physiological and pathological changes (105, 106).  
In addition to the rat, ultradian rhythms of GCs have also been observed in sheep 
(107), monkeys (108), and humans (109, 110). Importantly, pulsatile patterns of ACTH 
secretion have also been demonstrated in rats (111, 112), sheep (113), and humans (109), 
and these ACTH pulses precede the pulses of CORT (104, 109). Thus a pulse in ACTH causes a 
subsequent pulse in CORT, which is slightly delayed due to the synthesis of CORT which cannot 
be stored in vesicles. The concentrations of plasma and ACTH and CORT can be measured via 
blood sampling from, for example, a jugular vein cannula, however, measurement of CRH 
concentrations must be done in the hypophyseal portal system. Such surgery is very stressful 
for rats, and this together with low sensitivity of CRH assays, has resulted in a limited amount 
of studies investigating CRH release pattern in vivo. Nevertheless, it has been shown that CRH 
is secreted in a pulsatile manner in free-moving rats (114, 115) and sheep (116).   
The pulsatile pattern of CORT secretion is crucial for the responsiveness in the target 
tissue (117). Gene expression analysis in various GC target tissues shows that when the same 
dose of GCs is delivered either through a constant infusion or in a pulsatile manner, this 
results in a different pattern of gene regulation (118). Further, it has been shown that the 
pulsatile secretion of CORT from the adrenal gland is reflected in pulses of CORT in the 
hippocampus (119). Moreover, pulsatile CORT results in pulsatile PER1 transcription in cell 
lines and rat liver (118) and it has been shown that each pulse of CORT causes a rapid, but 
transient, increase in GR translocation and subsequent PER1 transcription in the hippocampus 
(120). Although further research is needed to elucidate the role of pulsatile CORT for gene 
regulation in target tissues current evidence indeed suggests a crucial role for pulsatile CORT 
secretion.  
 
1.4.4. Regulation of ultradian rhythms  
The regulation of circadian rhythmicity by the SCN is well characterised (121), and 
lesions of the SCN in rodents results in loss of circadian variations in CORT secretion as 
demonstrated by increased levels in the morning and hence a flattened curve of CORT 




lesion, or rats kept in constant light, the ultradian pulsatility is maintained even though the 
circadian rhythm was disrupted (85). This intriguing study suggested that the regulation of 
ultradian pulsatility might be separate from the central control of circadian rhythmicity of 
CORT concentrations. This is in contrast to the long-standing belief that the ultradian rhythms 
are under hypothalamic control. This is the case for other hormones such as luteinising 
hormone (LH) and growth hormone (GH) that are secreted in a pulsatile pattern from the 
pituitary gland as a consequence of a pulsatile hypothalamic releasing factor (125-127).   
Corticotrophin-releasing hormone is the hypothalamic releasing factor for ACTH and 
it has been demonstrated that CRH secretion follows a pulsatile pattern (114, 115, 128). It 
was therefore assumed that the hypothalamic pulse generator of pulsatile CRH generated the 
pulsatile ACTH release from the anterior pituitary gland and subsequent pulsatile CORT 
secretion. However, in the rat, CRH has a pulse frequency of approximately 3 pulses per hour, 
compared to the hourly pulses of ACTH and CORT (fig 1.2.). Moreover, the hypothalamic pulse 
generator was further questioned when it was demonstrated that blocking CRH by using a 
CRH antagonist, had no significant effect on ACTH pulsatile pattern in regards to pulse 
frequency, length, or amplitude (129). Similarly, in sheep, the ultradian pulses of CORT are 







Figure 1.2. Ultradian rhythms of the HPA axis activity and glucocorticoid secretion. The PVN 
is activated by SCN input and from limbic regions such as the hippocampus and amygdala, and 
rapidly releases CRH stored in vesicles. This, in turn, causes the release of ACTH from the 
anterior pituitary gland, which activates CORT synthesis and secretion from the adrenal 
glands. Note that the ultradian pulse frequency is approximately 3 pulses per hour for CRH, 
while for ACTH and CORT the pulse frequency is approximately 1 pulse per hour. From (130).  
 
Mathematical modelling combined with in vivo studies in the rat has provided further 
evidence for a sub-hypothalamic control of CORT ultradian pulsatility which is dependent on 
dynamic interactions of the pituitary gland and the adrenal gland (131, 132). The hypothesis 
of this pituitary-adrenal gland pulse generator comprises a positive feedforward by pituitary 
gland ACTH which drives adrenal gland CORT synthesis and secretion, and the CORT-mediated 
negative feedback turns off pituitary gland ACTH release. The secretory time delay in the 
adrenal gland following stimulation by ACTH, and the delay in the negative feedback 
mechanism at the pituitary gland, resulting in ultradian pulses of CORT secretion. The CORT 
and ACTH pulses have been well characterised both in the rat (111, 131, 133, 134) and in 
humans (109). As CORT is lipophilic and cannot be stored in vesicles, the CORT synthesis in 




to elucidate the generation of ultradian pulsatility, mathematical modelling of that HPA axis 
system has shown the CRH concentration is more important than the pulsatile pattern of CRH 
for subsequent pulses of ACTH and CORT (132). 
Furthermore, this mathematical model supports a sub-hypothalamic pulse generator 
indicated by predictions of a self-sustaining pituitary-adrenal gland loop of ACTH and CORT 
pulses (132). The model predicts a self-sustaining ACTH/CORT loop only when levels of CRH 
are ‘physiological’ i.e. equivalent to the circadian peak of HPA axis activity. The self-sustaining 
loop is lost when CRH levels exceed this, for example at constantly high CRH as observed in 
vivo during a stressor (105, 135)(figure 1.3). The validity of the model predictions was tested 
in vivo by administering rats a constant dose of CRH at a low (0.5 mg/h) or higher 
concentrations (1.0 mg and 2.5 mg/h) and measuring CORT concentrations at high-frequency 
intervals by automated blood sampling (figure 1.3.). The results showed that indeed a 
constant CRH infusion at a low concentration results in pulsatile CORT secretion, while a 
higher dose of CRH does not (85). Importantly, the resulting pulsatile pulses of CORT following 
the low CRH dose resemble those occurring during normal physiological conditions in the 
active phase in untreated rats (figure 1.3.). Furthermore, the study also showed that in the 
rats receiving the low CRH dose, a pulse of ACTH was followed by a pulse of CORT (131). 
Mathematical models can, therefore, be useful tools for examining pulsatile systems and 
when combined with in vivo data, support hypotheses.  
The hypothesis of a sub-hypothalamic pulse generator was further supported by in 
vitro evidence in cultured rat pituitary gland cells. When the cells were treated with constant 
CRH this resulted in ACTH secretion, which was then subject to inhibition by the resulting 
CORT. Further, it was shown that this inhibitory effect of CORT on the pituitary gland ACTH 
secretion was independent of gene transcription, instead suggesting a non-genomic 









Figure 1.3. The pituitary-adrenal model of ultradian rhythms. Mathematical modelling and 
experimental data show HPA axis dynamics to variations in CRH drive. (A) A computed two-
parameter bifurcation diagram predicts the difference in CORT oscillations in response to 
variable CRH drive. Point B illustrates CRH drive within the pulsatile region, which results in 
subsequent pulsatile CORT. Point C illustrates a point where the CRH drive is outside the 
pulsatile region and results in constant CORT response. (B) The top diagram shows a pulsatile 
CORT response to a CRH drive that is within the pulsatile region (point B in (A)). The bottom 
diagram shows a constant CORT response to a CRH drive, which is outside the pulsatile region 
(point C in (A)). (C) The top graph shows experimental data from rats that were injected with 
a constant dose of CRH at a concentration corresponding to a CRH drive within the pulsatile 
region which caused pulsatile CORT response. The bottom graph shows experimental data 
from rats injected with a higher dose of CRH, which is corresponding to a CRH drive outside 
the pulsatile region and resulted in constant CORT response. Reproduced with permission from 








1.5. Rapid non-genomic effects of glucocorticoids in the brain and pituitary 
gland 
There has been a long-standing notion that GCs are only responsible for the long term, 
delayed responses to stress, and that neurotransmitters and peptides, such as noradrenaline, 
cause the acute effects of stress (137). Although this is partly correct, GCs have a wide range 
of effects, some that occur within minutes and are hence too rapid to be genomic (138).  
The PVN of the dorsal hypothalamus is a crucial component of the HPA axis. The PVN 
neurons have a high expression of GR (66). Activation of GR in the PVN by CORT induce the 
negative feedback mechanism to inhibit HPA axis activity. The negative feedback occurs both 
in a delayed, genomic fashion (139) and in a rapid, non-genomic way (140, 141). Interestingly, 
one study showed that this rapid negative feedback occurred following the intra-PVN 
injection of dexamethasone conjugated to the membrane-impermeable BSA (DEX-BSA) (142). 
The same group showed that this was dependent on the cannabinoid receptor type 1 (CB1) 
(143). This indicates that in the PVN, GCs can rapidly reduce HPA axis activity by a membrane-
associated mechanism involving endocannabinoid signalling. Further progress in this area was 
made by Tasker et al. with their investigation on the miniature excitatory postsynaptic 
currents (mEPSCs) in PVN neurons (144). An mEPSC can be used to measure neuronal activity 
and is a measure of postsynaptic activity, caused by the release of a presynaptic glutamate 
vesicle (145). Importantly, the presynaptic activity determines the frequency of these 
mEPSCs. Tasker et al. showed that high doses of CORT (100nM to 1uM) or dexamethasone 
result in a decrease in the frequency of miniature excitatory postsynaptic currents (mEPSCs) 
in PVN neurons (144, 146). This effect occurred rapidly, within 5 minutes, and did not subside 
when the CORT was removed, suggesting that the effect is prolonged. Furthermore, the GC-
meditated effect on mEPSCs was not affected by GR or MR antagonists (144, 147). Current 
evidence suggests that this rapid negative feedback mechanism in the hypothalamus is 
initiated by GC binding to a G-protein coupled receptor (GPCR) at the postsynaptic terminal. 
This causes the production of the cAMP –PKA pathway which ultimately results in the 
production of anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The AEA and 2-AG 
activate presynaptic CB1 receptors which inhibit the release of glutamate vesicles from the 




As described in section 1.2. the hippocampus, amygdala, and prefrontal cortex provide 
limbic input to the PVN, hence control HPA axis activity, and are important for the adaptation 
to stressful stimuli (149). The limbic areas are involved in processing information to create a 
memory of the stressful event. In particular, the hippocampus is involved in contextual 
memory formation of the stressful event. Both GR and MR are highly expressed in the 
hippocampal subfields, although predominantly MR is expressed in the CA3 (66).  
Similar to the hypothalamus, the neurons in the hippocampus exhibit spontaneous 
activity of mEPSCs. Studies using hippocampal slices from mice have shown that the 
administration of CORT increases mEPSCs frequency in the CA1 region within 5 minutes of 
CORT administration (150, 151), opposite to the effects in the hypothalamus. Similar effects 
are seen in the dentate gyrus (152). It has been shown that these rapid effects are 
independent of gene transcription events and that they involve a receptor in the plasma 
membrane (150). Furthermore, these rapid effects in the hippocampus occur at a 10-fold 
lower dose of CORT compared to the hypothalamus. The effect is present in GR-knockout 
mice, but not MR-knockout mice suggesting that these rapid effects are MR-mediated (150).  
Furthermore, it was suggested that the MR is located at the plasma membrane and has a 
lower affinity to CORT than the cytoplasmic receptor (150), and will be activated when CORT 
concentrations rise quickly such as after stress (153). Further studies showed that this 
membrane-bound MR is present at the presynaptic membrane (151).  
In addition, a rapid increase in spine density in the hippocampus has been observed 
following exposure to GCs, and this effect is GR-dependent (154). Other, GC-mediated rapid 
effects in the hippocampus have been observed and are both MR and GR-independent, 
suggesting a role for a novel membrane receptor. These GC effects on the hippocampus 
include stimulation of the inhibitory projections from the hippocampus, a rapid increase in 
extracellular excitatory amino acids (155), LTP (156), NMDA-mediated neurotoxicity (157), 
and inhibition of NMDA signalling (158, 159).  
Emotional experiences usually create strong memories and this is, to a large part, 
dependent on the amygdala. The amygdala is implicated in emotional processing, typically 
associated with fear and anxiety, cued learning, and memory processing and is activated 
following a stressful event (160, 161). Both MR and GR are widely expressed throughout the 




memory processing (160, 161), thus making it sensitive to stressful events. Further, the 
amygdala receives input from the adrenergic system and both noradrenaline and adrenaline 
are secreted in the amygdala following stress. In mice and rats, intra-amygdala injections of 
noradrenaline in the BLA, but not the CeA, enhances stress-induced memory consolidation. 
Conversely, blocking the β-adrenoreceptor impairs memory consolidation (160, 161). 
Similarly, the administration of a GR agonist following an inhibitory avoidance paradigm 
enhances memory consolidation (162), while a GR antagonist impairs memory consolidation 
(163). This suggests that both the adrenergic system and the HPA axis are involved in 
amygdala-dependent memory formation following emotional arousing events. It is suggested 
that the effects of GC in enhancing memory formation is due to the adrenergic signalling. One 
study showed a rapid increase in noradrenaline in the amygdala following CORT 
administration, followed by enhanced memory formation (164). Further, membrane-
associated MR and GR have been found in amygdala neurons (165, 166). One study showed 
that GRs are located at the membrane of dendritic spines and post-synaptically (165), 
suggesting a role in the synaptic plasticity of emotional events.  
The PFC is an important area in decision-making and behaviour and has projections 
from the hippocampus and the amygdala (167). Few studies have investigated the rapid 
effects of GCs in the PFC. Studies using synaptosomes showed an enhanced uptake of 
glutamate following CORT administration (168). In vivo corticosterone or CORT-BSA injection, 
in the insular cortex of the PFC result in enhanced recognition in an object recognition test 
(169). This effect was not seen when a GR antagonist was co-administrated, indicating a 
membrane-mediated effect of the GCs involving GR. The same study also showed that PKA 
and CREB were involved in the memory facilitation.  
The important role of rapid GC-mediated negative feedback in the anterior pituitary 
gland was first reported in the 1970s and 1980s (170-172). The GR is highly expressed in the 
pituitary gland, while MR levels are low (173). These rapid negative feedback mechanisms are 
non-genomic and result in the inhibition of ACTH release being observed within 1 min of 
subsequent CORT administration (172). The rapid effects on inhibition of ACTH release were 
only seen when the CORT concentrations were increasing but not when the CORT 
concentrations were high already (170, 174, 175). The mechanism of ACTH inhibition will be 




1.6. Inhibition of CRH release 
CRH-producing neurons are located in the PVN of the dorsal hypothalamus. 
Corticotrophin-releasing hormone is stored in the axon terminals in the external zone of the 
median eminence. When the CRH neurons are stimulated by a calcium influx the CRH vesicles 
fuse with the membrane and are secreted, via exocytosis, close to the pituitary gland 
vasculature (12). Simultaneously, stimulation of the CRH neurons results in increased CRH 
transcription and subsequent increase in de novo synthesis of CRH peptide. Transcription of 
CRH is stimulated following activation of the cAMP/PKA pathway and involves the activation 
of pCREB which binds the CRE in the CRH promoter (176, 177). CRH transcription is also 
regulated by CREB binding to CREB regulated transcription coactivator 2 (CRTC2), a co-
regulator of transcription (178, 179). This de novo synthesis is vital to replenish the 
intravesicular storage of CRH and for the system to remain responsive (180).  
There is strong evidence that CORT may inhibit CRH synthesis and secretion (181-183). 
The CRH expression in the PVN of adrenalectomised rats is significantly higher than in intact 
animals (184). In addition, in ADX animals, even a mild stressor was significant to increase the 
CRH mRNA whilst this was not seen in the intact animals (185-187). Furthermore, mice with 
dysfunctional GRs in the PVN have increased CRH mRNA accompanied by hypersecretion of 
ACTH and CORT (188). The GC-mediated effects on CRH-expressing PVN neurons are partly 
mediated by the effects of GCs on brain regions with afferent projections to the PVN, those 
include the hippocampus, the prefrontal cortex, and the amygdala. However, CORT also has 
a direct negative feedback on the CRH-neurons in the PVN mediated by the GR (189, 190).  
 
1.6.1. Non-genomic and genomic mechanisms regulating CRH synthesis and secretion 
Non-genomic. The rapid, non-genomic effects of CORT in the PVN involve a putative 
membrane GR and involves endocannabinoid signalling (146). Whole-cell patch-clamp 
recordings in the hypothalamus have demonstrated that CORT decreases glutamatergic 
transmission post-synaptically in PVN neurons. This is, as previously mentioned, dependent 
on a post-synaptic G-protein coupled receptor and a pre-synaptic CB1 (144). Administration 
of dexamethasone conjugated to bovine albumin serum (DEX-BSA) inhibits HPA axis activity, 




that GR KO mice lack rapid GR-mediated negative feedback, suggesting that the classical 
membrane GR may be involved in addition to a membrane GR. Indeed, it has been proposed 
that classical GR may regulate the expression of the putative membrane GR (191).  
Genomic. The CORT-mediated negative feedback of CRH transcription is complex and 
not fully elucidated. No classical GRE was found in the CRH gene promoter in an in vitro study 
using AtT-20 cells with transfected human CRH. However, the same study demonstrated that 
GR binding to an nGRE in the CRH promoter results in repression of transcription (192, 193). 
Furthermore, other studies show that CORT mediates its inhibitory effects on CRH 
transcription by preventing CREB from binding to the CRE in the CRH promoter, and this is 
mediated via GR-CREB protein-protein interactions (194, 195). Amongst other factors, 
activation of CREB (pCREB) is regulated by CREB Regulated Transcription Coactivator 2 
(CRTC2). Unstimulated CRTC2 is found phosphorylated in the cytoplasmic compartment and, 
upon stimulation, CRTC2 is de-phosphorylated by various kinases, including salt-inducible 
kinase (SIK), and translocates to the nucleus. Once in the nucleus CRTC2 can enhance pCREB 
transcriptional activity (196, 197). Recent evidence suggests that the GR may be involved in 
regulating the phosphorylation and translocation of the CRTC2 in the hypothalamus. 
Dexamethasone administrations, and exposure to stress both cause increased 
phosphorylation of CRTC2 in mice (198). Finally, there is evidence that in addition to the 
effects on transcriptional regulation of CRH, CORT may affect the stability of the CRH mRNA 
(199).  
 
1.7. Inhibition of ACTH release 
Corticotrophs in the anterior pituitary gland are stimulated by CRH binding the CRHR1 
resulting in activation of ACTH synthesis and release via both genomic and non-genomic 
events (17).  
 
1.7.1. Non-genomic and genomic mechanisms regulating ACTH synthesis and secretion 
Non-genomic. In the corticotrophs, ACTH is stored in vesicles and when stimulated by 




levels and PKA activation which subsequently cause the phosphorylation of ion-channels and 
enhanced calcium influx which in turn causes ACTH vesicles to fuse to the membrane and are 
secreted via exocytosis (17). Glucocorticoids may inhibit this release by interfering with the 
electropotential properties of the corticotrophs. Corticotrophs have spontaneous firing and 
when stimulated with CRH this causes increased bursts and frequency of action potentials 
(200). Bursting enhanced calcium influx, therefore, may induce the release of the ACTH 
vesicles (201-203). Large-conductance calcium- and voltage-activated potassium (BK) 
channels are required for bursting firing in corticotrophs (200, 204, 205), and it is thought that 
the BK channels are therefore important for ACTH secretion. In murine corticotrophs, it has 
been shown that CORT administration leads to both reduced spontaneous firing and reduced 
bursts firing induced by CRH. In addition, the same study showed that this CORT-mediated 
decrease in burst firing caused reduced ACTH release and that this is BK channel-dependent 
(200). The mechanism of how CORT is mediating these effects is still unclear however it is 
suggested to be via PKA-dependent phosphorylation of the BK channels (206, 207).  
In addition to electropotential properties of the corticotrophs, Annexin1 (ANXA1) may 
also regulate ACTH vesicular release. Annexin1 is produced in folliculostellate cells in the 
pituitary gland and bind its putative receptor, the formyl peptide receptor. It is thought that 
ANXA1 causes the inhibition of CRH-mediated ACTH release by rearranging the cytoskeleton 
hence affecting vesicular transport, via a signalling pathway activated by cAMP and calcium 
influx (208). Glucocorticoids, in turn, can rapidly regulate ANXA1 activity by inducing 
translocation to the membrane from the cytoplasm by post-translational modifications (208). 
In addition, GCs enhance ANXA1 transcription which is a slower process and involves genomic 
events, however, it is important to replenish the cytoplasmic levels of the ANXA1 following 
CORT-induced translocation (209).   
Genomic. The genomic actions of CRH on ACTH production involve transcription of POMC, the 
precursor of ACTH. Corticotrophin-releasing hormone binding to the CRHR1 causes activation 
of the cAMP and subsequent PKA-mediated phosphorylation of CREB which binds the POMC 
promoter and stimulates transcription (210, 211). Furthermore, CRH –induced cAMP and PKA 
signalling activate the calcium/calmodulin kinase II and the MAPK pathway to increase 
expression of Nur77/Nurr1 (212, 213). Nur77 binds the NurRE in the POMC promoter and 




Glucocorticoid-meditated ACTH inhibition at a genomic level involves GR binding to the nGRE 
at the POMC promoter, which inhibits transcription (214, 215). Further, it has been 
demonstrated that the GR may prevent Nur77-mediated POMC transcription (213, 216). 
Recently, it has been suggested that this is mediated via NeuroD1. NeuroD1 is known to play 
a role in the regulation of POMC transcription (217) and when CORT is absent, the NeuroD1 
binds the E-box on the POMC promoter to cause transcription (218). When CORT 
concentrations rise, NeuroD1 expression is decreased (217) and therefore there will be less 
POMC expression and a subsequent decrease in ACTH levels.   
In summary, there are various ways that GCs and GR activity can affect both CRH and 
ACTH secretion. Although the exact mechanisms through which GR-mediated negative 
feedback regulates CRH and ACTH expression and secretion, and how GR activity is regulated, 
are not fully understood. Further insight into these mechanisms will be useful to further 
unravel the regulation of HPA axis activity.  
 
1.8. Adrenal Gland Negative Feedback 
Several studies support the idea of an intra-adrenal gland negative feedback system 
where CORT inhibits its own synthesis by directly affecting the steroidogenic pathway in the 
adrenal gland. The CORT-mediated effect on steroidogenesis has been shown both in vitro 
(219, 220) and in vivo (221, 222), even though the mechanism is not fully elucidated. Studies 
using dexamethasone indicate that GCs can inhibit steroidogenesis by enhancing the 
expression of  Dosage-sensitive sex reversal, adrenal hypoplasia critical region, on 
chromosome X, gene 1 (DAX-1), a negative regulator of the rate-limiting protein for 
steroidogenesis – StAR (223). Furthermore, similar to POMC regulation, CORT may inhibit 
StAR transcription by GR-mediated interaction with Nur77 (224, 225). Moreover, CRTC2 is not 
only involved in CRH regulation but is also involved in the transcriptional activity of 
steroidogenic genes in the adrenal gland, mediated via CREB activated transcription (226, 
227). One study showed that CORT inhibits the nuclear translocation of CRTC2 (198), a crucial 
part of its transcriptional function. Whether this occurs in the adrenal gland and is part of an 





 Both mathematical modelling and in vivo studies have provided some evidence for 
non-genomic and rapid effects of CORT on its synthesis and/or secretion (133, 134). It is 
suggested that CORT can regulate the activity of some of the steroidogenic proteins, however, 
the exact mechanism is yet to be elucidated. However, experimental work in the rat shows 
that a pulsatile pattern of ACTH administration causes a rapid increase in intra-adrenal gland 
CORT and subsequent activation of the GR as measured by phosphorylation at Serine 211 
(133). There is no evidence for CORT-mediated regulation of the steroidogenic protein activity 
yet, however, CORT has been shown to regulate the PKA by regulation of the catalytic subunit 
of the protein (228). As previously discussed, some of the non-genomic effects of CORT in the 
anterior pituitary gland are mediated by inhibition of ANXA1 (229), and ANXA1 is also present 
in the adrenal gland where it is also regulated by CORT (230). Isolated adrenal glands from 
ANXA1-null mice have a larger CORT response to ACTH compared to the adrenal glands from 
wild-type mice (230). This suggests that in addition to the regulation of ACTH secretion, 
ANXA1 may be involved in an intra-adrenal gland negative feedback loop by regulating the 
synthesis or secretion of CORT.   
 A deeper understanding of the role the adrenal glands play in the regulation of CORT 
secretion is crucial for further development of synthetic GCs used in the clinic. It is not 
currently known to what extent intra-adrenal gland GR-mediated negative feedback is 
involved in regulating CORT secretion.  
 
1.9. Sexual dimorphism in the HPA axis 
1.9.1. Rodent studies 
Numerous studies have demonstrated sexual dimorphism in HPA axis activity in both 
rodents and humans (231), characterized by hyperactivity of the HPA axis in females resulting 
in overall higher CORT levels. Several rodent studies have compared the circadian rhythm of 
ACTH concentrations in the basal state in males and females and the rhythms seem to be 
similar in both sexes (232-234). Although one study revealed a flatter ACTH pattern 
throughout the day in male rats while the females showed a circadian rhythm with higher 
levels before and during the dark phase. Following gonadectomy, this pattern was somewhat 




studies indicate that there is no difference in the basal concentrations of ACTH between males 
and females (236-238).  
  Further studies involving gonadectomised female and male rats show a difference in 
basal CORT concentrations measured over a 24-h period (239, 240)(fig 1.4). Sham female and 
sham male rats were compared to castrated female and castrated male rats. As expected, 
sham females had higher amplitude of CORT pulses compared to male rats (60.1 and 23.9 
ng/ml CORT, respectively), as well as higher frequency of the pulses (1.03 and 0.49 pulses per 
hour, respectively), with a higher number of total pulses in the females compared to males 
(24.3 and 11.5, respectively). Interestingly, the opposite was seen in the castrated animals; 
the castrated males displayed significantly higher pulse amplitude than the castrated females 
(63.1 and 29.1 ng/ml CORT, respectively), significantly higher frequency of pulses (0.95 and 
0.56 pulses per hour, respectively), and significantly higher number of total pulses (22.6 and 
13.1, respectively) (239). The same study investigated the mRNA expression of GR in the PVN 
and showed that castrated males had significantly lower GR mRNA levels than those observed 
in sham males, sham females had significantly lower levels than sham males and 
ovariectomized females. This suggests that GR is involved, plausibly lower levels of GR result 
in reduced negative feedback and higher CORT concentrations. Additionally, CRH mRNA levels 
in the PVN were significantly higher in sham females compared to sham males, and 
ovariectomized females and castrated males had higher CRH mRNA levels than sham males, 
sham females, and ovariectomized females. The same pattern was seen for the POMC mRNA 
levels in the anterior pituitary gland (239). In another study, the gonadectomised rats were 
given hormone replacement with either testosterone or dihydrotestosterone in the males or 
17b-oestradiol in the females. These hormone replacements reversed the effects seen by the 
gonadectomy in both sexes, in both CORT concentrations and the pulsatile pattern (240).  
In contrast to basal sex differences in the HPA axis activity, sex differences in stress-
induced ACTH and CORT suggest both a central and a peripheral involvement. Rodent studies 
show higher ACTH concentrations in females following various psychological and 
physiological stressors (236, 238, 239, 241-243). One study found that female rats had a 
significantly higher ACTH response to alcohol administration compared to males, irrespective 
of the oestrous cycle stage, although the ACTH response was higher in females in the 




colleagues showed that three hours post LPS injection, sham males and ovariectomized 
females had similar levels of ACTH whereas castrated males and sham females had similar, 
and significantly higher concentrations of ACTH. These effects of gonadectomy were reversed 
when the animals were given hormone replacement, dihydrotestosterone or testosterone, 
and 17b-oestradial, for males and females, respectively (239, 240).  
Numerous studies have reported higher absolute CORT concentrations in females 
compared to males following various stressors. For example, following a psychological 
stressor such as restraint stress, the CORT concentrations are higher in the females at the end 
of the stressor (238, 244-248). These differences are seen in various stressors such as the 
forced swim test, foot shock, alcohol administration, immobilisation, novel environment, 
ether and noise stress to name a few (236, 237, 239, 242, 249-253), and females show higher 
CORT responses to both predictable and unpredictable stressors (254). In addition, frequent 
sampling studies have shown that the CORT concentration in females, following a stressor, 
rises more quickly and stays elevated for longer, compared to males (241, 250, 251, 254, 255). 
Moreover, Seale and colleagues further investigated the effects of gonadectomy in rats. The 
sham and castrated females and males were subjected to noise stress and an immune 
stressor, on two different occasions. Post-stress CORT concentrations following the noise 
stress were significantly higher in the castrated males, compared to sham males as well as 
sham females and castrated females. Further, the LPS-mediated increase in CORT resulted in 
increased CORT concentrations in castrated males 90 min post LPS injection compared to 
sham males, castrated females, and sham females (239). In the same study, three hours post-
LPS administration, the levels of PVN AVP and CRH, and anterior pituitary gland POMC mRNA 
were measured in all four groups. Castrated males had significantly higher levels of all three 
genes compared to intact males, whilst lower levels were observed in the ovariectomized 
females compared to intact females. Moreover, GR mRNA expression in the PVN was 
significantly lower in castrated males compared to intact males and increased in 
ovariectomized females compared to intact female rats (239). These changes were reversed 
by the administration of respective sex hormones (240). These observations indicate a pivotal 
role of sex steroids in regulating HPA axis activity and suggest that androgens such as 




 To date, there are currently no reports of any ER response elements (EREs) or AR 
response elements (AREs) on the GR promoter, although it is a plausible mechanism for how 
sex hormones may affect GR expression and activity.  
 
 
Figure 1.4. Male and female CORT profiles. Blood corticosterone concentrations (ng/ml) 
measured every 10 min over 24 hours in basal conditions (from 07.00h to 07.00h) in a sham 
female rat (A), a sham male rat (B), an ovariectomized female rat (C), and a castrated male 
rat (D). The grey bar indicates lights off (19.00h to 05.00h). From (239). 
 
1.9.2. Human studies 
Compared to the rodent studies on the sexual dimorphism in the HPA axis, the human 
studies show more variable results, presumably due to the variation in age and demographics 
of the subjects, and the methodologies used. In human studies, both plasma and saliva 
hormone samples are used and only free CORT is measured in the saliva samples, while both 




stressors can be applied however the most standardised is the Trier Social Stress Test (TSST) 
which involves the most reliable tests in activation of the HPA axis: motivated performance, 
uncontrollability, and a social threat (256). The TSST involves a preparation period followed 
by a speech and a mental arithmetic task. Studies using the TSST or other similar tests have 
found higher ACTH response in males and similar CORT concentrations in both sexes (257-
260). One study also investigated the effect of oral contraceptives and found that there was 
no difference in total plasma CORT between males and females following the TSST, 
irrespective of the menstrual cycle stage, however, women using oral contraceptives had 
higher CORT concentrations than the males and other females (261). Furthermore, the saliva 
CORT concentrations were higher after the TSST in males and females in the luteal phase 
compared to the females in the follicular phase and on oral contraceptives (261). Tests with 
social interactions and rejection elicit higher free CORT concentrations in women, while men 
showed a greater increase in CORT following verbal and mathematical tests (262). These 
studies suggest that in humans, females show higher HPA axis activity following social 
rejection specifically, while men are more sensitive to most other psychological stressors.  
Moreover, for physical stressors, most studies show no sex difference or higher HPA 
axis activity in women. No sex difference in CORT was observed following intensive endurance 
exercise (263, 264) however when high-intensity exercise was preceded by dexamethasone 
administration, to activate GC negative feedback, the women had higher CORT 
concentrations (265), suggesting that there is less GC-mediated negative feedback in women 
following a physical stressor. Other forms of physical stress such as heat were found to result 
in increased ACTH and heart rate in women, while the CORT concentrations were similar in 
both women and men (266). Similarly, subsequent to one hour of exposure to cold, ACTH and 
CORT concentrations were significantly higher only in females (267).  
Similar to physiological stressors, pharmacological activation of the HPA axis results in 
higher hormone concentrations in women. Activation of the HPA axis by the administration 
of exogenous ovine CRH results in a larger increase in ACTH concentrations, and a longer CORT 
response in women compared to men (268). Another study with human CRH administration 
found no difference in the ACTH response, although a greater response in women was seen 
when CRH was co-administered with AVP (269). During the dexamethasone-CRH test (DEX-




followed by the administration of CRH the following day. The DEX-CRH test, therefore, 
assesses the GC negative feedback regulation. Interestingly, women show higher CORT 
concentrations following the Dex-CRH test compared to men, suggesting a lower GC negative 
feedback activity in women. (270).  
Conclusively, sex differences in HPA axis activity in humans are dependent on the type 
of stressor the subject is exposed to. Certain psychological stressors, such as social rejection 
(262), and pharmacological stressors (260) activate the HPA axis more in women, while most 
other psychological stressors affect men more (260). This is perhaps due to a difference in the 
brainstem or limbic structures in men and women.  
 
1.9.3. Central and peripheral molecular mechanisms of sexual dimorphism of the HPA axis  
With regards to molecular differences in the HPA axis in males and females, CRH and 
AVP expression in the PVN have been studied to elucidate any potential differences in central 
activation of the HPA axis. In rats, basal expression of PVN CRH is higher in females compared 
to males (238, 241, 271). Similarly, some studies show that following a stressor such as a 
footshock or an immune stressor, females show a greater increase, and a longer duration of 
PVN CRH expression (239, 241). However, these results are inconsistent with other studies 
indicating higher post-stress CRH expression in the PVN of males following restraint stress 
(238, 248). Thus, the differences in post-stress CRH expression increase appear to be largely 
dependent on the type of stressor. In humans, men have been shown to have more CRH-
expressing neurons in the PVN (272) which could account for the increased HPA axis response 
following certain stressors in men. Studies in rats have shown no clear difference in basal AVP 
mRNA expression in the PVN (238, 273-275) but a greater increase of AVP following stress in 
females (238, 239). Finally, no apparent difference in PVN neuronal activation, measured by 
c-Fos induction, has been established following stress in rats (238, 248, 250, 274).  
 
Glucocorticoid-mediated negative feedback is a pivotal mechanism for terminating 
the stress response and this is induced by circulating CORT binding to GR both centrally and 
peripherally. Moreover, CORT binding to the MR, mainly in the hippocampus, executes a tonic 




differences in GR and MR expression and binding in males and females, a few important 
observations have been made. The affinity of CORT for MR is markedly higher in male rats 
than in female rats (REF). The implication of this is that in male rats the MRs are 
predominantly occupied in the basal state, when CORT levels are low, whilst in females both 
MRs and GRs will be occupied. Thus, in female rats the MRs are partially unoccupied even at 
basal levels, and might not be filled until relatively high levels of CORT are reached (277). 
Studies show that progesterone may bind the GR, which causes a reduced binding of CORT to 
the GR (278) which might contribute to reduced GR-mediated GC negative feedback. 
Furthermore, oestrogen administration in OVX females for four days reduced the MR binding 
in the pituitary gland by 50%, and this effect was not present in males (279). It has also been 
shown that oestrogen treatment reduces GR binding in the hippocampus specifically (280). 
This inhibitory effect of oestrogen on GR and MR binding is predominantly seen at pro-
oestrus, when oestrogen levels are high and result in reduced negative feedback and higher 
basal levels of CORT. In contrast, testosterone has stimulatory effects on GR binding, 
anatomically distinct to AVP containing neurons, resulting in inhibition of AVP-mediated ACTH 
release from the anterior pituitary gland (reviewed in (277). Studies investigating  GR and MR 
expression have mainly focused on the hippocampus and hypothalamus, and most report no 
major differences in expression (277).  
Seale and colleagues investigated the expression of GR mRNA in the sub-regions of 
the hippocampus, and the anterior pituitary gland, in sham-operated males and females, and 
gonadectomised males and females. In the anterior pituitary gland, the expression of GR 
mRNA was lower in sham females compared to sham males and castrated males. In the 
hippocampus, there was no difference in GR mRNA across the groups (239). These results 
perhaps suggest that lower CORT binding to MR and GR in females, and lower GR expression 
in the anterior pituitary gland in females, could result in decreased GC-mediated negative 
feedback in females and subsequently higher CORT concentrations.  
There is a strong line of evidence that indicate sex differences in the adrenal gland’s 
capacity for CORT production. In rodents, females have heavier adrenal glands if expressed 
as a ratio of total body weight (281). More specifically this difference in size is due to a larger 
volume of the zona fasciculata of the adrenal cortex, the part of the adrenal gland where 




males (281, 282). The secretion capacity of CORT from the adrenal glands is higher in female 
rodents (242, 283), thus the same concentration of ACTH results in higher CORT secretion in 
females compared to males.  
In addition to sex differences in central and peripheral activation of the HPA axis, there 
are differences in the clearance and free CORT in males and females. Female rats have (282) 
shorter biological half-life of CORT (242, 284), due to a higher metabolism of CORT in the liver 
(285, 286). Corticosterone and cortisol are only biologically active in the target tissues when 
not bound to CBG (110). With approximately two-fold higher levels of CBG in adult female 
rats compared to male rats (287-291), this could contribute to reduced GC-mediated negative 
feedback in females.  
  
1.10. HPA axis, glucocorticoids, and depression  
The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria 
for major depression states that the patient must have experienced the symptoms as a 
change from their previous state and that the symptoms are present over 2 weeks. At least 
one of the patient’s symptoms must be either depressed mood experienced almost every day, 
or a loss of interest in all activities. The patient must also exhibit four of the following 
symptoms: significant alterations in appetite and/or weight (not due to dieting), insomnia or 
hypersomnia, psychomotor alterations; agitation or retardation, loss of energy or fatigue, 
feelings of guilt and worthlessness, indecisiveness or impaired ability to think, and frequent 
thoughts about death or suicide (292).  
Once the criteria for major depression are met, the DSM-5 divides depression into four 
subtypes or subcategories: postpartum depression, melancholic depression, atypical 
depression and catatonic depression (292). Interestingly, patients with different subtypes of 
depression show differences in HPA axis activity and their circadian profiles of the symptoms 
(293). In the majority of severely depressed patients, a hypercortisolism with intact circadian 
rhythmicity is often present, partly due to increased hypothalamic CRH secretion (294). This 
is particularly true for those patients with melancholic depression exhibiting most of their 
severe symptoms in the morning (292, 295, 296). Melancholic depression is characterised by 




disturbed psychomotor abilities, and guilt. These symptoms have been observed more in 
elderly patients than in younger patients (297-299). In addition, men are more likely to 
present with melancholic depression than women (300). Further epidemiological data 
regarding gender differences in depression have shown that the higher prevalence of 
depression described in women is only present for the atypical subtype of depression (301).  
Compared to patients with Cushing’s syndrome, characterised by elevated cortisol and 
a loss of circadian rhythmicity, melancholic depressed patients do not develop the clinical 
symptoms of Cushing’s despite similarly high circulating levels of GCs (292). This is likely to be 
due to a GC resistance in depressed patients. Even though depressed patients exhibit 
circadian rhythmicity of GC secretion, the circadian nadir is shorter and more pulsatile 
compared to healthy controls (302). Further, these patients have sleep disturbances; less 
deep sleep (slow-wave) and reduced latency to REM sleep (302). When the depressed patient 
is remitted, both the hypercortisolism and the alterations in circadian rhythms disappear, 
suggesting these effects are state-dependent rather than trait-dependent (295).  
On the other hand, atypical depression is characterised by a blunted circadian rhythm 
of cortisol secretion (292). Patients with atypical depression present with disturbances in the 
evening, such as fatigue, lack of energy, hypersomnia, and significant weight gain as a 
consequence of significantly increased appetite (292). In addition, patients suffering from 
atypical depression often exhibit variations in mood, leaden paralysis (feeling of limbs being 
weighed down), and sensitivity to rejection (292). The reduced circadian variation in cortisol 
concentrations is caused by a reduced HPA axis activity, the opposite of melancholic (typical) 
depression. This reduced HPA axis activity in atypical depression is caused at least partly by 
reduced activity of the CRH secreting neurons in the PVN, resulting in a subsequent lower 
circulating cortisol concentration (293). In addition to the gender differences in the 
prevalence in atypical depression, the atypical depression subtype has been associated with 
earlier onset in the sufferers, a chronic disease burden, and poor outcome to tricyclic 
antidepressants, suggesting specific biological features (303, 304).  
The initial evidence for a dysregulated HPA axis in some depressed patients emerged 
in the 1980s, where it was shown that depressed patients had elevated plasma CORT and 
reduced GC negative feedback (305). Further studies evaluating HPA axis activity in 




involving challenging the HPA axis or the negative feedback mechanism. Studies using the 
former approach have used techniques including measuring cortisol in urine, blood, or saliva 
samples. The more sophisticated of those include frequent sampling over 24 hours for cortisol 
and ACTH. The challenging tests mostly involve stimulating the negative feedback mechanism 
with the GR agonist, dexamethasone (306), the so-called dexamethasone-suppression test 
(DST), or a combination of DEX and CRH (DEX-CRH) to investigate pituitary gland function 
(307). The DST results in suppressors, with a normal response to the DEX, and non-
suppressors, with impaired negative feedback mechanisms. In the melancholic subtype of 
depression, around 50 % are non-suppressors in the DST (308). Further, increased ACTH and 
cortisol responses have been reported following the DEX-CRH test in patients with major 
depression, however differences in subtypes were not investigated (307). This increased DEX-
CRH response suggests decreased sensitivity in the pituitary gland negative feedback. Further, 
is has been shown that in elderly patients with depression the relationship between cortisol 
and depression was U-shaped and the elderly with lowest CORT concentrations scored higher 
on the depression scale than patients with higher CORT (309).  
These studies highlight the differences in HPA axis activity, and symptoms, amongst 
patients diagnosed with depression. To be able to understand and treat the altered HPA axis 
activity in these patients, a deeper understanding of the HPA axis, and especially how GC 
ultradian rhythms are regulated, is needed.  
 
1.11. The FK506-binding protein 51 and 52 
The FK506 binding proteins 51 and 52 (FKBP51 and FKBP52) were discovered over 20 
years ago and first identified as part of the steroid receptor complex (310, 311). Since then, 
both proteins have gained interest in their ability to regulate these steroid receptor activities 
and the effects on hormone signalling. Due to their effect on endocrine regulation, both 
FKBP51 and FKBP52 have been investigated as potential therapeutics for endocrine-related 
pathologies including prostate cancer, breast cancer, metabolic disorders, and stress-related 
diseases (312). 
Both FKBP51 and FKBP52 bind the hsp-90 of various steroid hormone receptor (SHR) 




FKBP52 share 70% similarity in structure and both contain a peptidyl-prolyl isomerase (PPIase) 
domain, and two N-terminal domains FK1 and FK2, in addition to the TPR domain. FKBP51 
regulates SHR activity by regulating the translocation of the receptors and hence their 
genomic activity. FKBP52 has been shown to promote receptor translocation and hence the 
transcriptional activity of the GR (65), progesterone receptor (PR) (314), and the androgen 
receptor (AR) (315), but not the oestrogen receptor (ER) or the MR (65). In contrast, FKBP51 
is a negative regulator of most SHRs (72) including the GR and MR. These two FKBPs compete 
for the binding of the SHR and hence if FKBP51 is overexpressed, the SHRs will be less 
regulated by the FKBP52 (65). Some studies also indicate that hormone-binding affinity is 
significantly decreased when the SHR is bound to FKBP51 (316).  
Further, it is suggested that FKBP51 attaches to the receptor complex at the later 
stages of the chaperone cycle, and shows preferential binding to hsp-90 complexes that are 
bound to a ligand-free SHR, for example, the GR (317-320). The mechanism of the preferential 
binding to ligand-free GRs and other SHRs is not yet clear. In addition to the inhibitory 
properties on nuclear translocation, FKBP51 had been shown to decrease the hormone-
binding affinity to its ligand (321, 322). It is not clear whether this is due to direct inhibitory 
effects of the FKBP51, or indirect effects by preventing the binding of FKBP52. Indeed, in vitro 
studies have shown FKBP51 reduces the rate of nuclear translocation of GR by preventing 
FKBP52-mediated translocation of the receptor (323).  
The FKBP51 gene FKBP5 has a functional GRE, and thus, an intracellular short feedback 
loop exists whereby less FKBP51-induced GR translocation and binding to the GRE on the 
FKBP5 gene induces more FKBP51 expression and thus reduced GR translocation (324-326). 
In addition to its role in GR and MR translocation FKBP51 can also regulate the activity of 
certain kinases, including AKT (327) and GSK3β (328), which in turn can regulate GR activity 
(329, 330). 
 Although it is well-known that FKBP51 inhibits GR translocation hence GR genomic 
activity (65), it is not established to what extent this affects the role of GR in regulating GC-
mediated negative feedback. It is currently unknown how central and peripheral FKBP51 may 





1.12. FKBP51 and glucocorticoid resistance 
The FKBP51 gained a lot of interest when it was found that there was a link between 
FKBP51, increased cortisol concentrations and GC resistance in squirrel monkeys (322). It was 
shown that squirrel monkey lymphocytes (SML) had increased levels of FKBP51 and that this 
was implicated in the GC resistance and high circulating levels of cortisol seen in those 
monkeys (322). The increase in circulating cortisol compensates for the decreased affinity of 
the GRs as a result of the increased expression of the FKPB51 (331). The transcriptional 
activity of GR in the squirrel monkeys is similar to those of human GR as demonstrated by in 
vitro studies with the two different GRs transfected into cells (332). The effect of the FKBP51 
on GR binding was assessed and it was found that in the squirrel monkeys the increased 
expression of FKBP51 did indeed cause a substantial decrease in GR binding (332). Hence it is 
the increase in FKBP51 and the resultant decrease in GR binding which results in GC resistance 
and increased cortisol concentrations in squirrel monkeys. This led to the intriguing 
hypothesis that the FKBP51 could be implicated in mental disorders caused by an increased 
HPA axis activity in humans.  
 
1.13. FKBP51 and polymorphism – link to mental disorders 
In humans, a breakthrough in the research of mental illnesses came when Binder and 
colleagues were the first to demonstrate a relationship between functional polymorphisms in 
the FKBP5 gene and the response to antidepressants in patients with major depressive 
disorders.  The study investigated the correlation between 57 single nucleotide 
polymorphisms (SNPs) in the genes encoding for known co-chaperones to the GR: BAG1, 
STUB1, TEBP, FKBP4 and FKBP5 (333) and the GR itself (NR3C1), and the outcome of 
antidepressant treatment following 2 and 5 weeks of hospitalization and at remission in 
patients with major depressive disorders (n=294) and matched controls (n=339). The results 
showed a correlation between three SNPs (rs1360780, rs1334894, and rs755658) in the 
FKBP5 gene with the treatment outcome of at least two out of three time points of recovery 
or remission in the depressed patients (334). To investigate whether this correlation was 
solely due to the FKBP5 or if it involved adjacent genes, further analysis investigated 27 SNPs 




genes (TULP1, FLJ25390, and CLPS). An analysis of linkage equilibrium was performed and 
further analysis for the correlations of antidepressant treatment and SNPs in these regions 
was conducted.  
With regard to the SNP rs1360780 (with two possible alleles; C/T), a study showed a 
significant interaction between allele and outcome of antidepressant treatment after two 
weeks of treatment (334). The patients were genotyped into CC, CT or TT and the outcome 
after two weeks were non-responders: CC:25; CT:16, TT:1, and responders: CC:14; CT:24; 
TT:5. Notably, the rs3800373 (G/A) showed a trend of correlation (p=0.053), with AA allele 
patients displaying a higher rate of response to the treatment. Nevertheless, the SNP 
rs1360780 was selected for further analysis, including physiological and molecular studies. 
Firstly, the analysis showed that TT patients had a significantly higher number of previously 
recorded depressive episodes, more than twice as many as the CC and CT genotypes. Thus, 
although the patients with the TT genotype are more responsive to treatment, they are also 
more prone to develop depressive episodes, suggesting a strong involvement of a 
dysregulated HPA axis. Further molecular analysis of the FKPB51 level in lymphocytes 
revealed higher protein levels of FKBP51 in the TT patients compared to CC and CT genotypes. 
However, when the peripheral blood monocytes were analysed for FKBP5 mRNA levels the 
results showed no difference between the three genotypes. This suggests that increased 
FKBP51 protein levels are due to increased translation or increased protein stability. 
 Furthermore, the ACTH and cortisol levels in the patients were examined; the TT 
genotypes had lower ACTH concentrations compared to the CR and CC genotypes following a 
DEX-CRH test, however, there was no difference in the cortisol concentrations between the 
three genotypes, although all three genotypes displayed significantly higher CORT 
concentrations compared to healthy controls. The morning after the DEX-CRH test the cortisol 
levels were significantly lower in all three genotypes compared to their respective basal 
cortisol however there was no difference between the TT and the CC or CT genotypes. 
Interestingly, although no difference in FKBP5 mRNA levels or plasma cortisol levels were 
present in the three genotypes in healthy controls, the TT genotypes showed a stronger 
positive correlation between FKBP5 mRNA levels and plasma cortisol, which was significantly 




Another group performed correlation studies of the SNP rs1360780 and found an 
association between the less common TT genotype and depression in men but not women 
when investigating the prevalence of major depression, mixed anxiety depression and 
dysthymia (335) suggesting a sexual dimorphism in FKBP51-mediated regulation of HPA axis 
activity. Lekman et al., performed a large comparison study of three FKBP5 SNPs; rs1360780 
(C/T), rs4713916 (A/G), and rs3800373 (A/C) across three different populations: all, white 
non-Hispanic, and black, investigating the prevalence of depression, remission, and response 
to treatment. Both genotype- and allele-wise comparison tests were performed on cases and 
controls, remitters and non-remitters, and responders and non-responders. The genotype TC 
in the rs1360780 was overrepresented in cases (46% vs 38%) in the white non-Hispanic group. 
Further, in the genotype-based association test, there was a significant association between 
the rs4713916 (A/G) and remission in the white non-Hispanic group. In the allele-wise 
comparison, the A allele was significantly over-represented in the remitters when all groups 
were combined (336).  
In addition to the effects of certain SNP genotypes of the FKPB5 and association with 
the various effects on mood disorders, some studies have investigated the effect on the TSST. 
Ising and colleagues investigated the effect of genotype in common FKBP5 SNPs, the ACTH 
and cortisol concentrations, and self-reported anxiety during the TSST. Patients with the TT 
genotype of the rs1360780 SNP, the GG genotype of the rs3800373 SNP, and the AA genotype 
of the rs4713916SNP all had higher plasma cortisol concentrations during the recovery period 
in their first and second TSST. Additionally, the GG genotype of the rs3800373 SNP and the 
AA genotype of the rs4713916SNP also had higher self-reported anxiety during the recovery 
of the second TSST (337).   
The association between the genotypes of the rs1360780 SNP and cortisol response 
to the TSST was tested in one study with combined men and women in healthy controls and 
patients with remitted major depression. Surprisingly, there was no effect of the genotypes 
in the remitted group. There was, however, a strong significant effect of genotype in the 
healthy controls. Subjects with the TT genotype had higher cortisol concentrations 15 minutes 
following the TSST. During the baseline and the test, there was no difference in cortisol 
concentrations. Furthermore, the same study investigated the levels of FKBP5 mRNA during 




showed induction of FKBP5 mRNA following the TSST and had significantly higher FKBP5 
mRNA at the 70 minute post-stress time point, whilst there was a blunted response of FKBP5 
mRNA induction in the TT and CT healthy controls (338). The above studies have shown a 
strong link between FKBP5 genotypes and psychiatric disorders, however, they did not show 
a clear association between FKBP5 expression and depression, and did not investigate the 
expression of FKBP5 in the brain. However, a few studies have indeed shown an increased 
FKBP5 mRNA expression in patients with MDD. For example, Mamdhani and colleagues 
showed a significant 2.36 fold increase of FKBP5 mRNA in the hippocampus in patients with 
MDD compared to controls in a post-mortem study (339).  
 The studies above suggest that FKBP51 has a strong role in psychiatric disorders, 
plausibly by affecting the GR activity and hence the GC-mediated negative feedback. Although 
this is yet to be fully elucidated, it provides a strong hypothesis for further research to unravel 
the complexity of the molecular mechanism underlying psychiatric disorders with altered HPA 
axis activity.  
 
1.14. FKBP51 and rodent studies 
1.14.1. Overexpression of FKBP51 in the mouse 
Studies in mice overexpressing FKBP51 in the basolateral amygdala (BLA) induced 
anxiety-like behaviour in the mice (340). An adenovirus vector overexpressing the FKBP5 gene 
was injected bilaterally in the BLA and post-mortem gene expression analysis showed a 
threefold increase in FKBP5 mRNA expression compared to vehicle-treated mice (339). The 
FKBP51 overexpressing animals showed significantly reduced entries and time spent in the 
open arms of the elevated plus maze test, indicating an increased anxiety phenotype in these 
animals (340). Similar results were seen when the FKBP51 was overexpressed in the central 
amygdala, suggesting that both areas of the amygdala are involved in anxiogenic behaviour. 
Further, viral-mediated overexpression of FKBP51 in the dorsal hippocampus, dentate gyrus 
and CA1, did not affect anxiety-related behaviour, indicating that this is not mediated by the 
hippocampus (340). The amygdala projects to the PVN and causes an increase in ACTH release 
and hence subsequent CORT release, believed to be involved in some of the anxiety-related 




Glucocorticoid actions in the amygdala have been demonstrated to be involved in 
regulating a positive feedback loop that ultimately potentiates the activity of the HPA axis. 
Additionally, studies in mice have shown decreased GR expression and increased anxiety-like 
behaviour which is reversed by viral-mediated restoration in GR levels (341). This suggests 
that increased amygdala FKBP51 expression, or decreased GR expression, induces anxiety in 
mice. This suggests that GCs and the GR in the amygdala are involved in regulating HPA axis 
activity and that an increase in FKBP51, or decrease in GR, and subsequent decrease in nuclear 
GR induced increased HPA axis activity and anxiety.  
It is not currently known whether overexpression of FKBP51 in other brain areas 
influences HPA axis activity and further research in this area will be useful to establish the 
role of central FKBP51 activity.  
 
1.14.2. FKBP51 Knock-out studies in the mouse 
In contrast to the FKBP51 overexpression studies, a knockout mouse model was 
developed to study the effects of decreased FKBP51 levels, and whether this altered the HPA 
axis activity. In male FKBP51 knock-out (51KO) mice, there was no difference in basal morning 
CORT levels, or 15 min after an FST. However, 90 min after the FST, CORT levels were 
significantly lower in the 51KO mice. The other group of 51KO mice was subjected to 21 days 
of social defeat stress and morning CORT levels were significantly lower in the stressed 51KO 
group compared to the stressed wild type (WT) group. Similarly, CORT concentrations 15 min 
post-FST and 90 min post-FST were significantly lower in the stressed 51KO mice.  The mice 
were tested for behavioural effects using the FST, the elevated plus maze, and the open field 
test. There was no significant effect of genotype except for the time spent swimming in the 
FST where stressed 51KO mice showed increased time spent swimming (342). The same tests 
were performed in female 51KO mice, with similar results, although there was a significant 
decrease in morning CORT levels in non-stressed animals as well as stressed animals. This 
might be because female mice have higher basal CORT levels, whereas in male mice, 
especially in the morning, CORT levels are low and therefore the effect of genotype is not 




These data suggest that significantly reducing the levels of FKBP51 enhanced the 
ability to terminate the stress response in both female and male mice. However, in the above 
studies the CORT concentrations were only measured at two time points in the basal 
conditions, and at one time point following the stressor. A complete 24-hour profile of basal 
CORT following altered FKBP51 expression or activity has not yet been established.  
 
1.15. FKBP51 antagonists: SAFit1 and SAFit2 
The two natural ligands for FKBP51, FK506 and Rapamycin, both have inhibitory 
effects on FKBP51 activity and bind the FK1 domain of the FKBP51 (344). However, the main 
effects of FK506 and Rapamycin are, respectively, calcineurin inhibition and mTOR inhibition 
hence are immunosuppressive and limit their use in living organisms. Therefore, a search for 
non-immunosuppressant FKBP51 inhibitors began, however, this was for a long time hindered 
by the structural similarity to FKBP52, as the FK506-binding sites are conserved (345). 
Selective inhibition is crucial due to the opposite effects of FKBP51 and FKBP52 on 
glucocorticoid signalling (346). 
A breakthrough came when a research team at Max Planck Institute of Psychiatry lead 
by Dr Felix Hausch developed two potent ligands for selective inhibition of FKBP51. The two 
ligands, SAFit1 and SAFit2 (short for selective antagonist of FKBP51 by induced fit) showed 
over 10,000-fold selectivity for the FKBP51 over FKBP52. Moreover, both SAFit1 and SAFit2 
have a 10-fold selectivity for the related FKBP51 protein FKBP12. Importantly the SAFit1 and 
SAFit2 have a 100-fold higher affinity for the FKBP51 (347). The two SAFit compounds bind 
the 506-binding pocket but lack the effector domain that mediates the binding to calcineurin 
or mTOR and are therefore not immunosuppressive (347). Although the SAFit1 and SAFit2 are 
the best FKBP51 inhibitors published to date, the physicochemical properties are not 
optimum for CNS-directed drugs (348) and further optimisation is required. Nevertheless, 
after an injection of 10 mg/kg (i.p.) in male mice, it was shown that SAFit2 has a half-life of 
9.7 hours and SAFit1 2.5 hours. The Cmax (maximum concentration) for SAFit2 was 2094.8 and 
was reached after 0.3 hours (Tmax). In contrast, the Cmax for SAFit1 was 1383.0 ng/ml and the 
Tmax  1.0 hours (347). This suggests that SAFit2 reached a higher concentration compared to 




plasma ratio for SAFit2 is 16.7%, while for SAFit1 it is <0.5%, demonstrating that SAFit2 
penetrates the brain and SAFit1 does not (347).  
 
 
Figure 1.5. Chemical structure of FK506, the natural ligand for FKBP51, and of SAFit2. From 
Hahle et al. (349).  
 
 
Figure 1.6. Chemical structures of iFit1 and iFit4, two early precursors in the SAFit 




1.16. Pre-clinical studies using SAFit2 
Early studies with SAFit2 in mice showed that a single i.p. injection with SAFit2 
(20mg/kg) could reduce anxiety-like behaviour caused by FKBP51 overexpression in the BLA. 
The mice injected with SAFit2 spent more time in the open arms in the elevated plus maze 
test, more time in the lit compartment, and made more entries to the lit compartment in the 
light-dark box test, both indicating reduced anxiety (340). Furthermore, mice treated with 
SAFit2 demonstrated decreased CORT concentrations at the circadian peak, but not at the 
trough (347). Mice treated with SAFit2 and exposed to the DEX/CRH test showed enhanced 
suppression by DEX, which remained enhanced after stimulation with CRH as shown by 
decreased CORT concentrations (347). This suggests that the SAFit2 enhances the negative 
feedback mechanisms activated by DEX administration. Furthermore, SAFit2 had 
antidepressant properties in the forced-swim test, similar to those of commonly used 
antidepressants (347).  
Another study investigated the effects of SAFit2 treatment on the efficacy of a highly 
prescribed selective serotonin reuptake inhibitor (SSRI), escitalopram, used for depression 
and anxiety treatment. The co-administration of SAFit2 reduced the efficacy of the SSRI, 
however, it increased the stress-coping behaviour in the mice. Mice were injected with an 
empty or SAFit2 loaded vesicular phospholipid gel (VPG), which allowed for prolonged 
treatment with SAFit2. Behavioural testing was performed on day 2 to 5 with an 
intraperitoneal (i.p.) injection of escitalopram or vehicle 30 minutes before the testing. In 
addition to behavioural data, the basal CORT and stress-induced CORT were also investigated. 
It was found that SAFit2 mitigated the anxiolytic effects of escitalopram in most of the 
behavioural tests performed. In contrast, SAFit2 increased struggling time in the forced swim 
test. When investigating the effects of SAFit2 on CORT concentrations it was found that SAFit2 
when combined with escitalopram, had no effect on the stress-induced CORT however, it 
reduced the recovery time when compared to empty-VPG and escitalopram treated mice 
(350). The same group investigated the effect of SAFit2 on metabolism and its potential 
involvement in obesity. The study showed that 51KO mice are resistant to high fat diet-
induced obesity. Furthermore, treatment with SAFit2 in mice mimics these effects on body 
weight and glucose tolerance. In addition, the SAFit2-mediated improvement in glucose 




behind these effects involved the AS160, an AKT2 substrate. Treatment with SAFit2 increased 
the AS160 phosphorylation, which in turn increased the expression of the glucose transporter 
4 at the plasma membrane, and hence improved glucose uptake in skeletal myotubes (351).  
 
1.17. Rationale, Aims, and Hypotheses 
Previous work involving FKBP51 in regulating the HPA axis has shown intriguing links 
between FKPB51 and CORT regulation. Studies performed in animals using SAFit2 have 
demonstrated a potential of FKBP51-inhibition to decrease HPA axis activity and ultimately 
CORT concentrations following a stressor. However, the studies investigating the effect of 
SAFit2 on basal HPA axis activity are limited and there are to date no studies investigating the 
effect of FKBP51-inhibition on the 24-hour pulsatile pattern of CORT release. In addition, 
SAFit1 has not been well characterised in regards to its effects in vivo and it has interesting 
potential as a peripheral-only FKBP51 inhibitor. Furthermore, the 51KO mice showed a 
stronger effect on basal HPA axis activity in the female mice compared to male mice, however, 
no studies using SAFit2 have been performed in females.  
Because global knock-out of FKBP51 reduced both basal CORT concentrations (in 
females only) and stress-induced CORT concentrations in male and female mice, I was 
interested in investigating if similar results would be observable in rats. Because I did not have 
the availability of 51KO rats I decided to use two FKBP51-specific inhibitors, SAFit2 and SAFit1. 
The results from the 51KO mice studies, coupled with the results from studies in primates 
indicating that increased expression of FKBP51 causes GC resistance (321), and recent findings 
in humans (334), were all foundations to the rationale for my project.  
The studies presented in this thesis were performed in rats, as more blood samples 
can be taken in a short period and frequent blood sampling and CORT concentration 
measured throughout 24 hours. The CORT concentrations were measured during 24-hours to 
establish whether the SAFit compounds affect the ultradian pulsatility of CORT secretion. 
The overall aim of this research was to further characterise the involvement of GR and 




would be altered, and this would affect the GC negative feedback (fig 1.7.). The specific aims 
for the overall project were the following:  
Aim 1: To elucidate the effects of SAFit2 and SAFit1 treatment on HPA axis activity in male 
rats. 
Aim 2: To elucidate the effects of SAFit2 and SAFit1 treatment on HPA axis activity in female 
rats. 
Aim 3: To elucidate the molecular mechanisms underlying the effects of SAFit2 and SAFit1 on 
HPA axis activity described in aim 1 and 2. 
 The objectives of the project were to elucidate these 3 aims by using an automated 
blood sampling system to measure CORT concentrations during 24 hours following both acute 
and sub-chronic (5 days) SAFit2 or SAFit1 treatment. To quantify the potential changes in 
CORT concentrations, and ultradian pulsatility, the PULSAR algorithm was used to analyse the 
pulsatile dynamics of CORT. Moreover, to characterise at what level of the HPA axis the SAFit1 
and SAFit2 are active, the anterior pituitary gland and adrenal gland were stimulated with 
CRH, and ACTH, respectively. To elucidate the molecular mechanism behind any potential 
effects, subcellular translocation of GR following SAFit2 or SAFit1 was quantified.  
The general hypothesis driving the rationale and aims for this project is that by 
inhibiting FKBP51, the GR will be activated and induce GC-mediated negative feedback, which 
ultimately will cause a reduction in CORT concentrations. More specifically, the hypothesis 
was that FKBP51 inhibition will cause GR to translocate to the nucleus and induce negative 
feedback regulation by inhibiting gene transcription, and/or secretion of CRH and 
POMC/ACTH, resulting in reduced CORT secretion from the adrenal glands. There is a long-
standing notion that the CORT ultradian pulsatility is under hypothalamic regulation, however 
recent evidence suggests a role for a pituitary-adrenal gland feed-forward/feedback loop 
(132), though few studies have shown a change in pulsatility. It is feasible to hypothesise that 
inhibition of FBKP51 by the peripheral-only SAFit1 can influence the ultradian CORT 
pulsatility.  Furthermore, because of the well-known sexual dimorphism in HPA axis activity, 
it is plausible that SAFit2 and SAFit1 will affect males and females differently, although the 
complexity of HPA axis regulation makes it difficult to hypothesise where or how this 




Emerging evidence suggests a strong link between FKBP51 and psychiatric disorders 
with dysregulated HPA axis activity, such as depression (334). The FKBP51 is a promising 
target for novel therapeutics and further knowledge in the FKBP51-mediated regulation of 
HPA axis negative feedback will be of great importance for advancement in this area.  
 
 
Figure 1.7. Hypothesis for the effects on HPA axis activity following FKBP51 antagonism. 
FKBP51 and FKBP52 compete for binding to the GR and thus inhibition of FKBP51 would 
increase the binding of FKBP52 to the GR. This, in turn, will increase FKBP52 and dynein-
mediated translocation of GR. Once in the nucleus, the GR can repress the transcription of HPA 









Chapter 2: General methods 
 
2.1. Animals 
Male and female Sprague-Dawley rats were used in all experiments (except 
experiment 14) and were 7-8 weeks of age (190-224g) at the time of arrival in the animal 
facility. The rats were allowed to acclimatise to the facility and were handled once a day for 
one week before surgery or to the start of the experiment. Animals were maintained on 14 
hours of light: 10 hours of darkness (lights on at 05.00h) except where otherwise indicated 
and had ad libitum access to food and water.  The animals were group-housed, four per cage, 
except those subject to surgery, which were single-housed from one day before the surgery 
and during the experiment. The animals subjected to intracranial virus injection were singly 
housed for 5-7 days after the surgery, then regrouped until the surgery for jugular vein 
cannulation as described below. All experimental procedures were approved by the 
University of Bristol Animal Welfare Ethical Review Board and were conducted in accordance 
with the Home Office guidelines and the UK Animals (Scientific Procedures) Act, 1986. 
 
2.2. Drugs  
For the SAFit2 and SAFit1 experiments, the animals were treated via a subcutaneous 
(s.c.) cannula with either:  
Vehicle: 4% EtOH, 5% Tween80 and 5% PEG300 in 0.9% sterile saline, SAFit2: 20mg/kg/ml, or 
SAFit1:  20mg/kg/ml.  
For experiment 4, rats were injected in the intravenous (i.v.) cannula with 150ng CRH (1.5 
μg/ml, Tocris, Bristol, UK) diluted in sterile saline. 
For experiment 5, rats were injected in the i.v. with 40 ng ACTH (0.4 μg/ml, Synacthen, ACTH- 
(1–24) fragment; Alliance Pharmaceutical, Chippenham, UK) diluted in sterile saline. 
For experiment 6, sterile saline was mixed with 2-hydroxypropyl-β-cyclodextrin (HBC) or 
CORT-HBC (0.3 mg/kg/ml- Sigma Aldrich, Missouri, USA) and administered as intraperitoneal 




2.3.  Experiments 
The details of the experimental design of each study are outlined in the individual 
chapters. In brief, the following experiments were performed: 
Experiment 1: Effect of acute SAFit2 treatment on CORT ultradian rhythm and stress-induced 
CORT secretion in male rats (chapter 3).  
Experiment 2: Effect of acute SAFit1 treatment on CORT ultradian rhythm and stress-induced 
CORT secretion in male rats (chapter 3).  
Experiment 3: Effect of acute SAFit1 and SAFit2 on basal ACTH concentrations in male rats 
(chapter 3). 
Experiment 4: Effect of acute SAFit1 and SAFit2 on CRH-induced ACTH and CORT secretion in 
male rats (chapter 3). 
Experiment 5: Effect of acute SAFit1 and SAFit2 on ACTH-induced CORT secretion in male rats 
(chapter 3). 
Experiment 6: Effects of SAFit1 and SAFit2 on subcellular localisation and activation of GR and 
MR in the hippocampus and anterior pituitary gland in male rats (chapter 3). 
Experiment 7: Effect of sub-chronic SAFit2 treatment on CORT ultradian rhythm and stress-
induced CORT secretion in male rats (chapter 4).  
Experiment 8: Effect of sub-chronic SAFit1 treatment on CORT ultradian rhythm and stress-
induced CORT secretion in male rats (chapter 4).  
Experiment 9: Effect of acute SAFit2 treatment on CORT ultradian rhythm and stress-induced 
CORT secretion in female rats (chapter 5).  
Experiment 10: Effect of acute SAFit1 treatment on CORT ultradian rhythm and stress-
induced CORT secretion in female rats (chapter 5).  
Experiment 11: Effect of sub-chronic SAFit2 treatment on CORT ultradian rhythm and stress-
induced CORT secretion in female rats (chapter 5).  
Experiment 12: Expression of FKBP, GR, and MR in male and female brain and anterior 




Experiment 13: The effects of AAV-mediated overexpression of FKBP51 in the PVN on CORT 
ultradian rhythms and stress-induced CORT secretion in male rats (chapter 6). 
Experiment 14: Characterisation of FKBP5 mRNA expression in the hypothalamus and 
anterior pituitary gland of Fischer and Lewis male rats (chapter 6).   
 
2.4. Intravenous and subcutaneous cannulation surgery  
Rats were handled individually for approximately 5 minutes per day for 5 days prior to 
surgery. The rats were fitted with a Covance Infusion Harness (Instech Laboratories Inc., 
Plymouth, PA, USA, see fig 2.1) on the day before surgery and were singly housed until the 
end of the experiment. This allowed the rats to acclimatise to the harness and single housing 
conditions. Rats were anaesthetised using isoflurane mixed with oxygen (1L/min): an 
induction chamber was used with 5% isoflurane until the rats were unconscious. 
Subsequently, the rats were moved to the shaving area and placed on a heating pad and kept 
under anaesthesia on 3% isoflurane. The rats were shaved on the ventral side between the 
head and the right front leg (approximately 2.5 x 2.5 cm) and the back between the shoulder 
blades after being wetted with 70% ethanol. A sharp scalpel and an electric shaver were used 
on the head and back, respectively. Once the rats had been shaved, they were moved to the 
surgical area and kept on 2.3-2.7% isoflurane throughout the surgery depending on the 
weight of the animal. During the shaving and surgery, the isoflurane was delivered using a 
fitted mask placed on the nose of the animal.  
Once prepared for surgery the rats were placed on a heating pad covered in a sterile 
surgical drape. They were placed with the ventral side up, then covered in sterile plastic drape 
with a hole over the site of incision for the cannulation surgery. The skin at the site of incision 
was sterilised using chlorhexidine skin solution applied with a sterile cotton ball. Once the 
skin was sterilised, a scalpel was used to make an approx. 1.5 cm incision through the skin on 
top of the right jugular vein, lateral to the midline between the right front leg and the head, 
where the right jugular artery can be seen to pulsate.  
Two tweezers were used to blunt dissect the underlying muscle and connective tissue 




heart. Further, two smaller tweezers were used to isolate the right jugular vein and once 
isolated, a sterilised hairpin was pulled dorsally to the vein to secure it. Two 30 cm pieces of 
sterilised cotton thread were pulled underneath the hairpin and the rostral thread was tied 
around the vein to stop the blood flow from the head towards the site of the incision on the 
vein. The caudal thread was left loosely tied so that once the cannulation had occurred the 
caudal thread could quickly be securely tied around the cannula and the vein to stop any 
potential bleeding.  
A thin ended tweezer was used to slightly lift the vein and small scissors were used to 
cut an approx. 1 mm incision in the vein, close to the rostral part of the hairpin. A pre-made 
cannula was custom cut to each animal, approx. 2.7 to 3.2 cm depending on the size of the 
animal and filled with heparinised isotonic sterile saline by attaching a saline-filled syringe 
connected with 0.5 ESCO tubing (Appleton Woods, Birmingham, UK) and a blunt pin. A small 
amount of saline was used to wet the vein and a thin tweezer was inserted into the incision 
to stretch it open so the tip of the cannula could be inserted. The cannula was then carefully 
inserted until the incision was at the point of the first lug (see fig 2.1.) and the end of the 
cannula was presumably at the opening of the right atrium. The saline-filled syringe was used 
to aspirate and make sure there was blood flushing through the cannula. Once the cannula 
was in place and flushing correctly, the cotton threads were tied and secured by making 3 
knots, then the syringe and tubing were detached, and a bulldog clip was placed at the end 
of the cannula tubing to prevent blood leaking from the vein.  
The next part of the surgery comprised exteriorisation of the cannula and the insertion 
of a subcutaneous cannula for drug administration. A sterile swab was placed on the open 
incision and the animal was moved to a supine position with the dorsal side facing up. The 
shaved area between the shoulder blades was sterilised using chlorhexidine applied with a 
cotton ball. A sterile 19G needle was used to pierce the skin at a point slightly lateral to the 
midline (to the right side of the rat) between the shoulder blades and a blunt needle attached 
to a saline-filled syringe was used to enlarge the hole. The same syringe and needle were used 
to make a narrow pocket directly underneath the skin from the incision between the shoulder 
blades to the incision of the cannulation. The blunt needle was cleared from any tissue and 
the cannula attached to it before passing it back through the small pocket underneath the 




cannula and the cannula was flushed using the flushing syringe. To insert the subcutaneous 
cannula, the 19G needle was used to pierce the skin at a point slightly lateral to the midline 
(to the left side of the rat) between the shoulder blades and a blunt needle attached to a 
saline-filled syringe was used to enlarge the hole. A small metal stick was used to make a 
subcutaneous pocket directly under the skin, long enough to fit the sub-cutaneous part of the 
cannula (8.5 cm – see fig 2.1). The cannula was inserted in the subcutaneous skin pocket and 
secured by a suture through the skin and wrapped between two lugs on the cannula, exterior 
to the skin.  
The animal was put with the dorsal side up and the cannulation incision was sutured, 
and wound powder placed on the sutured incision. The isoflurane was turned down to setting 
1 and finally, the intravenous and sub-cutaneous cannulas were attached to a metal stick and 
passed through a metal spring attached to the harness. The harness was pulled over the head 
of the rat and the two front legs passed through the side holes of the harness. Lastly, the 
animal was injected with an analgesic solution (Rimadyl, 200µl), the isoflurane was turned off 
and the animal was placed on a heated recovery area and monitored until fully awake. Once 
the animal was fully awake, it was transferred back in his cage and moved to the soundproof 
room where the automated blood sampling system is located. The rats were monitored 
regularly during recovery and kept on heated pads (on a timer: one hour on, one hour off) 





Figure 2.1. Covance Infusion Harness and cannula used for the jugular vein cannulation. (A) 
The Covance Infusion harness in model CH105 was used to attach the metal spring in which 
the jugular vein cannula was passed through. (B) Schematic of the jugular vein cannula used, 
made from ESCO 0.5 x 0.5 (Appleton Woods, Birmingham, UK), silastic 02 tubing (Appleton 
Woods, Birmingham, UK), and portex 800/100/200 (Smith Medicals, Ashford, UK). (C) 
Schematic of the subcutaneous cannula used for SAFit2 and SAFit1 injections. The 
subcutaneous cannula was made from ESCO 0.5 x 0.5, and portex 800/100/200.  
 
2.5. Adrenalectomy 
In experiment 6, to remove endogenous corticosterone, and ensure that similar levels 
of plasma corticosterone were achieved after intraperitoneal injection of preformed water-
soluble corticosterone 2-hydroxypropyl-β-cyclodextrin (HBC), all rats were bilaterally 
adrenalectomized. The anaesthetized rat was placed ventral side down on a warm pad. The 
area on the mid-dorsum was shaved and chlorhexidine skin solution applied to the area with 
a sterile cotton ball. A midline incision of approximately 2 cm long was made just caudal to 




through the incision and used to bluntly dissect the connective tissue, muscle, and 
peritoneum in both sides at approximately 2 cm below the last rib. Curved forceps were 
inserted through the incision into the peritoneal cavity to help locate each gland, then using 
the same forceps each adrenal gland was manipulated by grasping peri-adrenal fat and 
exteriorized taking good care to not to grasp the gland itself, because tearing of the gland 
may result in leaving functional residual tissue within the abdomen. The skin incision was then 
sutured, and powder applied. After the surgery, rats were subcutaneously injected with a 
solution of glucose in 0.9% saline and with an analgesic solution (Rimadyl, 200 μl). After 
recovery, drinking water was replaced with corticosterone (15 μg/ml) dissolved in 0.1% 
ethanol in 0.9% saline. Twelve hours before the onset of the experiment the rats were given 
0.9% saline solution as drinking water.  
 
2.6. Automated blood sampling 
To allow for frequent, and stress-free blood samples to be collected from the rats, an 
automated blood sampling (ABS) system was used (93, 106, 352). This system has been used 
previously as a reliable blood sampling apparatus (106, 239, 240, 352, 353). The cannula 
collects blood from the rat with the help of a peristaltic pump which drives the collection. The 
blood is collected via the swivel and a 3-way valve to the reservoir (10 cm portex 
800/100/580/100). The 3-way valve is connected to the cannula, the pump line which 
contains the reservoir, and the fraction line. The fraction line collects the 37.7 μl for each 
blood sample from the reservoir and via the fraction line is collected in microtiter tubes in the 
fraction collector (fig 2.2 -2.4.)  
The pump line is made from portex 800/100/200, black/black tube, ESCO 0.5 x 0.5 
mm, and silastic 03 (Smiths Medical Inc, Minneapolis, MN, US). The fraction line is made from 
portex 800/100/100, fraction head tubing, silastic 01, ESCO 0.5 x 0.5 mm (Smiths Medical Inc, 
Minneapolis, MN, US), and the needle used is a 22G or 23G blunt needle. The cannula 
implanted in the rat is described above.  
The ABS was programmed to collect blood samples every 10 minutes for 25 hours 
starting at 07.00h. Each blood sample contained 37.7 μl blood and was diluted in a ratio of 





Figure 2.2. Overview of the automated blood sampling system (ABS). The ABS allows for 
frequent blood sampling and is controlled remotely to avoid interference with the animals. 





Figure 2.3. Specifications for the pump line. The reservoir holds a larger amount of the blood 
for the collection of the exact 37.7 μl via the fraction line by switching the 3-way valve. The 








Figure 2.4. Specifications for the fraction head. The blood is collected via the cannula to a 
reservoir connected to a 3-way valve. To collect the blood samples in the microtiter tubes, the 
fraction line collects blood from the reservoir and deposit in the tubes via the 22G or 23G 
needle attached to the fraction head. The fraction head moves along two axes to allow for the 
precise deposit of the blood in the correct tubes.  
 
2.7. Manual blood sampling  
From each rat, blood samples were taken by hand using a cannula implanted in the 
right jugular vein (see surgery section 2.4). The blood samples were taken using a blunt needle 
attached to a 1 ml syringe. A flushing syringe comprising a 30cm ESCO 0.5 x 0. 5mm tubing 
attached to a blunt needle and 1 ml syringe was used before the blood sample to aspirate 
blood through the cannula. Approximately 200 μl blood was taken from each rat at each time 
point and to maintain blood volume, each blood sample was replaced by 200 μl of heparinised 
saline. The blood was deposited in a 1.5 ml Eppendorf tube, containing 10 μl EDTA to prevent 




at 4°C at 4000 rpm for 15 minutes to separate the plasma. The plasma was aliquoted in two 
tubes; one for CORT measurements (~10 μl) and one for ACTH measurements (~110 μl), then 
snap-frozen on dry ice, and stored at -80°C until processing for ACTH and CORT 
measurements.  
 
2.8. Corticosterone measurement 
The CORT concentrations in unextracted blood or plasma samples were measured by 
radioimmunoassay (RIA). A specific rabbit polyclonal anti-corticosterone antibody developed 
by Professor Gabor Makara (Institute of Experimental Medicine, Budapest, Hungary)(354), 
and kindly donated to us by Dr D’ora Zelena (Institute of Experimental Medicine, Budapest, 
Hungary) was used at the final dilution of 1:40000. I125–labelled corticosterone was used as a 
tracer (Institute of Isotopes, Budapest, Hungary) and dissolved in 1 ml of distilled water and 
then further diluted in a citrate buffer (14.6 g trisodium citrate, Sigma-Aldrich; 13.8 g sodium 
dihydrogen orthophosphate, Sigma-Aldrich; 2 g bovine serum albumin (BSA), Sigma-Aldrich; 
2 l purified water; hydrochloric acid to pH 3.0) to achieve an activity of 3500-4000 CPM in 50 
µl of tracer solution. To measure CORT in blood samples obtained from male rats using the 
ABS, 50 µl of the blood-heparin saline mix was further diluted in 50 µl of citrate buffer. The 
use of a low pH citrate buffer allows denaturation of plasma corticosteroid-binding globulin 
(CBG), which can interfere with the assay. Dilution of samples obtained from female rats was 
20 µl blood in 80 µl citrate buffer to avoid female CORT levels to fall outside the corticosterone 
standard curve range (0.1-100 ng/ml). For the hand samples, 5 µl of plasma was diluted in 495 
µl citrate buffer and processed in triplicates. The samples were incubated with 50µl of 
corticosterone tracer and 50 µl antibody at 4°C overnight. The following day 500 µl charcoal-
dextran was added to each sample, the samples were mixed thoroughly and immediately 
centrifuged (4000 RPM, 4°C for 15 min). The precipitant solution allows the I125-corticosterone 
that did not bind to the antibody to be captured and precipitate. The liquid phase from each 
sample was then aspirated using a fixed water pump and each tube containing the charcoal 
pellet was loaded and counted using a Wizard II Gamma Counter (Perkin Elmer, MA, US). The 
quality of the CORT RIA was verified by using internal controls of known CORT concentration 




“totals” (i.e. tracer only) and “blanks” (i.e. tracer and charcoal). A standard curve (figure 2.5) 
was used to calculate the CORT concentrations in the samples. The intra- and inter-assay 
coefficients of variation of the corticosterone RIA were 14.1% and 15.3 %, respectively. The 
lowest detectable limit was 0.1 ng/ml.   
 
 
Figure 2.5. CORT RIA standard curve. A representative of the standard curve from one of the 
CORT radioimmunoassay performed as previously described.  The CORT concentrations 
(ng/ml) for each standard are plotted against the corrected CPM (%). Each standard 
comprised of three replicates.  
 
2.9. ACTH measurement 
For the ACTH measurement, the 0.2 ml blood samples from the hand sampling 
procedures were collected in ice-cold tubes containing 10 μl EDTA (0.5 M; pH 7.4) and 10 μl 
aprotinin (500,000 KIU/ml, Trasylol; Bayer, Newbury, UK). The tubes were immediately 
centrifuged (4000 RPM, 4°C for 15 min) to separate the plasma, and the plasma was stored at 




using ImmuChem Double Antibody 125I RIA Kit (MP Biomedicals, Orangeburg, NY, USA) in 
accordance with the manufacturer’s protocol.   One measurement per sample was used due 
to the low volume of blood obtained from the sampling.  
The samples were incubated with 100 µl of ACTH 125I tracer and 100 µl antibody at 
4°C overnight. The following day 500 µl precipitate solution was added to each sample, the 
samples were mixed through and immediately centrifuged (4000 RPM, 4°C for 15 min). The 
liquid phase from each sample was aspirated using a fixed water pump and each tube 
containing the precipitated pellet was loaded and counted using a Wizard II Gamma Counter 
(Perkin Elmer, Waltham, MA, US). The quality of the ACTH RIA was verified by using two 
internal controls of known ACTH concentration (which varies between ACTH kits). The 
concentrations of the samples were calculated using a standard curve (figure 2.6). The intra- 
and inter-assay coefficients of variation of the ACTH RIA were 6.8% and 10.7 %, respectively. 










Figure 2.6. ACTH RIA standard curve. A representative of the standard curve from one of the 
ACTH radioimmunoassay performed using the ImmuChem Double Antibody 125I RIA Kit (MP 
Biomedicals, Orangeburg, NY, USA) as previously described.  Three replicates were used for 
each standard and the ACTH concentrations (pg/ml) are plotted against the corrected CPM 
(%).  
 
2.10. Tissue collection  
At the end of experiments 1, 2, 6-12 and 14, the brain and pituitary gland tissue was 
collected for examination of the effects of SAFit1 and SAFit2 on the expression of genes of 
interest. Rats were rapidly euthanized with either isoflurane (less than 15 seconds exposure; 
experiment 6 and 12 only) or pentobarbitone (all other experiments; 0.2 ml, I.V., Merial, UK) 
followed by decapitation with a guillotine. After decapitation, the skull was opened using 
scissors, the brain excised and the hypothalamus, prefrontal cortex, and hippocampus 
dissected out. The pituitary gland was excised, and the intermediate and posterior lobe 
removed. All areas were snap-frozen on dry ice and stored at -80°C until processed for real-




Work from our group and others has shown that this technique used for euthanising 
rats does not induce an increase in ACTH or CORT secretion (133, 355). 
 
2.10.1. Anatomical boundaries for brain dissection 
Prefrontal cortex: the brain was placed with the ventral side facing the metal plate and 
using a sharp razor blade the olfactory bulb was removed and an approximately 5 mm thick 
slice containing the prefrontal cortex was cut (figure 2.7). 
Hypothalamus: the brain was placed with the ventral side facing up and using curved 
fine forceps the area between the optic nerve chiasm and the mamillary body was dissected 
(figure 2.7). 
Hippocampus: the brain was placed with the ventral side facing the metal plate and 
using a sharp razor blade the two cerebral hemispheres were separated. From each 
hemisphere, the cortex was lifted to expose the hippocampus that was gently rolled out using 
curved forceps (figure 2.7). 
Anterior pituitary gland: after collection, the pituitary gland was placed with the 
posterior lobe facing up and using a sharp blade the two lobes at each side of the intermediate 





Figure 2.7. Anatomical boundaries for brain dissection. Representative images of the 
dissection of the prefrontal cortex, hypothalamus, hippocampus, and the anterior pituitary 
gland from the rat.  
 
2.11. RNA extraction and Reverse Transcript 
TRIzol (Invitrogen, Hopkinton, MA, USA) was used to isolate RNA from the 
hippocampus (experiment 12 only), the pre-frontal cortex (experiment 12 only), 
hypothalamus and anterior pituitary gland. RNA purification and removal of genomic DNA 
were performed using RNeasy mini kit reagents and column DNase digestion (Qiagen 
Valencia, CA, USA) respectively, as described by the manufacturer.  
The RNA concentration and quality were measured using a NanoDrop Microvolume 




obtained by reverse transcription with Cloned AMV First-Strand cDNA synthesis kit 
(Invitrogen, Hopkinton, MA, USA) from 1 µg of total RNA. For each sample, 1µg of RNA was 
diluted in 11 µl RNase-free water and 1µl deoxynucleotide triphosphate (dNTP) mix, and 1 µl 
random primers (both provided by Invitrogen), and the samples were mixed for 5 seconds. 
The samples were centrifuged briefly and incubated for 5 minutes at 65°C using a PCR system 
9700 Fast Thermal Cycler (GeneAmp, Thermo Fischer Scientific). Following the incubation, 4µl 
of provided 5x buffer, 1 µl 0.1M dithiothreitol (DTT), 1 µl RNase OUT, and 1 µl Cloned RT was 
added to each sample. The samples were vortexed and centrifuged briefly and then incubated 
for 10 minutes at 25°C, 50 minutes at 50°C, and 15 minutes at 70°C in the same PCR thermal 
cycler.  
Genomic DNA contamination was assessed in 1 to 3 samples/reaction set by omitting 
the reverse transcriptase enzyme from the reaction mix.  The absence of amplification 
products was then verified by RT-qPCR as described below, indicating the absence of genomic 
DNA contamination. 
 
2.12. Real-Time qPCR 
In each experiment a 1:10 dilution of stock cDNA was made to achieve a working 
concentration of cDNA of 1 ng/μl; 2 μl per sample of cDNA was used in duplicates. Fast SYBR 
Green Master Mix (Applied Biosystems, Foster City, CA, USA) and forward and reverse primers 
at a final concentration of 200 nm were added to the amplification mixture to make up the 
final reaction volume of 25 μl. A spectrofluorometric thermal cycler (7500 Real-Time PCR 
System; Applied Biosystems) was used to perform the PCR reactions, comprising an initial 
cycle at 50°C for 2 minutes, 95°C for 10 minutes and subsequently 40 to 45 cycles at 95°C for 
20 seconds, and 60°C for 1 minute. Primers were designed using Primer Blast (NIH, US 
National Library of Medicine) to span across exon-exon to amplify specifically cDNA 
corresponding to the mRNA of target genes (table 2.1). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA expression was determined and used as the house-keeping 
gene to normalise all target gene expression levels. Glyceraldehyde 3-phosphate was used 





Table 2.1. List of primers used for RT-qPCR 
Gene Forward primer Reverse primer 
AVP TGCCTGCTACTTCCAGAACTGC AGGGGAGACACTGTCTCAGCTC 
cFos AGCATGGGCTCCCCTGTCA GAGACCAGAGTGGGCTGCA 
CRH  CTCTCTGGATCTCACCTTCCAC CTAAATGCAGAATCGTTTTGGC 
FKBP5 GAACCCAATGCTGAGCTTATG ATGTACTTGCCTCCCTTGAAG 
GAPDH  CCATCACTGCCACCCAGAAGA GACACATTGGGGGTAGGAACA 
GILZ CCATGGATCTAGTGAAGAATCATTTG CCACCTCCTCTCTCACAGCATAC 
GR CACAGCTCACCCCTACCTTG TTTCTGAAGCCTGGTATCGCC 
MR CAAGGACCATCGGTGAACT TTGGTCCTCGAGAGGCAAGT 
PER1 CCTCGATGTAACGGCTTGTGT GTCCGAGTGGCCAGGATCT 
POMC AGAGCTGGCTTTCCGCGACA GGGCCCCTGAGCGACTGTAG 
SGK1 CGTACGACCGGACAGTGGA GATATTTGGTTTCAGCTGGAGAGG 
 
2.13. Subcellular fractionation 
Cytoplasmic, membrane, nuclear and chromatin extracts were obtained using an 
extraction kit (Subcellular Protein Fractionation Kit, Thermo Fisher Scientific Inc., Rockford, IL, 
USA) according to the manufacturer's protocol. Thermo Scientific™ Halt™ Protease Inhibitor 
Cocktail was added at 1:100 dilution to the Cytoplasmic extraction buffer (CEB), membrane 
extraction buffer (MEB), and nuclear extraction buffer (NEB), and the buffers were kept on 
ice. Each extraction buffer contains detergents to extract the proteins sequentially (figure 
2.8.).  
The hippocampus and anterior pituitary gland were homogenised in 1000 µl 
(hippocampus) or 200 µl (anterior pituitary gland) CEB using a Dounce homogeniser and were 
vortexed for 5 seconds and then centrifuged (3000 RCF for 5 minutes). The supernatant 
(soluble cytoplasmic extract) was transferred to a fresh, pre-chilled tube. Further, 650 µl 
(hippocampus) and 100 µl (anterior pituitary gland) MEB was added to the pellet and the 
tubes were vortexed and then incubated for 10 minutes on ice with occasional mixing, before 
being centrifuged (3000 RCF for 5 minutes). The supernatant (soluble membrane-bound 
extract) was transferred to new pre-chilled tubes. The NEB (225 µl for the hippocampus, 40 
µl for the anterior pituitary gland) was added to the pellet, the tubes vortexed and then 
incubated on ice for 30 minutes with occasional mixing. The tubes were centrifuged (5000 
RCF for 5 minutes) and the supernatant (soluble nuclear extract) transferred to a new, pre-




100 µl of NEB, and 170 µl (hippocampus) and 40 µl (anterior pituitary gland) of CB was added 
to the pellet. The tubes were vortexed for 15 seconds. The tubes were then incubated at room 
temp for 30 mins or in 37°C water bath for 15 mins followed by mixing for 15 seconds and 
centrifuged (16000 RCF for 5 minutes), and the supernatant was collected (soluble chromatin-
bound extract).  
 
 
Figure 2.8. Schematic of the subcellular fractionation protocol. Extracted using differential 
detergents. CEB = cytoplasmic extraction buffer; MEB = membrane extraction buffer; NEB = 
nuclear extraction buffer; NEB + MNase = nuclear extraction buffer plus micrococcal nuclease 
(chromatin-bound fraction).  
 
The protein concentrations for all extracts were measured by spectrophotometry by 
using a bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA). The cytoplasmic fractions 
(and the nuclear fractions for hippocampus) were measured in a 1:10 dilution with 
cytoplasmic extract, and the membrane, nuclear, and chromatin fractions were measured in 
a 1:2 dilution in the respective extract. Following dilution, each sample was loaded in 
duplicates on a 96-well plate.  Standards with known concentrations of 0.05 to 1.0 mg/ml 
were loaded in duplicates to create a standard curve. The BCA mixture was prepared by 
mixing Protein buffer B with Protein buffer A in a 1:50 dilution, and 200 µl was added to each 
well, containing the samples of unknown concentrations and the standards. The plate was 
covered with aluminium foil and incubates at 37°C for approximately 40 minutes. An iMARK 







2.14. Western immunoblotting 
Samples from each region were run on a 4-15% Tris-glycine gel (Bio-Rad, Hercules, CA, 
US). Sodium dodecyl sulphate (SDS) buffer was used to make the final protein concentration 
of either 1 μg/μl (for the anterior pituitary gland) or 2 μg/μl (for the hippocampus). 10 μl of 
each sample was loaded and run on premade gels (BioRad) for approximately 1 hour on 35mA 
(2 gels), or 70 mA (4 gels). The samples were then transferred onto a polyvinylidene fluoride 
(PVDF) membrane (GE Amersham Biosciences, Piscataway, NJ, US) for 90 minutes at 250 mA.  
The transferred membranes were then blocked using 1% BSA (Sigma) or 5% milk in 1x 
Tris buffer saline with 0.05% Tween 20 (TBST). Membranes were then probed overnight with 
primary antibodies (table 2.2), washed with TBST and then probed with secondary antibody 
(anti-rabbit or anti-mouse, all at 1:10000 dilution) for 1 h at room temperature. After further 
washes in TBST, Luminata Forte Western HRP Substrate (Millipore Corporation, Billerica, MA, 
US) was used for chemiluminescence and developed using G-Box (Syngene Int. Ltd., 
Bangalore, India). 
The proteins were quantified using ImageJ to determine the relative optical density of 
each band for the protein of interest, which was then normalised to the background optical 













Table 2.2. Primary and secondary antibodies for Western immunoblotting.  The primary and 
secondary antibody dilutions were made in TBST and incubated overnight at 4°C.  
 








1:1000 in 0.1% milk Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA 
Rabbit anti-
pGR 




1:1000 in 1% BSA Cell Signaling Technology, Inc., Danvers, 
MA, USA 
Rabbit anti-H1 1:1000 in 1% BSA Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA 
Rabbit anti-
GAPDH 
1:1000 in TBST Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA 
Rabbit anti-
Pan-cadherin 




1:1000 in 5% milk Santa Cruz Biotechnology, Inc., Santa 






1:10 000 in 1% BSA or 5% milk Santa Cruz Biotechnology, Inc., Santa 






1:10 000 in 1% BSA or 5% milk Santa Cruz Biotechnology, Inc., Santa 







2.15. PULSAR analysis 
The PULSAR algorithm (356) was used for comparison of pulse parameters from the 
ABS experiments. The PULSAR algorithm is based on the parameters of the specific hormone 
measured (e.g. plasma half-life), detail of the measurement assay (minimum detectable 
concentration) the performance of the hormone assay, and detail of the experimental design 
(e.g. frequency of sampling, duration of the experiment, number of samples). The 
measurement assay performance (i.e. the standard deviation, SD) is calculated for the assay 
used and the estimated SD-values can then be fitted to a quadratic regression curve from 
which the parameters A, B, and C can be calculated. For example, if the B=10, and the A=0, 
and B=0, this tells us that the coefficient of variation (CV) is 10%. These parameters must be 
calculated for each specific assay performed. I used the triplicates of the CORT RIA standards 
to calculate the SD for the respective standard concentrating. A curve was fitted to the values 
to obtain the A, B, and C values which in my setting were: A=0.035, B=2.63, C=6.15 (figure 
2.9.). When the hormone data are analysed using PULSAR, a baseline is calculated to which 
the pulsatile data is compared. If a single time point has a higher value (in SD-units) than the 
G1 value, then that time point is considered a peak (pulse). Two adjoining time points which 
both have higher values than the G2 value are considered a peak, and so on.  
The following G-values were employed: G1=5, G2=3, G3=2, G4=1.5, and G5=0.8 together 
with a peak splitting parameter of 3 (S.D. units). The splitting parameter indicates how many 
SD units a trough must consist of in order to split a peak into two. These values were obtained 








Figure 2.9. Generation of A, B, and C parameters for the PULSAR algorithm. The mean SD 
values from CORT RIA standard triplicates for respective concentrations. A curve was fitted to 
the values and used to calculate the A, B, and C values for PULSAR.  
 
The PULSAR algorithm can quantify the following parameters: mean CORT (the 
average concentrations of CORT during the 24-hours measurements), maximum CORT (the 
highest concentrations of CORT during the 24-hours measurements, baseline CORT (the 
average concentrations of CORT at the troughs of each pulse during the 24-hours 
measurements), number of pulses, pulse amplitude, pulse height, pulse length, pulse area, 
inter-pulse interval (IPI), area under the curve (AUC) basal, and AUC total. Some of them are 
explained below (figure 2.10.). The AUC basal is the area under the curve calculated from the 
baseline, whereas the AUC total is the total area under the curve. Finally, to quantify the 





Figure 2.10. The parameters quantified by PULSAR algorithm. The baseline is an estimated 
line that should go along the base of each pulse. 
 
2.16. Statistics 
All statistical analyses were performed using SPSS version 11.5 for Windows (SPSS Inc., 
12 Chicago, IL). Differences between groups were analysed by Tukey’s post hoc test, or 
Fisher’s least significant difference (LSD) post hoc test (experiment 4 and 5 only). Statistical 














Chapter 3: Acute treatment with FKBP51 inhibitors in male rats 
 
3.1. Introduction 
In this chapter data on the effects of acute SAFit1 and SAFit2 treatment on the HPA 
axis activity in male rats will be presented. As explained in the introduction, SAFit1 and SAFit2 
are FKBP51 inhibitors that differ in a few aspects. Firstly, SAFit1 does not penetrate the blood-
brain barrier (BBB), hence it is only peripherally active; furthermore, it has a shorter half-life 
compared to SAFit2 (SAFit1 half-life: 2.5 hours, SAFit2 half-life: 9.7 hours). These differences 
might, therefore, contribute to differential effects between the two compounds. By inhibiting 
FKBP51 it would be expected to observe an increase in GR translocation into the nucleus, and 
subsequent increase or decrease in GR-regulated gene transcription, depending on whether 
GR activity is enhancing or inhibiting gene transcription (e.g. if GR bind to a GRE or an nGRE). 
The GR is involved in fast negative feedback, both in the brain and the pituitary gland (148). 
Therefore, the effects of acute treatment with SAFit1 and SAFit2 on basal CORT secretion 
were investigated. The hypothesis is that FKBP51 inhibition will enhance GR binding to the 
nGRE in the POMC gene in corticotrophs of the anterior pituitary gland or bind to CREB in CRH 
producing cells of the PVN, resulting in reduced transcription of the POMC and the CRH genes, 
and subsequently reduced CORT plasma levels. Many studies have demonstrated central 
regulation of the stress-induced CORT negative feedback, however, the stress response is also 
regulated by fast negative feedback occurring at the level of the pituitary gland (357). 
Therefore, whether inhibition of FKBP51 had any effect on stress-induced CORT secretion and 
whether these effects were different following treatment with SAFit1 or SAFit2 were also 
investigated. 
Previous studies using male FKBP51 knockout mice (51KO) revealed no major 
differences in basal behaviour or neuroendocrine effects compared to wild-type littermates, 
although a dampened stress response was seen in the 51KO mice (358). This led to the 
interest in characterizing the effects of SAFit2 in male rats. Further, the effects of the 
peripheral-only FKBP51 inhibitor SAFit1 have not been characterised in mice nor rats and 
rendered a novel opportunity to investigate the effects of SAFit1. Although previous studies 




rhythmicity of CORT secretion, rats were used in the studies presented in this thesis. The rat 
is larger and therefore frequent blood sampling can be performed to obtain basal, 24-h CORT 
profiles in unstressed freely moving rats.  Moreover, manual sampling procedure can be done 
in the rat to obtain larger volumes of blood (~ 200 µl) without the stress of the handling 
procedure, to allow for measurement of ACTH concentrations.  
 
3.2. Methods and experimental design  
In all the studies reported in this chapter, except for experiment 6, male Sprague-
Dawley rats were subject to the jugular vein and subcutaneous cannulation (see section 2.4 
in the methods) and allowed to recover for at least 5 days before the start of the experiment, 
unless stated otherwise. 
 
3.2.1.  Experiments 1 and 2: Effect of acute SAFit2 and SAFit1 treatment on CORT ultradian 
rhythm and stress-induced CORT secretion in male rats  
These experiments aimed to assess the potential changes in basal CORT 
concentrations over 24 hours following acute SAFit2 or SAFit1 treatment. The hormone data 
obtained were analysed using the PULSAR algorithm (see section 2.15) to determine any 
changes in ultradian pulsatility. A further aim was to investigate the effects of SAFit2 and 
SAFit1 on stress-induced CORT secretion, which was done by exposing the rats to noise stress 
during the ABS.  
For SAFit2 experiments rats were treated with either vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in 0.09% sterile saline; 2 ml/kg; s.c. n=8) or SAFit2 (20 mg/kg; s.c.; n=6) 
at 09.00h and 17.00h on the day of blood sampling. For SAFit1 experiments, rats were treated 
with either vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in 0.09% saline; 2 ml/kg; s.c. 
n=7) or SAFit1 (20 mg/kg; s.c.; n=6) at 09.00h, 14.00h and 19.00h on the day of blood 
sampling. Note that this experiment protocol differed from the SAFit2 experiment only in the 
times for the administration of the SAFit compounds, due to a shorter half-life of SAFit1 this 




For both SAFit1 and SAFit2 experiments, automated-blood sampling (six samples per 
hour) for measurement of basal CORT was conducted from 07.00h on day 1, until 07.00h the 
following day. At 07.00h of day 2, all rats were subject to noise stress (10 min, 96dB, white 
noise) and blood sampling collection continued for one more hour. Immediately after the 
sampling had stopped at 08.00h, the rats were euthanized using pentobarbitone injection in 
the i.v. cannula, followed by decapitation with a guillotine. The brains were dissected to 
isolate specific areas, and, along with the anterior pituitary gland and adrenal glands, were 




Figure 3.1. Experimental schedule for the acute SAFit2 and SAFit1 treatment in male rats.   
 
3.2.2. Experiment 3: Effect of acute SAFit1 and SAFit2 on basal ACTH concentration in male 
rats  
To determine whether the potential effect of SAFit2 and SAFit1 on CORT 
concentrations was reflected in the ACTH concentrations, this experiment aimed to 
investigate the effect of SAFit2 and SAFit1 on basal ACTH concentrations by manual sampling 




In this experiment, the rats were used as both the control group and the treated 
group. This was achieved by administering the vehicle to all rats on day 1 and administering 
either SAFit2 or SAFit1 to the rats on day 2. On day 1 of the experiment rats were treated with 
the vehicle at 09.00h and 14.00h (SAFit1 experiment, n=7), or 09.00h and 17.00h (SAFit2 
experiment, n=7) and blood samples were taken manually from the jugular vein cannula at 
09.00h, 11.00h, 13.00h, 15.00h, 17.00h and 19.00h. On day 2 of the experiment vehicle-
treated rats were treated with SAFit1 at 09.00h and 14.00h, or with SAFit2 at 09.00h and 
17.00h and blood samples were taken at the same time points as on day 1. From each sample, 
plasma was separated, and ACTH concentration was measured by RIA (see section 2.9).  
 
3.2.3. Experiment 4: Effect of acute SAFit1 and SAFit2 on CRH-induced ACTH and CORT 
secretion in male rats  
To investigate whether SAFit2 and SAFit1 exert any effects on ACTH the aim was to 
stimulate the anterior pituitary gland with CRH and measure the ACTH and CORT 
concentrations. This would allow me to demonstrate whether SAFit2 and SAFit1 have direct 
effects on the anterior pituitary gland.   
This study was conducted using three groups, vehicle, SAFit1, and SAFit2. All three 
groups were acutely treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in 
0.09% saline; 2 ml/kg; s.c.; n=5), SAFit1 (20 mg/kg/2 ml, n=4 ) or SAFit2 (20 mg/kg/2 ml, n=5 ) 
the day prior to the experiment. The SAFit1 was administered at 09.00h, 14.00h and 19.00h, 
and the SAFit2 was administered at 09.00h and 17.00h. To control for the difference in timing 
of the SAFit1 and SAFit2 treatments, vehicle was administered either at 09.00h, 14.00h and 
19.00h or 09.00h and 17.00h; however, as further hormone measurements revealed that 
there was no effect of the timing of the vehicle treatment, the data were combined and used 
as one vehicle group. The CRH (150 ng/rat in 100 µl saline, i.v.) was injected via the cannula 
implanted in the jugular vein at 07.00h on the day of the experiment. Blood samples were 
collected manually from the implanted jugular vein cannula before CRH injection (0), and at 
1, 5, 15, 30, and 60 minutes after the CRH injection. From each blood sample, plasma was 
separated and stored at -80°C. ACTH and CORT concentrations were measured by RIA (see 




3.2.4. Experiment 5: Effect of acute SAFit1 and SAFit2 on ACTH-induced CORT secretion in 
male rats  
To investigate whether SAFit2 and SAFit1 exert any effects on the adrenal glands, the aim was 
to stimulate the adrenal glands with ACTH and measure plasma CORT concentrations, to 
demonstrate whether the SAFit2 and SAFit1 have direct effects on the adrenal glands.  
Three experimental groups were acutely treated with either vehicle (VEH: 4% Ethanol; 
5% PEG300; 5% Tween 80 in 0.09% saline; 2 ml/kg; s.c.; n=4), SAFit1 (2 mg/kg, s.c., at 09.00h, 
14.00h and 19.00h, n=3), or SAFit2 (2 mg/kg, s.c., at 09.00h and 17.00h, n=5) the day prior to 
the experiment (day 1). At 07.00h on day 2, ACTH was injected in the intravenous cannula (40 
ng per rat) and blood samples were collected manually from the implanted jugular vein 
cannula before ACTH injection (basal) and at 5, 15, 30, 45, and 60 minutes following ACTH 
injection. From each blood sample, plasma was separated and stored at -80.  ACTH 
concentration was measured by RIA (see section 2.9).  
 
3.2.5. Experiment 6: Effects of SAFit1 and SAFit2 on subcellular localisation and activation 
of GR and MR in the hippocampus and the anterior pituitary gland in male rats  
Rats were injected subcutaneously with either SAFit1 (20 mg/kg/ml), SAFit2 (20 
mg/kg/ml), or vehicle (4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg).  After 60 
minutes rats were injected with either vehicle (HBC in saline, 0.3 ml, i.p.) or CORT (0.3 
mg/kg/ml HBC-CORT, i.p.) so that the experimental groups were the following: vehicle-HBC, 
vehicle-CORT-, SAFit1-CORT, and SAFit2-CORT. 30 minutes after CORT injection animals were 
sacrificed with isoflurane and their brains and pituitaries dissected. The hypothalamus, 
hippocampus, and anterior pituitary gland were processed using a kit for subcellular 
fractionations (Subcellular Protein Fractionation Kit, Thermo Fisher Scientific Inc., Rockford, 
IL, USA) to separate the tissue into the cytoplasmic, membrane, nuclear, and chromatin-
bound extract (see section 2.13 in general methods). Western immunoblotting was used to 
quantify the GR and MR in each cellular extract from the different experimental groups. 
Phosphorylated GR (pGR) was quantified to investigate the effect of SAFit1 and SAFit2 on the 




The 30 minutes post-CORT time point and the CORT dose used here (0.3mg/kg) is 
based on a previous study (359) which showed enhanced nuclear level GR in the 
hippocampus, hypothalamus and the anterior pituitary gland following the CORT injection. 
More importantly, 0.3mg/kg does not elicit a maximum translocation as demonstrated by 
further significant enhancement of nuclear GR following administration of 1mg/kg CORT 
(353). This is noteworthy as in this experiment the aim was to be able to see any increase in 
receptor translocation following SAFit2 and SAFit1 treatment and therefore it was important 
that the translocation in the vehicle -CORT group was not the maximum capacity.  
 
3.3. Results  
3.3.1. The effect of acute SAFit2 treatment on basal CORT concentrations and ultradian 
rhythms in adult male rats  
Eight vehicle-treated rats and six SAFit2-treated rats were subjected to ABS every 10 
minutes for 24 hours. The blood samples were assayed for CORT concentrations and the mean 
was calculated for each time point for both groups. The resultant average 24-h profiles are 
















Figure 3.2. The effect of acute SAFit2 treatment on ultradian CORT secretion in male rats. 
Mean + SEM (A) CORT concentrations, and representative individual profiles (B-E) from male 
adult rats treated with vehicle (B, C; VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 
ml/kg; s.c.; n=8) or SAFit2 (D, E; 20 mg/kg, s.c.; n=6) at 09.00h, and 17.00h. Blood samples 
were collected via a cannula implanted in the right jugular vein every 10 min for 24 hours using 
an automated blood sampling system. Plasma corticosterone was measured by 




  To allow for quantitative comparison of numerous parameters of CORT secretion, the 
PULSAR algorithm (see section 2.15) was used to analyse each corticosterone profile through 
the full 24-h period (figure 3.3). The PULSAR analysis and subsequent unpaired t-test revealed 
a significantly lower concentrations of maximum CORT in SAFit2-treated rats compared to 
vehicle-treated rats (t(12)=2.21, P=0.047). There was no significant effect of SAFit2 treatment 
compared to vehicle-treated rats on mean CORT (t(12)=1.64, P=0.127), baseline CORT 
(t(12)=1.23, P=0.240), number of pulses (t(12)=-0.19, P=0.852), pulse amplitude (t(12)=1.52, 
P=0.154), pulse height (t(12)=1.52, P=0.154), pulse length (t(12)=0.29, P=0.777), pulse area 
(t(12)=1.49, P=0.161), IPI (t(12)=1.69, P=0.984), pulse frequency (t(12)=-0.19, P=0.852), AUC 











Figure 3.3. The effect of acute SAFit2 treatment on PULSAR parameters in male rats. Mean 
+ SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated with 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; n=8) or SAFit2 (20 
mg/kg, s.c.; n=6) at 09.00h, and 17.00h. Amp=amplitude, IPI=inter-pulse interval, AUC= area 
under the curve. *P<0.05 compared to vehicle-treated rats, with unpaired t-test.  
 
These data indicate that inhibition of FKBP51 by SAFit2 in the rat decreases only the 
maximum CORT concentrations. This appears to be due to lowered pulse height and 
amplitude and hence reduce pulse area, although these were not significantly decreased in 
the SAFit2-treated rats compared to vehicle-treated rats. There was no effect on the inter-
pulse interval or pulse length, indicating that SAFit2 does not alter the dynamic of each pulse 
of CORT.   
Even though these data show that FKBP51 is involved in the regulation of CORT 
secretion in the rat, SAFit2 is active in the whole body, including the brain and the anterior 




FKBP51 is required to reduce CORT concentrations. Furthermore, this study does not reveal 
at what level of the HPA axis the effects of SAFit2 occur.  
 
3.3.2. The effect of acute SAFit1 treatment on basal CORT concentrations and ultradian 
rhythms in adult male rats  
The same protocol as above was used to perform acute treatment with SAFit1, the 
peripheral-acting FKBP51 inhibitor, to further deduce the role of FKBP51 in regulating HPA 
axis activity, and to investigate if peripheral inhibition is sufficient to decrease basal CORT 
concentrations. The pituitary-adrenal gland pulse generator hypothesis (131, 132) described 
in section 1.4.4 of the introduction suggests that interactions between the adrenal gland and 
pituitary gland represent the main system responsible for maintaining the pulsatile pattern 
of CORT secretion. If we assume that SAFit1 is in very low concentrations in the brain, and is 
only active in the periphery, FKBP51 inhibition in the pituitary gland and/or the adrenal gland 
could alter the CORT pulsatility pattern.   
Using the ABS, blood samples were collected every 10 min for 24h from 7 vehicle- and 
6 SAFit1-treated male rats and the samples were assayed for CORT concentrations. Individual 
profiles from each experimental group are reported in figure 3.4 (B-E). The mean CORT 
concentration at each time point was calculated for both groups to produce a mean 24-h 








Figure 3.4. The effect of acute SAFit1 treatment on ultradian CORT secretion in male rats.  
Mean + SEM (A) CORT concentrations, and representative individual profiles (B-E) from male 
adult rats treated with vehicle (B, C; VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 
ml/kg; s.c.; n=8) or SAFit1 (D, E; 20 mg/kg, s.c.; n=6) at 09.00h, and 17.00h. Blood samples 
were collected via a cannula implanted in the right jugular vein every 10 min for 24 hours using 
an automated blood sampling system. Plasma corticosterone was measured by 





The PULSAR analysis and subsequent unpaired t-test of the 24-h  CORT profiles (figure 
3.5) revealed no effect of SAFit1 treatment compared to vehicle treatment on mean CORT 
(t(11)=-1.35, P=0.202), maximum CORT (t(11)=-0.42, P=0.684), baseline CORT (t(11)=-0.77, 
P=0.452), number of pulses (t(11)=-0.03, P=0.974), pulse amplitude (t(11)=-1.45, P=0.173), 
pulse height (t(11)=-1.36, P=0.201), pulse length (t(11)=0.59 P=0.565), pulse area (t(11)=-0.51, 
P=0.616), IPI (t(11)=0.48, P=0.637), pulse frequency (t(11)=-0.03, P=0.974), AUC basal (t(11)=-
1.37, P=0.197),  or AUC total (t(11)=-1.25, P=0.236).  
 
 
Figure 3.5. The effect of acute SAFit1 treatment on PULSAR parameters in male rats. Mean 
+ SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated with 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit1 (20 
mg/kg, s.c.; n=6) at 09.00h, and 17.00h. Amp=amplitude, IPI=inter-pulse interval, AUC= area 





These data indicate that acute SAFit1 treatment does not affect CORT secretion under 
basal conditions, suggesting that peripheral-only inhibition of FKBP51 is not sufficient to 
generate the effects seen in the acute SAFit2 experiments. It is noteworthy that the shorter 
half-life of SAFit1 might contribute to the lack of effect, although the treatment protocol was 
adjusted to avoid complete clearance of SAFit1. Nevertheless, central inhibition of the FKBP51 
is likely required for a reduction in basal CORT concentrations in male rats.  
 
3.3.3. The effect of acute SAFit2 or SAFit1 treatment on stress-induced CORT secretion in 
adult male rats  
Previous studies using the SAFit2 in male mice showed decreased CORT 
concentrations following a stressor whilst there were no effects on basal CORT (340). In the 
above study, significantly lower maximum CORT secretion was observed in the SAFit2-treated 
male rats, suggesting that there might be an effect on the stress response as well. 
Furthermore, another aim was to deduce whether SAFit1 would influence post-stress CORT 
secretion, considering that this compound is not centrally active. There is evidence for rapid 
pituitary gland negative feedback induced by GCs, however, it is generally accepted that the 
stress-induced negative feedback mechanism is mainly centrally regulated. For this 
experiment, the rats were all subject to a noise stressor, as this test has been used previously 
in our group and previous studies have shown it induces a robust but transient increase in 
CORT secretion in both male and female rats (239, 240). Furthermore, exposure to noise 
stress can be performed remotely (see general methods section 2.6.), hence without inducing 
further stress due to handling the rats. 
Following 24-h blood sampling and treatment with SAFit2 or SAFit1, the rats were 
subjected to noise stress and blood sampling continued for 60 minutes following the noise 
stress (see schematic figure 3.1).  
The mean CORT concentration at each time point was calculated for each group as 
shown in figure 3.6. In the SAFit2 experiment, repeated measure analysis showed an overall 
significant effect of time (F(2.9, 34.2)=90.9, P<0.0001), a significant interaction of time and 
treatment (F(2.9, 34.2)=90.9, P=0.033), and a significant effect of treatment (F(1,12)=7.7, 




vehicle-treated rats at the 10 (P<0.0001), 20 (P<0.0001), 30 (P<0.0001), and 40 (P<0.0001) 
minutes time points, compared to vehicle-treated rats at the 0 minute time point.   In 
comparison, a significant increase in stress-induced CORT in SAFit2-treated rats was observed 
at the 10 (P<0.0001), 20 (P<0.0001), and 30 (P<0.0001) minutes time points, compared to 
SAFit2-treated rats at the 0 minute time point.  Moreover, there was a significant reduction 
in CORT secretion in the SAFit2-treated rats at the 20 minutes time point compared to vehicle-
treated rats at the 20 minutes time point (P=0.01) (figure 3.6. A). There was no difference 
between the baseline CORT at the 0 minute time point between vehicle-treated rats and 
SAFit2-treated rats. 
In the SAFit1 experiment repeated measures analysis showed an overall significant 
effect of time (F(2.3, 23,1)=31.217, P<0.00001), but no significant interaction between time 
and treatment (F(2.3, 23,1)=1.638, P=0.214), and no effects of treatment (F(1,10)=0.009, 
P=0.928). Further, post hoc analysis revealed a significant increase in stress-induced CORT in 
vehicle-treated rats at the 10 (P<0.0001), 20 (P<0.0001), and 30 (P<0.0001) minutes time 
points, compared to vehicle-treated rats at the 0 minute time point.   Similarly, a significant 
increase in stress-induced CORT in SAFit2-treated rats was observed at the 10 (P<0.0001), 20 
(P<0.0001), and 30 (P<0.0001) minutes time points, compared to SAFit1-treated rats at the 0 
minute time point (figure 3.6. B). Further, there was no significant difference between the 
SAFit1-treated rats and the vehicle-treated rats at any of the time points. There was no 
difference between the baseline CORT at the 0 minute time point between vehicle-treated 








Figure 3.6. The effect of acute SAFit2 and SAFit1 treatment on stress-induced CORT secretion 
in male rats. (A) Mean + SEM corticosterone levels during noise stress (96dB, 10 minutes, 
white noise, 07.00h) from male adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 
5% Tween 80 in saline; 2 ml/kg; s.c.; n=8) or SAFit2 (20 mg/kg, s.c.; n=6) at 09.00h, and 17.00h 
on the day prior to the noise stress. (B) Mean + SEM corticosterone levels during a noise stress 
(96dB, 10 minutes, white noise, 07.00h) from male adult rats treated with vehicle (VEH: 4% 
Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=6) 
at 09.00h, 14.00h, and 19.00h on the day prior to the noise stress. Blood samples were taken 
every 10 minutes from a cannula implanted in the right jugular vein and CORT concentrations 
measured with CORT RIA. The grey bar indicates noise stress. *P<0.05; compared to rats 
treated with vehicle, with Tukey’s post hoc test. 
 
These data indicate that there is an overall decrease in stress-induced CORT secretion 
in the SAFit2-treated group, while there was no difference between SAFit1-treated and 
vehicle-treated animals. This suggests that because the SAFit2 can cross the BBB it may 
enhance glucocorticoid-mediated negative feedback to reduce the stress response, in line 
with numerous studies suggesting a central regulation of the fast glucocorticoid negative 
feedback following a stressor.  Even though the half-life of SAFit1 is shorter, any potential 
genomic effects of SAFit1 should still be present at the time of the noise stress, which was 
performed at 07.00h the day following treatment with SAFit1 or vehicle. It is also likely that 




effects, including for example the hippocampus and the amygdala (360) and that this might 
contribute to the different effects from the two SAFit compounds in these experiments. 
Studies have shown that, in addition to the PVN, several other areas are activated following 
audiogenic stress in rodents, these areas include the BNST, the lateral septum, some preoptic 
areas, and the orbitofrontal cortex (361). These areas all project to the PVN and hence may 
regulate HPA axis activity.  
 
3.3.4. The effect of acute SAFit2 and SAFit1 treatment on basal ACTH concentrations in 
adult male rats  
In the previous studies, it was shown that acute administration of SAFit2 decreases 
both basal and stress-induced CORT secretion in male rats. In contrast, there was no effect of 
acute SAFit1 treatment. This suggests a central regulation of the levels of CORT, as the main 
difference between the SAFit2 and SAFit1 is the penetration of the BBB, and SAFit1 is only 
active in the periphery. Enhanced central negative feedback by SAFit2 would reduce CRH 
concentrations and subsequently reduce ACTH secretion from the pituitary gland. To 
investigate this further, ACTH concentrations were measured over 12 hours, in animals 
treated with SAFit2 or SAFit1, or vehicle.  
The CORT concentrations in the 24-h profiles were obtained from blood samples from 
the ABS. This is a remote system where the samples are stored at room temperature until the 
end of the sampling. However, because ACTH is not stable at room temperature for more 
than 6 hours (362), we cannot measure ACTH concentrations in these samples. Therefore, to 
measure ACTH concentrations, the animals must be sampled by hand, so the blood can 
instantly be separated into plasma and snap-frozen on dry ice. Moreover, the ACTH RIA used 
to measure the ACTH concentrations require 100ul of blood which is far greater than the 
volume sampled by ABS.   Blood samples were taken from a cannula in the right jugular vein 
(see methods) every two hours from 09.00h to 19.00h. All rats were treated with vehicle and 
the following day with either SAFit2 or SAFit1. The samples were assayed for ACTH and CORT 
concentrations.  
The mean + SEM ACTH concentrations for each time point was calculated for both 




revealed no effect of time (F(3.4,41.2)=1.2, P=0.333), no interaction of time and treatment 
(F(3.4,41.2)=0.1, P= 0.956), and no effect of treatment (F(1,12)=0.013, P=0.910). In the SAFit1 
experiment (figure 3.7. B), repeated measures revealed a significant effect of time 
(F(3.8,45.5)=4.1, P=0.007), no interaction between time and treatment (F(3.8,45.5)=0.9, 
P=0.485), and no significant effect of treatment (F(1,12)=0.475, P=0.504). Tukey’s post hoc 
test did not reveal any differences between the different time points.  
 
 
Figure 3.7. The effect of acute SAFit2 and SAFit1 treatment on basal ACTH concentrations in 
male rats. Mean + SEM ACTH concentrations after treatment with vehicle (VEH: 4% Ethanol; 
5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=4-6), SAFit1 (SF1; 20mg/kg; s.c.; n=5) or 
SAFit2 (SF2; 20mg/kg; s.c.; n=6). Blood was collected via a jugular vein cannula and plasma 
ACTH concentrations measured with ACTH RIA.  
 
Complete 24-hour CORT concentration profiles following acute SAFit2 and SAFit1 
treatment in male rats have been established previously in this chapter.  However, I wanted 
to see if the differences could be detected in these blood samples.  The CORT concentrations 
were measured in all samples and are shown in figure 3.8. Repeated measures ANOVA for the 
SAFit2 experiment revealed an overall effect of time (F(2.9,35) =6.2,P=0.002), but not of 
treatment (F(2.9,35)=0.7,P=0.573), and there was no interaction (F(1,12)=0.020, P=0.889). 
Similar results were seen in the SAFit1 experiment, with an overall effect of time 
(F(2.5,24.6)=14.4,P=<0.00001), but not of treatment (F(2.5,24.6)=0.5,P=0.637), and no 






Figure 3.8. Comparison of CORT concentrations for basal ACTH measurements following 
acute SAFit2 and SAFit1 treatment in male rats. Mean + SEM CORT concentrations after 
treatment with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; 
n=4-6), SAFit1 (SF1; 20mg/kg; s.c.; n=5) or SAFit2 (SF2; 20mg/kg; s.c.; n=6). Blood was 
collected via a jugular vein cannula and plasma CORT concentrations measured with CORT 
RIA.  
 
3.3.5. The effect of acute SAFit2 and SAFit1 treatment on CRH stimulation  
In the previous experiment, no significant difference in the ACTH concentrations 
between the respective vehicle and SAFit1 or SAFit2-treated animals was detected. 
Therefore, to establish further whether the effects of SAFit2 on basal and stress-induced 
CORT secretion are mediated by decreased negative feedback at the level of the anterior 
pituitary gland corticotrophs, ACTH secretion was stimulated by injecting the rats with CRH. 
CRH binds CRHR1 in the anterior pituitary gland which causes the release of ACTH (12, 16), 
which in turn will increase the CORT production and release from the adrenal glands. To 
deduce which level of the HPA axis the SAFit1 and SAFit2 are affecting both the ACTH 
concentrations and the CORT concentrations were determined following an intravenous 
injection with 150 ng CRH per rat. Previous studies indicate a rapid increase in ACTH following 
CRH injection (363). If the SAFit1 and SAFit2 increase the negative feedback in the anterior 
pituitary gland, the same dose of CRH should result in a smaller ACTH increase in the SAFit-




negative feedback in the adrenal glands, we would expect no effect on ACTH concentration, 
however a decrease in CORT concentration.  
In the stress experiments, a lower response to the noise stress was only observed in 
the SAFit2 group, suggesting that SAFit2 is acting centrally to reduce CRH. Further, noise stress 
is known to activate other brain areas in addition to the PVN (361). In the present experiment, 
the CRH was administered intravenously through a jugular vein cannula to minimise a stress 
response thus the central activation of endogenous CRH release. Moreover, the experiment 
was performed in the morning when CRH peptide stores are low (364) and therefore we 
would expect low basal endogenous levels of CRH and similar CRH levels following the CRH 
injection.  
Rats were treated with SAFit2, SAFit1, or vehicle, and the following day all animals 
were injected with 150 ng CRH. Blood samples were manually taken from the rats before the 
injection (time 0 min) and then 1, 5, 15, 30, and 60 minutes following the CRH injection. The 
samples were assayed for ACTH and CORT concentrations. The vehicle was given at 09.00h 
and 17.00h, or at 09.00h, 14.00h, and 19.00h, to account for the different treatment times 
for SAFit2 and SAFit1. As there was no difference in hormone secretion within the vehicle 
groups data from all vehicle-treated rats were merged. 
The mean ACTH concentrations following CRH administration are shown in figure 3.9. 
Repeated measures revealed a significant effect of time (F(1.5,16.4)=4.1, P=0.046), no 
interaction of time and treatment (F(2.9, 16.4)=0.8, P=0.492), and no effect of treatment 
(F(1,13)=0.756, P=0.492). Interestingly, the post hoc analysis revealed significantly higher 
ACTH concentrations in vehicle-treated rats at 15 (P=0.005), and 30 minutes time points 
(P=0.009), compared to vehicle-treated rats at the 0 minute time point. In comparison, there 






Figure 3.9. The effect of acute SAFit2 and SAFit1 treatment on CRH-induced ACTH secretion 
in male rats. Mean + SEM ACTH concentration following CRH injection (150ng) in animals 
treated with Vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=6), 
SAFit2 (20 mg/kg, s.c.; n=6, at 09.00h and 17.00h), or SAFit1 (20 mg/kg, s.c.; n=4, at 09.00h, 
14.00h, 19.00h) the day prior to CRH administration. Blood samples were collected via a 
jugular vein cannula and ACTH measured with ACTH RIA. *P<0.05 compared to respective 0 
minute time point, with LSD. 
 
The mean CORT concentrations following CRH administration are shown in figure 3.10. 
Repeated measures revealed a significant effect of time (F(2.6,33.6)=5.4, P=0.006), but no 
interaction (F(5.2,33.6)=0.8, P=0.535), and no effect of treatment (F(1,13)=2.292, P=0.140). 
Interestingly, post hoc analysis revealed significantly higher CORT concentrations in vehicle-
treated rats at the 15 (P=0.012), and 30 minutes (P=0.012) time points, compared to vehicle-
treated rats at the 0 minute time point. In comparison, there was no significant increase in 




respective 0 minute time points. Further, significantly lower CORT concentration was 
observed in the SAFit1-treated rats at the 30 minute time point compared to vehicle-treated 
rats at the 30 minute time point. There was no difference between the baseline CORT at the 
0 minute time point between vehicle-treated rats and SAFit2-treated rats, or between 
vehicle-treated rats and SAFit1-treated rats. 
 
Figure 3.10. The effect of acute SAFit2 and SAFit1 treatment on CRH-induced CORT secretion 
in male rats. Mean + SEM CORT concentration following CRH injection (150ng per rat) in 
animals treated with Vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; 
s.c.; n=6), SAFit2 (20 mg/kg, s.c.; n=6, at 09.00h and 17.00h), or SAFit1 (20 mg/kg, s.c.; n=4, 
at 09.00h, 14.00h, 19.00h) the day prior to CRH administration. Blood samples were collected 
via a jugular vein cannula and CORT measured with CORT RIA. *P<0.05 compared to respective 
0 minute time point, with LSD.  #P<0.05 compared to vehicle-treated rats at the same time 
point, with LSD.   
 
The results from this experiment demonstrate a significant increase in both ACTH and 




that both SAFit2 and SAFit1 increase the GC negative feedback to significantly reduce the 
release of ACTH and subsequently CORT.   Hence both SAFit2 and SAFit1 act in the anterior 
pituitary gland to reduce ACTH release following CRH stimulation. As GR is widely expressed 
in the anterior pituitary gland (365), it is likely that both SAFit2 and SAFit1, by inhibiting 
FKBP51, cause an increase in GR activity and thus increased GC negative feedback and lower 
ACTH concentrations.  
 
3.3.6. The effect of acute SAFit2 and SAFit1 treatment on ACTH stimulation  
In the previous section, the data demonstrated that acute administration of SAFit1 
and SAFit2 before CRH injection did not cause an increase in ACTH concentrations, as seen in 
the vehicle-treated rats. This indicates that both SAFit1 and SAFit2 directly affect the secretion 
of ACTH, potentially by increasing the GR-mediated negative feedback at the level of the 
anterior pituitary gland corticotrophs. To investigate whether the lowered CRH-mediated 
CORT concentrations in SAFit1 and SAFit2 animals were due to lower ACTH concentrations, 
or whether SAFit1 and SAFit2 can affect the adrenal gland directly, the next experiment 
involved stimulation of the adrenal gland with ACTH and measuring the CORT concentrations.  
The potential of GR to induce intra-adrenal gland negative feedback is not yet fully 
elucidated. Some evidence suggests that CORT-bound GR in the adrenal gland can bind the 
activity of the transcription factor SF-1. This causes induction of DAX-1 transcription, a 
negative regulator of StAR, the rate-limiting protein for CORT production in the adrenal gland 
(223). Furthermore, a recent study has shown, by using mathematical modelling, that 
activation GR can also affect the rapid synthesis, and thus secretion, of corticosterone in the 
adrenal gland (134). As FKBP51 is expressed in the adrenal gland, a potential inhibition of 
FKBP51 could affect GR activity and hence this proposed intra-adrenal gland rapid negative 
feedback.  
The mean CORT concentrations following ACTH administration are shown in figure 
3.11. Repeated measures revealed a significant effect of time (F(2.1,18.9)=52.6, P<0.000001), 
no effect of time and treatment interaction (F(4.2, 18.9)=1.1, P=0.362), and no effect of 
treatment (F(1,9)=2.206,P=0.166). Post hoc analysis revealed significantly higher CORT 




(P=0.006) time points, compared to vehicle-treated rats at the 0 minute time point. 
Significantly higher CORT concentrations were observed in SAFit2-treated rats at 5 
(P<0.0001), 15 (P<0.0001), and 30 minutes (P<0.0001) time points, compared to SAFit2-
treated rats at the 0 minute time point. Further, significantly higher CORT concentrations 
were observed in SAFit1-treated rats at 5 (P=0.012), and 15 minutes (P<0.0001) time points, 
and a trend of effect at 30 minute (P=0.006) time point, compared to SAFit1-treated rats at 
the 0 minute time point. There was no difference between the baseline CORT at the 0 minute 
time point between vehicle-treated rats and SAFit2-treated rats, or between vehicle-treated 
rats and SAFit1-treated rats. 
 
Figure 3.11. The effect of acute SAFit2 and SAFit1 treatment on ACTH-induced CORT 
secretion in male rats. Mean + SEM CORT concentration following ACTH injection in animals 
treated with Vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.;  n=4), 
SAFit2 (20 mg/kg, s.c.; n=4, at 09.00h and 17.00h), or SAFit1 (20 mg/kg, s.c.; n=3, at 09.00h, 
14.00h, 19.00h) the day prior to CRH administration. Blood samples were collected via a 
cannula implanted in the right jugular vein. *P<0.05 compared to respective 0 minute time 




This is a very important finding in that it suggests that the site of action of the SAFit 
compounds responsible for the lower CRH-induced CORT secretion observed is in the anterior 
pituitary gland. It is not clear why SAFit2 and SAFit1, in this experiment, did not affect the 
ACTH-mediated CORT secretion from the adrenal glands. Even though it is hypothesised that 
an intra-adrenal gland GC negative feedback system exists, it is plausible that it is regulated 
differently than in the pituitary gland and the brain, hence why no effect of SAFit2 and SAFit1 
were observed in this experiment.  However, it should be noted that due to technical 
difficulties the animal numbers are low and further investigation will be needed to conclude 
whether SAFit2 and SAFit1 have any effects on GC-mediated negative feedback in the adrenal 
glands.  
 
3.3.7. The effect of acute SASFit1 and SAFit2 treatment on subcellular localisation of GR 
and MR in the hippocampus and anterior pituitary gland of adult male rats  
It is clear from the data reported in this chapter that inhibition of the FKBP51 has 
effects on the HPA axis activity, both under basal conditions and following stress. FKBP51 is a 
negative regulator of GR transcriptional activity by preventing the translocation of the 
receptor complex. Thus, inhibition of the FKBP51 by SAFit1 and SAFit2 is expected to enhance 
the nuclear levels of the GR. However, whether this is indeed occurring has not previously 
been tested. The FKBP51 is also a negative regulator of the MR, as well as of several protein 
kinases including GSK3B (328) and AKT (366) which both can regulate GR activity (367, 368). 
Therefore, this study aimed to further investigate the molecular effects of SAFit1 and SAFit2. 
Specifically, the effect of SAFit1 and SAFit2 on subcellular localisation of GR and MR following 
a CORT injection in adrenalectomized rats were investigated. This experiment was performed 
with the help of Miss Kajol Parikh.  
In addition to nuclear localisation of the receptors, there is emerging evidence of 
cytoplasmic membrane-bound GR and MR (369) involved in the rapid effects of GC-mediated 
negative feedback both in the brain and the pituitary gland. The hypothesis suggests that 
SAFit1 and SAFit2 will enhance GR activity by inducing translocation of the receptor complex. 
However, as previously discussed, FKBP51 can also regulate kinases involved in mediating 




immunoblotting was used to measure GR, phosphorylated-GR, and MR levels in the 
membrane, cytoplasm, nucleus, and chromatin-bound protein extract.  
To further characterise the differences between the SAFit1 and SAFit2 and their 
central versus peripheral effects GR and MR subcellular localisation in both the brain and the 
anterior pituitary gland were investigated. Unfortunately, due to technical difficulties in 
performing the subcellular fractionation, as well as the relatively low expression of GR and 
MR in the hypothalamus, no reliable data for GR and MR activation and subcellular 
localisation in the hypothalamus were produced. Instead, the hippocampus and anterior 
pituitary gland were used to distinguish between central and peripheral effects, respectively. 
Indeed, if there is an effect of SAFit1 or SAFit2 on CORT-induced sub-cellular translocation or 
activation of the GR and MR, these effects will be easier detected in a brain area with high GR 
and MR expression such as the hippocampus (66).   
Firstly, to ensure that the levels of CORT were similar across the experimental groups 
at the time of kill, adrenalectomized animals were used. The adrenalectomy will remove 
endogenous CORT, which must be replaced by including CORT in the drinking water. Twelve 
hours before the experiment the CORT is removed from the drinking water to ensure the 
depletion of CORT. Corticosterone concentrations were measured in the trunk blood plasma, 
and the average values for each group are shown in figure 3.12. One-way ANOVA revealed a 
significant overall effect of the treatment (F(3,18)=8.112, P=0.001) with a robust increase of 
CORT in all three experimental groups, with similar CORT concentrations across the groups: 
88.60 ng/ml in the vehicle-CORT, 65.97 ng/ml in the SAFit1-CORT, and 77.96 ng/ml in the 
SAFit2-CORT. The vehicle-SAL had average CORT concentrations of 23.40 ng/ml, which is 
higher than expected as these rats were adrenalectomized and should have no endogenous 
CORT. A similar study showed non-detectable CORT concentrations in the vehicle-saline group 
(359). The CORT concentration in the vehicle-saline group (figure 3.12) suggests that the 
adrenalectomy was only partial in some rats, and this should be taken into account when 
interpreting the results. The post hoc analysis did reveal significantly higher levels, compared 
to vehicle-SAL, in the vehicle-CORT group (P=0.001), in the SAFit1-CORT group (P=0.029), and 
in the SAFit2-CORT group (0.007), indicating that the CORT injection did cause an increase in 
CORT. Importantly, no significant difference in CORT levels was found between the three 






Figure 3.12. The effect of adrenalectomy on CORT concentrations. Mean + SEM plasma CORT 
concentrations in Vehicle-Saline (VS, n=6), Vehicle-CORT (VC, n=5), SAFit1-CORT (SF1, n=6), 
and SAFit2-CORT (SF2, n=5) groups. Animals were treated with vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.), SAFit1 (20mg/kg; s.c.), or SAFit2 (20mg/kg; s.c.), 
and 60 minutes later injected with saline (Vehicle-Saline; i.p.) or CORT (Vehicle-CORT, SAFit1-
CORT, SAFit2-CORT; i.p.). *P<0.05 compared to Vehicle-Saline, with Tukey’s post hoc test.  
 
The levels of GR, pGR, and MR were quantified in each sub-cellular extract for all 
animals using western immunoblotting. Figure 3.13 shows a representative blot of GR, MR, 
and pGR from each group in the hippocampus and the anterior pituitary gland sub-cellular 
extracts.  
In the hippocampus there was no significant difference in GR or pGR levels between 
the groups in any of the sub-cellular extracts (figure 3.14). Further, two-way ANOVA revealed 
that the MR levels in the hippocampus cytoplasmic extract were significantly lower in the 
vehicle-CORT (P=0.004), in the SAFit1-CORT (P=0.009), and the SAFit2-CORT (P=0.013) groups, 
compared to vehicle-SAL. Although there was no significant effect on MR levels in any of the 
other extracts in the hippocampus, it would be expected that the MR leaves the cytoplasm 




the unclear results. From the mean values it appears that there is an increase in the SAFit2-
CORT group in nuclear MR, however, as this is not significant it is difficult to draw any 
conclusions. Work from Spiga and colleagues (359) has shown a robust GR translocation in 
the hippocampus 30 minutes following 0.3mg/kg CORT administration, but this is not seen in 
the present experiment. This might be due to the CORT concentrations in the CORT injected 
animals in our experiment were lower, and comparable to the 0.1mg/kg CORT group in the 
aforementioned study, where no significant effect on GR translocation in the hippocampus 
was seen.  
In the anterior pituitary gland one-way ANOVA revealed a trend of effect on nuclear 
pGR levels (P=0.072), as shown by an increase in pGR in all three CORT groups.  Moreover, 
there was also a trend of effect on chromatin-bound MR (P=0.093) (figure 3.15.). One-way 
ANOVA revealed no significant effects on GR, pGR, or MR in any of the other anterior pituitary 
gland sub-cellular extracts, however, the mean values suggest there is an increase in both 
nuclear GR and MR levels. Furthermore, although not significant, the mean values show an 
increase in membrane pGR in the anterior pituitary in the SAFit1 and SAFit2 groups (figure 
3.15). However, it is difficult to draw any definite conclusions due to the large variability in 
the samples. A final observation, and perhaps the most interesting finding in this study, was 
the lack of any detectable MR in the membrane in the anterior pituitary. This is interesting 
because in the hippocampus MRs were present in the membrane, suggesting a differential 
cellular distribution of MR in the brain versus pituitary gland. It has been demonstrated that 
MR is present on the post-synaptic membrane in neurones in the amygdala (166), and 
synaptic GR in the hippocampus (154). It has also been shown that membrane GR and MR in 
the brain are involved in the regulation of synaptic structure and function, important in 
memory and learning (369). This study is consistent with previous reports of hippocampal GR 








Figure 3.13. The effect of acute SAFit2 and SAFit1 treatment on GR and MR subcellular 
localisation. Representative western immunoblotting images for the hippocampus, and 
anterior pituitary gland, for GR, pGR, and MR. Animals were treated with vehicle (VEH: 4% 
Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.), SAFit1 (20mg/kg; s.c.), or SAFit2 
(20mg/kg; s.c.), and 60 minutes later injected with saline-HBC (0.3 ml/kg, i.p.) or CORT-HBC 
(0.3 mg/kg; i.p.) to obtain the following groups: Vehicle-saline (VS, n=6), Vehicle-CORT (VC, 
n=5), SAFit1-CORT (SF1, n=6), and  SAFit2-CORT (SF2, n=5). Size of the proteins: GR: ~90kDa, 





   
 
Figure 3.14. Quantification of the effect of acute SAFit2 and SAFit1 treatment on GR and MR 
subcellular localisation in the hippocampus. Mean + SEM quantification of western 
immunoblotting images for hippocampal GR, pGR, and MR. Animals were treated with  vehicle 
(VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.), SAFit1 (20mg/kg; s.c.), or 
SAFit2 (20mg/kg; s.c.), and 60 minutes later injected with saline-HBC (0.3 ml/kg; i.p.) or CORT-
HBC (0.3 mg/kg; i.p.) to obtain the following groups: Vehicle-saline (VEH-SAL, n=6), Vehicle-
CORT (VEH-CORT, n=5), SAFit1-CORT (SF1-CORT, n=6), SAFit2-CORT (SF2-CORT, n=5). *P<0.05 





Figure 3.15. Quantification of the effect of acute SAFit2 and SAFit1 treatment on GR and MR 
subcellular localisation in the anterior pituitary gland. Mean + SEM quantification of western 
immunoblotting images for GR, pGR, and MR in the anterior pituitary gland of animals treated 
with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.), SAFit1 
(20mg/kg; s.c.), or SAFit2 (20mg/kg; s.c.), and 60 minutes later injected with saline-HBC (0.3 
ml/kg; i.p.) or CORT-HBC (0.3 mg/kg; i.p.) to obtain the following groups: Vehicle-saline (VEH-
SAL, n=6), Vehicle-CORT (VEH-CORT, n=5), SAFit1-CORT (SF1-CORT, n=6), SAFit2-CORT (SF2-
CORT, n=5).  
 
3.3.8. Stress-induced gene expression in the hypothalamus and anterior pituitary gland 
following acute SAFit2 or SAFit1 treatment in male rats 
To further investigate potential genomic changes induced by the SAFit2 and SAFit1 the 
gene expression was characterised following noise stress. Animals from the 24h sampling 
studies were subject to noise stress, and at 60 minutes post-noise they were euthanized, and 
their tissues dissected and processed for mRNA and subsequent RT-qPCR analysis. The 




pituitary gland, to investigate whether the SAFit2 or SAFit1 had any direct effects on these 
genes. It has been shown that in female rats, CRH mRNA in the hypothalamus is not increased 
at 4 hours post-noise (352). Another study showed that CRH mRNA only increased following 
chronic exposure to noise stress but not after acute exposure (370). To investigate whether 
there was a difference in AVP-induced ACTH secretion following SAFit administration, the AVP 
mRNA expression was measured. Furthermore, GR and MR mRNA in the hypothalamus and 
anterior pituitary gland was quantified to gain a better understanding of whether the SAFit 
compounds affect the expression of the receptors themselves. It has been shown that GR 
mRNA in the hypothalamus does not change following noise stress (370).  
The GR is constitutively expressed in most tissues, and the levels vary as a result of, 
for example, neuroendocrine changes (371-373) and different stages of the cell cycle (374). 
The expression of GR is regulated by a variety of different pathways including GR 
autoregulation and second messengers such as cAMP. Glucocorticoids have been shown to 
downregulate the expression of GR (375) in human, rat, and mice cell lines, up to 8 hours 
following DEX administration, and that this downregulation is dependent on GR binding to 
GRE in its gene (376, 377). Since FKBP51 regulates GR transcriptional activity it is plausible 
that the SAFit compounds could affect GR expression.  
Furthermore, the expression of c-Fos can be used as a marker for neuronal activity 
(378) and c-Fos expression is increased by exposure to stress and following noxious stimuli in 
rats (361). Therefore, c-Fos mRNA was measured in both the hypothalamus and the anterior 
pituitary gland following noise stress. Moreover, GILZ, PER1, SGK1, and FKBP5 itself are all 
well-known GR-inducible genes and hence can be used partly at least to establish GR 
transcriptional activity. The quantification of these genes was performed in the hypothalamus 
and the anterior pituitary gland as these areas are mainly involved in HPA axis activity. Other 
brain areas are involved in HPA axis negative feedback, for example, the hippocampus, 
however, due to time restraints, I chose to focus on the hypothalamus and the anterior 
pituitary gland.   
The same experimental design was used for all ABS experiments, and hence the noise 
stress was performed at the same time, and rats sacrificed at the same time point, for all ABS 
experiments. The rats were sacrificed 60 to 90 minutes after the noise stress in order to 




concentrations are back to basal concentrations at 60 minutes post-stress in both male and 
female rats (239, 379).   
 
3.3.8.1. Hypothalamus  
The relative expression of GR, MR, CRH, AVP, and c-Fos mRNA in the hypothalamus 
following the noise stress in the acute male SAFit2 experiment are shown in figure 3.15 A. An 
unpaired t-test revealed no effect of treatment on GR (t(11)=0.05, P=0.954), MR (t(11)=-0.38, 
P=0.734), CRH (t(11)=-1.78, P=0.102), AVP (t(11)=1.07, P=0.306), or c-Fos mRNA (t(11)=-0.39, 
P=0.704).  
Furthermore, for the acute SAFit1-treated males, GR, MR, CRH, AVP, and c-Fos mRNA 
in the hypothalamus following noise stress are shown in figure 3.15 B. An unpaired t-test 
revealed an effect of treatment on MR (t(10)=-2.417, P=0.036), with higher relative 
expression in the SAFit1 group compared to the vehicle-treated group. There was no effect of 
treatment on GR (t(10)=-0.454, P=0.659), CRH (t(10)=-1.06, P=0.314), AVP (t(10)=-0.13, 
P=0.896), or c-Fos mRNA (t(10)=0.37, P=0.707), revealed by an unpaired t-test.  
For the GR-inducible genes, FKBP5, GILZ, PER1, and SGK1 mRNA expression in the 
hypothalamus following the noise stress in the acute male SAFit2 experiment are shown in 
figure 3.15 C. There was no effect of treatment on FKBP5 (t(11)=0.23, P=0.822), GILZ (t(11)=-
0.41, P=0.689), PER1 (t(11)=0.22, P=0.826), or for SGK1 mRNA (t(11)=-0.24, P=0.812) as shown 
by an unpaired t-test. 
 Figure 3.15 D shows the relative expression of FKBP5, GILZ, PER1, and SGK1 in the 
hypothalamus of acutely SAFit1-treated males following the noise stress. An unpaired t-test 
did not revealed any effect of treatment on either genes: FKBP5 (t(10)=-0.93, P=0.373), GILZ 






Figure 3.16. The effect of acute SAFit2 and SAFit1 on stress-induced gene expression in the 
hypothalamus of male rats. Mean + SEM of GR, MR, CRH, AVP, and c-Fos mRNA in the 
hypothalamus of male rats treated with either vehicle or SAFit2 (A; n=6 and 8, respectively) or 
SAFit1 (B; n=7 and 6, respectively). Mean + SEM of FKBP5, GILZ, PER1, and SGK1 mRNA in the 
hypothalamus of male rats treated acutely with SAFit2 (C; n=6 and 8, respectively) or SAFit1 
(D; n=7 and 6, respectively). *P<0.05 compared to vehicle-treated rats, with unpaired t-test.  
 
3.3.8.2. Anterior pituitary gland 
The relative expressions of GR, MR, POMC, and c-Fos mRNA in the anterior pituitary 
gland following noise stress in the acute male SAFit2 experiment are shown in figure 3.16 A. 
An unpaired t-test did not show any effect of treatment on GR (t(11)=-0.23, P=0.818), MR 




Similarly, in the acute male SAFit1 experiment, there was no effect of treatment on 
GR (t(9)=-0.38, P=0.712), MR (t(9)=-0.75, P=0.468), POMC (t(9)=1.55, P=0.278), or for c-Fos 
mRNA (t(9)=0.107, P=0.917), as revealed by an unpaired t-test (figure 3.16 B).  
Quantification of the GR-inducible genes, FKBP5, GILZ, PER1, and SGK1 mRNA in the 
anterior pituitary gland following noise stress in the acute male SAFit2 experiment is shown 
in figure 3.16 C. Similar to the results from the hypothalamus, an unpaired t-test revealed no 
effect of treatment on FKBP5 (t(11)=-0.15, P=0.883), GILZ (t(11)=-0.92, P=0.374), PER1 
(t(11)=0.09, P=0.924), or on SGK1 mRNA (t(11)=-0.57, P=0.576).  
Further, relative expression of FKBP5, GILZ, PER1, and SGK1, in the anterior pituitary 
gland following noise stress in the acute male SAFit1 experiment is shown in figure 3.16 D. 
There was no difference in expression between the two groups, as shown by an unpaired t-
test, for FKBP5 (t(9)=-0.47, P=0.645), GILZ (t(9)=0.82, P=0.433), PER1 (t(9)=0.16, P=0.873), or 







Figure 3.17. The effect of acute SAFit2 and SAFit1 on stress-induced gene expression in the 
anterior pituitary gland of male rats. Mean + SEM of GR, MR, CRH, AVP, and c-Fos mRNA in 
the anterior pituitary of male rats treated with SAFit2 (A; n=6 and 8, respectively) or SAFit1 (B; 
n=7 and 6, respectively). Mean + SEM of FKBP5, GILZ, PER1, and SGK1 mRNA in the anterior 
pituitary gland of male rats treated acutely with SAFit2 (C; n=6 and 8, respectively) or SAFit1 
(D; n=7 and 6, respectively). *P<0.05 compared to vehicle, with unpaired t-test.  
 
3.4.  Discussion 
  In this chapter, data has been presented on the effect of acute SAFit2 and SAFit1 
administration on basal and stress-induced HPA axis activity in adult male rats. It was 
demonstrated that acute SAFit2 administration decreased both max CORT and stress-induced 
CORT secretion, while there was no effect of acute SAFit1 treatment. This suggests that 
central inhibition of FKBP51 is required to affect CORT secretion in basal and stress-induced 




peripheral FKBP51-inhibition has a stronger effect than peripheral-only FKBP51-inhibition, 
and perhaps a higher dose of SAFit1 would reduce CORT concentrations.  
There was no difference in ACTH concentrations between vehicle and SAFit1 or SAFit2-
treated groups at any of the time points investigated. This suggests that SAFit1 and SAFit2 
have no major effect on ACTH production and/or secretion. However, it has been 
demonstrated in both rats and humans that ACTH is secreted in a pulsatile pattern (93) and 
therefore it is plausible that the rats were at different stages of the pulses when the blood 
samples were taken, which must be considered when analysing the present experiment. 
There may be a difference in ACTH concentrations between the groups, however not large 
enough to be detected with this experimental design. This experiment aimed to obtain an 
overall circadian profile of ACTH concentrations perhaps, however, more frequent blood 
sampling is necessary to detect a difference.  
In the same experiment, there was an overall circadian difference in the CORT 
concentrations.  In this experiment, however, there was no decrease in the SAFit2 group as 
seen in the ABS experiment. This is because the rats are not synchronised in their pulsatile 
pattern and therefore, they will be in different stages in their CORT ultradian pulses. 
Moreover, the decrease in the SAFit2 group in CORT concentrations in the ABS experiment 
was only significantly reduced in regards to the maximum CORT concentration, therefore it 
would be difficult to detect such decrease unless frequent sampling is performed. These data 
highlight the importance of performing complete 24-hour profiling of GC secretion to obtain 
potential differences subsequent a treatment that is aimed to alter HPA axis activity.  
In the next experiment rats were acutely treated with SAFit2 or SAFit1 or vehicle and 
at 07.00h the following day (the same time as the noise stress in the ABS studies), all rats were 
injected with CRH (150ng per rat). This caused a stimulation of the pituitary gland 
corticotrophs and subsequent secretion of ACTH and CORT was induced. However, this 
increase in ACTH and CORT was only significant in the vehicle group, indicating that both 
SAFit2 and SAFit1 diminish the ACTH and subsequent CORT response to CRH. This suggests 
that the SAFit compounds induce a negative feedback mechanism to reduce the secretion of 
ACTH, and possibly CORT. As described above, there are various ways in which activated GR 
can affect the ACTH secretion, both via genomic pathways and non-genomic pathways. For 




bind to the nGRE on the POMC gene to inhibit transcription of the ACTH precursor (214, 215). 
Moreover, non-genomic actions of CORT-activated GR includes regulation of the 
electropotential properties of the corticotropic cells in the anterior pituitary gland, and this 
can inhibit the vesicular secretion of ACTH (200). Secretion of ANXA1 from the nearby 
folliculostellate cells can act on the corticotrope cells and inhibit ACTH secretion by affecting 
the cytoskeleton and hence the vesicular transport of ACTH (208). Corticosterone may inhibit 
ACTH release by promoting the transport of ANXA1 from the cytoplasm to the plasma 
membrane (209). It is difficult to deduce whether the inhibitory effects of SAFit2 and SAFit1 
on CRH-mediated ACTH secretion observed in this experiment are due to genomic or non-
genomic GR actions. It is plausible that either of the pathways discussed above is activated by 
enhanced GR activity caused by FKBP51 inhibition following SAFit2 and SAFit1 treatment. 
There was large variability in the vehicle group and this variability in CRH response is expected 
as individual rats will secrete different amounts of ACTH and CORT in response to CRH 
stimulation. However, it is interesting to note that in the SAFit2 and SAFit1 groups, the 
variability is much smaller and all animals in the groups had lower ACTH and CORT 
concentrations compared to the vehicle groups. This suggests that indeed SAFit2 and SAFit1 
are effective in lowering CRH-mediated ACTH release, and in turn lower ACTH-mediated CORT 
release.  
In contrast, there was no difference in the CORT response from ACTH-mediated 
stimulation of the adrenal gland. This suggests that neither SAFit2 nor SAFit1 affects the 
adrenal gland directly to reduce CORT secretion. Hence, the lower CORT concentrations in the 
CRH experiment are expected to be due to lower ACTH secretion.  
The results from the CRH- and ACTH-injection experiments indeed suggest an anterior 
pituitary gland effect of both SAFit2 and SAFit1. Future experiments to confirm these results 
could include using pituitary gland primary cell cultures from rats or using the pituitary 
corticotrophs cell line, AtT-20. These cell cultures can be pre-treated with SAFit2, SAFit1, or 
vehicle. Once CRH is added the response can be measured with, for example, calcium imaging, 
or by measuring the ACTH concentrations directly. In addition, a time course of pre-treatment 
with the SAFit2 or SAFit1 can reveal whether the effects are genomic or non-genomic. For 




the response in ACTH is diminished compared to the vehicle-treated cells, these rapid actions 
could indicate a non-genomic effect.  
Finally, to elucidate the molecular mechanisms behind these results, the subcellular 
localisation of GR and MR in the hippocampus and anterior pituitary gland was quantified, 
with no clear results.  
The data reported in this chapter demonstrate that global FKBP51-inhibition by SAFit2 
is effective in reducing both maximum CORT concentrations and stress-induced CORT 
secretion. This effect appears to be due to lower ACTH secretion following CRH stimulation of 
the corticotrophs in the anterior pituitary gland.  
There were some limitations to the studies in this chapter. For the CRH and ACTH 
injection experiments, the animal numbers in each group were low, due to difficulty 
maintaining the jugular vein cannula patency throughout the experiment and limited 
availability of the SAFit2 and SAFit1 compounds.  
Furthermore, in the molecular mechanism experiment, the adrenalectomy appeared 
to be only partial in some of the rats, which could have contributed to variable results as it 
will affect the endogenous CORT concentrations. In addition, the technique used to quantify 
the nuclear translocation and the subcellular localisation in the same experiment was perhaps 
not sensitive enough to detect differences. Possibly a more suitable option would have been 
to perform chromatin immunoprecipitation (ChIP) on hypothalamic and anterior pituitary 
gland tissue from rats treated with either SAFit2, SAFit1, or vehicle and injected with CORT to 
stimulate GR translocation. Chromatin immunoprecipitation is used to investigate protein-
DNA interactions in vivo and can detect for example direct protein-DNA binding, histone 
modifications, and cofactors associated with the DNA (380). This could be a useful technique 
to determine whether SAFit2 and SAFit1 affect GR interactions with for example DNA or 
cofactors.  
Other limitations include a single time point for the gene expression analysis following 
the noise stress. The animals were euthanised at 60 minutes post-noise and the tissues were 
extracted and processed for RT-qPCR. It would have been ideal to have multiple time points, 
for example, 60, 120, and 180 minutes post-noise to obtain a better profile of the gene 




mRNA were significantly increased at 60 minutes post-stress in the ventral hippocampus, 
however, FKBP5 mRNA was only significantly increased at 180 minutes post-stress (355). The 
same study showed that hnRNA of all three genes showed a more robust increase than mRNA, 
and peaked at 30 minutes for PER1 and SGK1 and 60 minutes for FKBP5, in the ventral 
hippocampus (355).  The CORT concentrations peaked over 1000 ng/ml at 30 minutes post-
foot-shock in this experiment, compared to between 300-400 ng/ml in my noise stress 
experiment. It is plausible that an increase in the GR inducible genes would have been 
observed following higher CORT concentrations. Another study using female rats in pro-
oestrus and oestrus showed a robust increase in CRH mRNA at 60 minutes following restraint 
stress (13), although the CORT concentrations were around 1500 ng/ml at 60 minutes post-
stress which is substantially higher than in my experiments following noise stress. In 
summary, previous studies have shown a robust increase post-stress in some of the genes 
investigated in the present study (13, 355).  
Although more time points are needed to investigate the time course of stress-
induced expression of CRH, POMC, AVP, PER1, SGK1, GILZ, and FKBP5 in the hypothalamus 
and anterior pituitary gland that was beyond the scope of this thesis. It was simply not 
possible because a limited amount of SAFit2 and SAFit1 were available and to have included 
one more time point would have required twice as many animals. Nevertheless, a more 
suitable technique for analysing the gene expression, which would also produce an 
anatomical representation of the genes, is in situ hybridization (ISH). This technique uses 
labelled complementary DNA or RNA probes to identify the presence of the gene of interest 
(381) on, for example, brain slices. Moreover, recent advancement of ISH, RNA scope allows 
for signal amplification and simultaneous background noise suppression to allow for single-




Chapter 4: Prolonged treatment with FKBP51 inhibitors in male rats  
 
4.1. Introduction 
Acute administration of the central and peripheral FKBP51-inhibitor, SAFit2, results in 
decreased basal and stress-induced CORT concentrations in male rats. However, it is not 
known whether these effects are enhanced after prolonged treatment with SAFit2. 
Furthermore, as the peripheral-only FKBP51 antagonist SAFit1 did not have any effect on 
either the basal or stress-induced CORT concentrations, it is plausible that a sub-chronic 
treatment with SAFit1 necessary to see an effect on HPA axis activity.  
In this chapter data on the effect of sub-chronic treatment with SAFit2 and SAFit1 on 
basal CORT, ultradian pulsatility, and stress-induced CORT secretion will be shown. 
Furthermore, the effects of prolonged treatment with SAFit2 and SAFit1 on gene expression 
related to the HPA axis and GR-induced gene expression will be demonstrated. 
 Previous studies using a GR antagonist show enhanced effects in increasing CORT 
concentrations when the antagonist was delivered sub-chronically compared to acute 
administration (383). This suggests that prolonged treatment with a GR modulator will have 
stronger effects than when delivered acutely.   
 
4.2. Methods 
4.2.1. Experiments 7 and 8: Effect of sub-chronic SAFit2 and SAFit1 treatment on CORT 
ultradian rhythm and stress-induced CORT secretion in male rats. 
 These experiments aimed to investigate whether prolonged treatment with SAFit2 








Figure 4.1. Experimental schedule for the sub-chronic SAFit2 and SAFit1 treatment in male 
rats.   
 
For SAFit2 experiments rats were treated with either vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in 0.09% sterile saline; 2 ml/kg; s.c. n=7) or SAFit2 (20 mg/kg; s.c.; n=6) 
at 09.00h and 17.00h for 5 consecutive days, with the fifth day on the day of blood sampling. 
For SAFit1 experiments, rats were treated with either vehicle (VEH: 4% Ethanol; 5% PEG300; 
5% Tween 80 in 0.09% saline; 2 ml/kg; s.c. n=8) or SAFit1 (20 mg/kg; s.c.; n=6) at 09.00h, 
14.00h and 19.00h 5 consecutive days, with the fifth day on the day of blood sampling. Note 
that this experiment protocol differed from the SAFit2 experiment only in the times for the 
administration of the SAFit compounds, due to a shorter half-life of the SAFit1 this compound 
was administered three times compared to two times for the SAFit2.  
For both SAFit1 and SAFit2 experiments, automated-blood sampling for measurement 
of basal CORT was conducted from 07.00h on day 5, until 07.00h the following day. At 07.00h 
of day 6, all rats were subject to noise stress (10 min, 96dB, white noise) and blood sampling 
collection continued for one more hour. Immediately after the sampling had stopped at 
08.00h, the rats were euthanized using pentobarbitone injection in the i.v. cannula, followed 




along with the anterior pituitary gland and adrenal gland, were snap-frozen on dry ice to be 
used for further gene expression analysis.  
 
4.3. Results  
4.3.1. The effect of sub-chronic SAFit2 treatment on basal CORT concentrations and 
ultradian rhythms in adult male rats  
Seven vehicle-treated rats and six SAFit2-treated rats were treated for 5 consecutive 
days and on the fifth day they were all subject to ABS every 10 minutes for 24 hours. The 
blood samples were assayed for CORT concentrations and the mean was calculated for each 
time point for both groups. The resultant average 24-h profiles are shown in figure 4.2 (A) 
along with the individual representative profile (B-E). 
All the individual 24-hour profiles were analysed with PULSAR and the means for each 
parameter are shown in figure 4.3. Unpaired t-tests revealed a significant decrease in mean 
CORT (t(11)=2.86, P=0.014), max CORT (t(11)=3.44, P=0.006), pulse amplitude (t(11)=2.47, 
P=0.031), pulse height (t(11)=2.51, P=0.029), pulse area (t(11)=2.30, P=0.042), AUC basal 
(t(11)=2.73, P=0.017), AUC total (t(11)=2.72, P=0.020) in the SAFit2-treated rats compared to 
vehicle-treated rats. There was no significant effect on basal CORT (t(11)=1.57, P=0.143), the 
number of pulses (t(11)=0.344, P=0.738), the pulse length (t(11)=0.837, P=0.421), the IPI 







Figure 4.2. The effect of sub-chronic SAFit2 treatment on ultradian CORT secretion in male 
rats.  Mean + SEM CORT concentrations (A), and representative individual profiles (B-E) from 
male adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 
ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=6) at 09.00h, and 17.00h for five consecutive days. 
Blood samples were collected via a cannula implanted in the right jugular vein every 10 min 
for 24-h on the fifth day, using an automated blood sampling system. Plasma corticosterone 






Figure 4.3. The effect of sub-chronic SAFit2 treatment on PULSAR parameters in male rats.  
Mean + SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated 
with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit1 
(20 mg/kg, s.c.; n=6) at 09.00h, and 17.00h for five consecutive days. Amp=amplitude, 
IPI=inter-pulse interval, AUC= area under the curve. Amp=amplitude, IPI= inter-pulse interval, 
AUC= area under the curve. *P<0.05 compared to vehicle-treated rats, with unpaired t-test. 
 
These results indicate that SAFit2 treatment in male rats decreases the overall CORT 
concentrations, as seen by decreased mean CORT in the SAFit2 group. Moreover, this effect 
is due to a decrease in amplitude of the ultradian pulses while the pulse length, IPI, and the 
number of pulses are unaffected. This suggests that central and peripheral inhibition of 
FKBP51 for a prolonged time result in decreased basal CORT concentration however there is 
no change in the dynamic of ultradian CORT pulsatility. Compared to acute SAFit2 
administration in male rats, sub-chronic SAFit2 administration had more wide-ranging effects 




4.3.2. The effect of sub-chronic SAFit1 treatment on basal CORT concentrations and 
ultradian rhythms in adult male rats 
Even though there was no effect of acute SAFit1 on basal CORT secretion, the SAFit1 
group showed decreased ACTH and CORT response to a CRH injection, suggesting that 
inhibition of peripheral FKBP5, presumably at the level of the corticotrophs in the anterior 
pituitary gland, does inhibit HPA activity. The hypothesis of this study was therefore that 
prolonged treatment would enhance the negative feedback in the pituitary gland sufficiently 
to achieve a decrease in basal CORT. Furthermore, the aim was to investigate whether a sub-
chronic treatment with SAFit1 would affect the dynamics of ultradian pulsatility.  
The same protocol as for the sub-chronic SAFit2 experiment was followed except for 
treatment frequency. As SAFit1 has a shorter half-life (2.5 hours compared to 9 hours for 
SAFit2; (347)), all animals in this experiment were treated with either vehicle or SAFit1 three 
times daily (compared to twice daily for SAFit2). Five vehicle-treated rats and four SAFit1-
treated rats were treated for 5 consecutive days and on the fifth day they were all subject to 
ABS. Blood samples were taken every 10 minutes for 24 hours and processed for CORT 
concentrations. The mean was calculated for each time point for both groups and the average 
24-h profiles are shown in figure 4.4 (A) along with the individual representative profile (B-E). 
The individual 24-hour CORT profiles were separately analysed using PULSAR and the 
means for each parameter are shown in figure 4.5. There was a significant increase in the 
number of pulses (t(7)=-2.60, P=0.035), pulse frequency (t(7)=-2.60, P=0.035), and a 
significant decrease in the pulse length (t(7)=-2.61, P=0.037), the pulse area (t(7)=2.25, 
P=0.032), and the IPI (t(7)=2.22, P=0.028) in the SAFit1-treated rats compared to the vehicle-
treated rats, as shown by an unpaired t-test. There was no significant effect of treatment on 
mean CORT (t(7)=1.47, P=0.200), max CORT (t(7)=1.516, P=0.173), basal CORT (t(7)=0.131, 
P=0.900), pulse amplitude (t(7)=1.94, P=0.093), pulse height (t(7)=1.71, P=0.131), AUC basal 






Figure 4.4. The effect of sub-chronic SAFit1 treatment on ultradian CORT secretion in male 
rats.  Mean + SEM (A) CORT concentrations, and representative individual profiles (B-E) from 
male adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 
ml/kg; s.c.; n=5) or SAFit2 (20 mg/kg, s.c.; n=4) at 09.00h, 14.00h, and 19.00h for five 
consecutive days. Blood samples were collected via a cannula implanted in the right jugular 
vein every 10 min for 24-h on the fifth day, using an automated blood sampling system. Plasma 







Figure 4.5. The effect of sub-chronic SAFit1 treatment on PULSAR parameters in male rats.  
Mean + SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated 
with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=5) or SAFit1 
(20 mg/kg, s.c.; n=4) at 09.00h, and 17.00h. Amp=amplitude, IPI=inter-pulse interval, AUC= 
area under the curve. *P<0.05 compared to vehicle-treated rats, with unpaired t-test. 
 
These data indicate an effect of sub-chronic SAFit1 treatment on the dynamic of the 
pulse, rather than on the pulse amplitude and CORT concentrations. There is a higher number 
of pulses in the SAFit1 animals as seen by the increased number of pulses (23 pulses in the 
SAFit1-treated rats compared to 16 pulses in the vehicle-treated rats). The pulse length, pulse 
area, and IPI were both decreased in the SAFit1 animals. Interestingly there was no effect of 
SAFit1 treatment on mean CORT, basal CORT or total AUC. However, there was a trend 
towards decreased max CORT (P=0.059), pulse amplitude (P=0.080) and AUC basal (P=0.066) 




of the ultradian CORT pulses, rather than CORT concentrations, as observed following SAFit2 
treatment.  
 
4.3.3. The effect of sub-chronic SAFit2 and SAFit1 on post-stress CORT concentrations in 
adult male rats  
Following 24-h blood sampling and treatment with SAFit2 or SAFit1, the rats were 
subjected to noise stress on day 6 and blood sampling continued for 60 minutes following the 
noise stress (see schematics figure 4.1).  
The mean + SEM CORT concentration at each time point was calculated for each group 
as shown in figure 4.6. In the SAFit2 experiment (figure 4.6. A), repeated measure ANOVA 
analysis showed an overall significant effect of time (F(1.9, 15.0)=39.2, P=<0.00001), a 
significant interaction between time and treatment (F(1.9,15.0)=6.2, P=0.012), and a 
significant effect of treatment (F(1,8)= 6.92, P= 0.030). Further post hoc analysis revealed a 
significant increase in stress-induced CORT in vehicle-treated rats at the 10 (P=0.001), 20 
(P<0.0001), and 30 (P<0.0001) minute time points, compared to vehicle-treated rats at the 0 
minute time point.  
In comparison, no significant increase in stress-induced CORT in SAFit2-treated rats 
was observed at any time point. CORT was significantly lower in the SAFit2-treated rats at the 
20 (P=0.014) and 30 minutes (P=0.008) time points compared to vehicle-treated rats at the 
same time points (figure 4.6 A). There was no difference between the baseline CORT at the 0 
minute time point between vehicle-treated rats and SAFit2-treated rats. 
 These data indicate that sub-chronic SAFit2 treatment in male rats decreased the 
post-stress CORT concentrations sufficiently to diminish the stress response.   
In the SAFit1 experiment (figure 4.6. B), repeated measures ANOVA analysis showed 
an overall significant effect of time (F(2.4, 21.1)=22.7, P<0.000001), a significant interaction 
between time and treatment (F(2.4, 21.1)=3.9, P=0.031), and a significant effect of treatment 
(F(1,9)=6.4, P=0.032). Post hoc analysis revealed a significant increase in stress-induced CORT 
in vehicle-treated rats at the 10 (P<0.0001), 20 (P<0.0001), and 30 (P=0.001) minutes time 




significant increase in stress-induced CORT in SAFit1-treated rats was observed at any time 
point. There was a significant reduction in CORT in the SAFit1-treated rats at the 20 minutes 
(P=0.006) point compared to vehicle-treated rats at the respective time points. There was no 
difference between the baseline CORT at the 0 minute time point between vehicle-treated 
rats and SAFit1-treated rats. 
Similar to the SAFit2-treated rats, the stress-mediated increase in CORT is diminished 
in the SAFit1-treated rats following 10 minutes of noise stress. These data demonstrate that, 
in contrast to acute treatment, prolonged treatment with a peripheral-only FKBP51 inhibitor 
















Figure 4.6. The effect of sub-chronic SAFit2 and SAFit1 treatment on stress-induced CORT 
secretion in male rats. Sub-chronic treatment with either SAFit2 or SAFit1 both significantly 
lowered the noise-induced CORT secretion. (A) Mean + SEM corticosterone levels during a 
noise stress (96dB, 10 minutes, white noise, 07.00h) from male adult rats treated with vehicle 
(VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=5) or SAFit2 (20 mg/kg, 
s.c.; n=5) at 09.00h, and 17.00h for 5 consecutive days with the fifth day on the day before the 
noise stress. (B) Mean + SEM corticosterone levels during a noise stress (96dB, 10 minutes, 
white noise, 07.00h) from male adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 
5% Tween 80 in saline; 2 ml/kg; s.c.; n=3) or SAFit1 (20 mg/kg, s.c.; n=3) at 09.00h, 14.00h, 
and 19.00h for 5 consecutive days with the fifth day on the day prior to the noise stress. Blood 
samples were taken every 10 minutes from a cannula implanted in the right jugular vein and 
CORT concentrations measured with CORT RIA. *P<0.05; compared to rats treated with vehicle 
at the same time point, with Tukey’s post hoc test. #P<0.05; compared to vehicle-treated rats 
at time 0, with Tukey’s post hoc test.  
 
4.3.4. The effects of sub-chronic SAFit2 and SAFit1 on gene expression following noise 
stress in adult male rats 
In both experiments, the rats were sacrificed immediately following the collection of 
the last blood sample 60 minutes subsequent the noise stress. Tissues were dissected and 





The effect of SAFit2 and SAFit1 treatment on HPA axis activity in the hypothalamus 
was investigated by quantifying the expression of the GR and MR, and CRH, AVP, and c-Fos. 
The c-Fos expression is a marker of general neuronal excitability, with an increased expression 
suggesting increased neuronal firing. To evaluate whether either compound has any effect of 
GR transcriptional activity, the expression of several GR-inducible genes, including FKBP5, 
GILZ, PER1, and SGK1 were quantified.  
 
4.3.4.1. Hypothalamus  
The relative expression of GR, MR, CRH, AVP, and c-Fos mRNA in the hypothalamus 
following the noise stress in the sub-chronic male SAFit2 experiment are shown in figure 4.7 
A. An unpaired t-test revealed an effect of treatment on GR mRNA (t(11)=-2.34, P=0.039) with 
higher expression in the SAFit2-treated rats, and a trend towards higher c-Fos mRNA 
expression in the SAFit2-treated group was found (t(11)=-1.88, P=0.086). No significant 
effects of treatment on MR mRNA (t(11)=-0.46, P=0.650), CRH mRNA (t(11)=-1.51, P=0.158), 
or AVP mRNA (t(11)=-0.31, P=0.741) were found.  
For the sub-chronic male SAFit1 experiment GR, MR, CRH, AVP, and c-Fos mRNA in the 
hypothalamus following the noise stress in are shown in figure 4.7 B. There was an effect of 
treatment on c-Fos mRNA (t(10)=2.63, P=0.025), with lower expression in the SAFit1-treated 
rats, as shown by unpaired t-test. There was no significant effect of treatment on GR mRNA 
(t(10)=0.54, P=0.60), MR mRNA (t(10)=-0.46, P=0.651), CRH mRNA (t(10)=-0.42, P=0.678), or 
AVP mRNA (t(10)=0.34, P=0.741).  
Figure 4.7 C shows the hypothalamic mRNA expression of the GR-inducible genes, 
FKBP5, GILZ, PER1, and SGK1, in sub-chronically treated SAFit2 males following the noise 
stress. There was a significant effect of treatment on GILZ mRNA (t(11)=-2.43, P=0.033), and 
SGK1 mRNA (t(11)=-2.44, P=0.033), with increased expression in the SAFit2-treated rats. 
There was no significant effect of treatment on FKBP5 mRNA (t(11)=-1.28, P=0.191), or PER1 
mRNA (t(11)=-1.81, P=0.098) as revealed by an unpaired t-test.  
The mRNA expression following noise stress of the same GR-inducible genes from the 




effect of treatment on FKBP5 mRNA (t(10)=-0.41, P=0.690), GILZ mRNA (t(10)=0.04, P=0.965), 
PER1 (t(10)=1.22, P=0.250), and SGK1 mRNA (t(10)=1.59, P=0.141).  
 
 
Figure 4.7. The effect of sub-chronic SAFit2 and SAFit1 treatment on stress-induced gene 
expression in the hypothalamus of male rats. Mean + SEM expression of GR, MR, CRH, AVP, 
and c-Fos mRNA in the hypothalamus of male rats treated with Vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=5) or SAFit2 (20 mg/kg, s.c.; n=5) at 09.00h, 
and 17.00h for 5 consecutive days (A), and Vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 
80 in saline; 2 ml/kg; s.c.; n=3) or SAFit1 (20 mg/kg, s.c.; n=3) at 09.00h, 14.00h, and 19.00h 
for 5 consecutive days (B). Mean + SEM expression of FKBP5, GILZ, PER1, and SGK1 mRNA in 
the hypothalamus of male rats treated with Vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 
80 in saline; 2 ml/kg; s.c.; n=5) or SAFit2 (20 mg/kg, s.c.; n=5) at 09.00h, and 17.00h for 5 
consecutive days (C), and Vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 
ml/kg; s.c.; n=3) or SAFit1 (20 mg/kg, s.c.; n=3) at 09.00h, 14.00h, and 19.00h for 5 consecutive 




4.3.4.2. Anterior pituitary gland 
The expression of the same genes was characterised in the anterior pituitary gland 
and GR, MR, POMC, and c-Fos mRNA expression in the anterior pituitary gland following the 
noise stress in the sub-chronic male SAFit2 experiment is shown in figure 4.8 A. An unpaired 
t-test revealed a trend for an effect of treatment on c-Fos mRNA (t(11)=-2.11, P=0.059), with 
higher expression in the SAFit2 group. There was no effect of treatment on GR mRNA (t(11)=-
0.95, P=0.363), MR mRNA (t(11)=-1.31, P=0.216), or POMC mRNA (t(11)=-1.14, P=0.188). 
In the sub-chronic male SAFit1 experiment, an unpaired t-test revealed no effect of 
treatment on GR mRNA (t(10)=0.89, P=0.391), MR mRNA (t(10)=0.22, P=0.827), POMC mRNA 
(t(10)=-1.73, P=0.113), or c-Fos mRNA (t(10)=0.25, P=0.804), shown in figure 4.8 B.  
The relative expression of FKBP5, GILZ, PER1, and SGK1 mRNA in the anterior pituitary 
gland following the noise stress in the sub-chronic male SAFit2 experiment is shown in figure 
4.8 C. An unpaired t-test revealed a trend towards a significant effect of treatment on GILZ 
mRNA (t(11)=-1.93, P=0.079) with higher expression in SAFit2-treated rats. There was no 
significant effect of treatment on FKBP5 mRNA (t(11)=-0.08, P=0.921), PER1 mRNA 
(t(11)=0.02, P=0.983), and on SGK1 mRNA (t(11)=-0.633, P=0.531).  
The same GR-inducible genes were measured in the anterior pituitary gland of the 
sub-chronic SAFit1 males, and are shown in figure 4.8 D. There was no effect of treatment on 
FKBP5 mRNA (t(10)=-0.78, P=0.495), GILZ mRNA (t(10)=-0.05, P=0.954), PER1 mRNA 









Figure 4.8. The effect of sub-chronic SAFit2 and SAFit1 treatment on stress-induced gene 
expression in the anterior pituitary gland of male rats. Mean + SEM expression of GR, MR, 
CRH, AVP, and c-Fos mRNA in the anterior pituitary gland of male rats treated with Vehicle 
(VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=5) or SAFit2 (20 mg/kg, 
s.c.; n=5) at 09.00h, and 17.00h for 5 consecutive days (A), and Vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3) or SAFit1 (20 mg/kg, s.c.; n=3) at 09.00h, 
14.00h, and 19.00h for 5 consecutive days (B). Mean + SEM expression of FKBP5, GILZ, PER1, 
and SGK1 mRNA in the in the anterior pituitary gland of male rats treated with Vehicle (VEH: 
4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=5) or SAFit2 (20 mg/kg, s.c.; 
n=5) at 09.00h, and 17.00h for 5 consecutive days (C), and Vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3) or SAFit1 (20 mg/kg, s.c.; n=3) at 09.00h, 







This chapter highlights the difference between the effects of SAFit2 and SAFit1 both 
on CORT pulsatility and on GR transcriptional activity. However, 5 days treatment with the 
central and peripheral FKBP51-inhibitor SAFit2, or the peripheral-only FKBP51-inhibitor, 
SAFit1, both result in lower stress-induced CORT secretion.  
Sub-chronic SAFit2 resulted in decreased basal CORT, indicated by lower mean CORT, 
max CORT, pulse amplitude and height, and AUB. However, pulsatile dynamic analysis using 
the PULSAR algorithm revealed an effect of SAFit1 on pulsatility, with shorter pulses, shorter 
IPI and increased number of pulses in the SAFit1 group compared to vehicle-treated rats, an 
effect that was not seen in the SAFit2 group.  This suggests that prolonged inhibition of 
FKBP51 in the periphery only causes a change in CORT ultradian pulsatility. In contrast, 
central, and peripheral inhibition of FKBP51 does not alter the CORT ultradian pulsatility 
however reduces CORT concentrations.  
For decades it was thought that the CORT pulsatility was under hypothalamic control, 
and it is not until recently that a model of a pituitary-adrenal gland feed-forward/feedback 
loop was suggested to produce the ultradian pulses (130, 132). Walker and colleagues showed 
that pulsatile CORT secretion occurs without a pulsatile CRH input to the pituitary gland (130). 
For example, a constant infusion of a physiological dose of CRH results in pulses of ACTH, 
followed by pulses of CORT (131). In contrast, inhibiting the SCN output disrupts the circadian 
rhythmicity of CORT secretion however the ultradian CORT pulses remain intact (131).  
Interestingly, the pulse-generator model proposed by Walker and colleagues (131, 
132) suggests that if the adrenal gland delay is reduced (produced by decreased ACTH) and 
the CRH drive remains constant, this will produce shorter CORT pulses. This is consistent with 
the result seen in the SAFit1 experiment. The model also predicts that a decrease in adrenal 
gland delay and a simultaneous decrease in CRH drive would cause no difference in the CORT 
pulse length. This is consistent with the results of the SAFit2 experiment. The exact 
mechanism of ultradian CORT pulsatility is yet to be unravelled however this study is the first, 
to my knowledge, to show that altering GR activity in the periphery only (with SAFit1), 




in gaining further knowledge in the regulation, and hence the importance of ultradian CORT 
pulses and their regulation.  
What is the physiological relevance of CORT pulsatility? As both ACTH and CORT are 
released in pulsatile manners, the two cognate receptors are exposed to their ligands in 
oscillatory signals and these oscillations of ligands are important for a rapid response in the 
target tissues. Indeed, an in vivo study in the rat investigated the effect of constant versus 
pulsatile ACTH infusion on the CORT response and showed that only the pulsatile ACTH 
infusion elicited a CORT response (384). Similarly, in vitro studies in AtT-20 cells indicates that 
a pulse of CORT activates intracellular GR in a rapid and transient manner (385).  
Physiological conditions such as ageing and certain disease states produce an 
alteration in this ultradian CORT pulsatility (302). Cushing’s syndrome refers to adrenal gland 
hyperactivity irrespective of aetiology (386), whilst Cushing’s disease is a secondary 
hypercortisolism caused by overproduction of ACTH from the anterior pituitary gland, often 
as a result of a pituitary gland tumour (387). In Cushing’s disease the majority of patients 
exhibit a blunted circadian cortisol secretion, however, in a third of patients there is an 
increase in the magnitude of the ultradian pulses (302). Similarly, patients with primary 
adrenal gland Cushing’s syndrome exhibit overall increased cortisol concentrations 
throughout the day, and this is produced by an increase in amplitude and frequency of the 
ultradian cortisol pulses (388). Furthermore, patients suffering from melancholic depression 
have overall increased circulating cortisol as a result of the increased amplitude of the 
ultradian pulses throughout the day (300). It is not yet understood how these disease states 
produce these alterations to the ultradian pulsatility however it is thought that a 
dysfunctional GC negative feedback mechanism is involved. The changes in ultradian pulse 
frequency following sub-chronic SAFit1 administration (figure 4.3. and 4.4.) is possibly the 
first study to date to show that changes in peripheral GR activity, and hence changes in the 
pituitary-adrenal gland pulse generator, can alter the frequency of ultradian CORT pulses.  The 
increase in pulse frequency in the SAFit1-treated animals is likely to be due to a lower ACTH 
secretion from the pituitary gland caused by enhanced GR-mediated negative feedback 
(section 3.3.5), although the molecular mechanism is yet to be unravelled.  
In this chapter, it was also demonstrated that sub-chronic SAFit2 treatment induced 




genes GILZ and SGK1 in the hypothalamus. There was no effect of SAFit1 treatment on any of 
the GR-inducible genes measured and this is not surprising as the SAFit1 should not be active 
centrally. In the hypothalamus, the c-Fos mRNA expression increased following noise stress 
in the SAFit2 group and decreased in the SAFit1 group compared to respective vehicle-treated 
rats. As c-Fos in the brain can be used as a marker of general neuronal activity (378), this 
suggests an increase in neuronal activity in the hypothalamus following SAFit2 treatment and 
a decrease in neuronal activity in the hypothalamus following SAFit1 treatment.  
Although SAFit1 does not cross the BBB, this effect is rather surprising and could be 
due to a decrease in neuronal activity unrelated to the effects of SAFit1. As c-Fos expression 
can be used as a marker of general neuronal expression (378), this suggests that prolonged 
SAFit2 treatment increases the neuronal activity in the hypothalamus following the noise 
stress. It is difficult to determine what exact neuronal activity is enhanced, however, it is 
tempting to speculate that it is related to the GC-mediated negative feedback to reduce the 
stress-induced CORT in the SAFit2-treated rats. It is likely that the decrease in c-Fos in the 
SAFit1-treated rats, as the SAFit1 does not reach the brain, is secondary to the effects of 
SAFit1 in the periphery. Hence this effect would be present in the SAFit2-treated rats too, and 
the overall increase in c-Fos expression is specific to the effects of SAFit2.  
Further, the results show an increased GR transcriptional activity in the hypothalamus 
following the SAFit2 treatment, despite a lower secretion of CORT following stress in this 
group, whilst there was no effect of the SAFit1 treatment. This indicates that sub-chronic 
SAFit2 treatment enhances GR transcriptional activity, and it is plausible that this is by 
increasing nuclear GR as a result of less FKBP51-bound GRs, caused by the SAFit2. In 
comparison, the SAFit1 does not enter the brain and thus is it not surprising that there was 
no increase in those GR-inducible genes.  
The expression of GR is regulated by various pathways, including cAMP and 
autoregulation where GR can bind to a GRE within its gene (376, 377).  Indeed, it has been 
shown that GCs, such as DEX, can downregulate GR expression (375). Thus, perhaps GR 
expression is increased following sub-chronic SAFit2 administration as a result of decreased 




These data indicate a small increase in GR transcriptional activity in the hypothalamus 
following SAFit2 treatment at 60 minutes post-noise stress. This effect was not observed in 
the SAFit1 group. The expression of these GR-inducible genes was measured 60 minutes 
following noise stress and the expression profiles are likely different under basal conditions. 
Nevertheless, these results indicate that there is no enhancement in transcriptional GR 
activity following SAFit1, and a slight enhancement following SAFit2. Interestingly, both SAFit2 
and SAFit1 resulted in lower stress-induced CORT increase following sub-chronic treatment. 
It is plausible that SAFit2 causes this reduction in CORT by the enhanced transcriptional GR 
activity, as a result of increased nuclear GR. This could enhance GR binding the nGRE in the 
POMC gene and reduce ACTH concentrations, and reduce CORT secretion. Although there 
was no reduction in POMC mRNA expression observed in this study only one time point was 
used and the whole anterior pituitary gland for measurements. Perhaps additional time 
points and a more anatomically sensitive technique would reveal differences in POMC 
expression. Moreover, studies suggest that GR can interact with CREB in the PVN to prevent 
CREB binding to the CRE on the CRH promoter (194, 195). Thus, it is plausible that increased 
nuclear GR will result in reduced CRH and subsequently CORT, and perhaps this is the 
mechanism by which SAFit2 reduces the CORT concentrations. Although there was no 
difference in CRH mRNA expression in the SAFit2-treated animals compared to the vehicle-
treated animals, the expression was measured in whole hypothalamic extract and therefore 
does not only include the PVN but also other nuclei. The CRH mRNA expression was measured 
at one time point only, and given that changes in CRH expression in response to stress are 
highly dynamic (389) this may not be the time point at which the difference is most apparent. 
In contrast, there was no effect of sub-chronic SAFit1 treatment on the GR-inducible genes 
measured in this experiment. This suggests that perhaps the effects of SAFit1 are due to non-
genomic GR activity.  It is also possible that the peak expression of the GR-inducible genes 
was missed in this experiment.  
Perhaps a more suitable technique for measuring gene expression would have been 
ISH which allows for anatomical quantification of the gene expression. Alternatively, punching 
out specific areas, such as the PVN, from brain slices and performing RT-qPCR would have 




for a timeline of gene expression following stress however, as previously mentioned, the 
limited availability of the SAFit compounds meant this was not possible.  
Further, neither SAFit2 nor SAFit2 caused induction of any of the GR-inducible genes 
measured in the anterior pituitary gland. Since SAFit1 is only active peripherally, this indicates 
that either the peak of the transcriptional activity of these GR-inducible genes are at a 
different time point, or that the actions of SAFit1 at the pituitary gland are non-genomic.  
In this chapter, evidence for altered pulsatility following peripheral-only FKBP51 
inhibition is presented. There has been a long-standing notion that ultradian CORT pulsatility 
is centrally regulated, however, recent evidence suggests a system comprising a pituitary-
adrenal gland feed-forward/feedback loop to regulate CORT pulsatility (131, 132). The data 
in this chapter support this model and highlights the important role of the pituitary-adrenal 


















Chapter 5: Treatment with FKBP51 inhibitors in female rats 
 
5.1. Introduction  
Substantial evidence indicates sexual dimorphism in the HPA axis, both in humans and 
in rodents. Female rats have higher overall basal and stress-induced CORT concentrations 
(reviewed (231)), and ovariectomized females show similar CORT concentrations as sham 
males (239). This suggests a strong role of sex steroids in influencing HPA axis activity. Global 
FKBP51-knock out in female mice had a stronger effect than in male mice, with reduced basal 
and stress-induced CORT concentrations, whereas there was no effect on basal CORT 
concentrations in male 51KO (342, 343). This evidence suggests that perhaps FKBP51 has a 
more prominent role in regulating HPA axis activity in female mice.  
Therefore, in this chapter data showing the effects of SAFit2 and SAFit1 administration 
in female adult rats on both basal and stress-induced CORT secretion will be presented. 
Furthermore, the expression of GR, MR, and FKBP51 in male and female control animals will 
be shown, and the effect of SAFit2 and SAFit1 on gene expression following noise stress will 
be discussed.  
 
5.2. Methods 
All the female rats used for the experiments in this chapter were freely cycling 
Sprague-Dawley and no tests for the stage of the oestrus cycle were performed.  
 
5.2.1. Experiments 9 and 10: Effect of acute SAFit2 and SAFit1 treatment on CORT ultradian 
rhythm and stress-induced CORT secretion in intact female rats.  
For the SAFit2 experiments rats were treated with either vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in 0.09% sterile saline; 2 ml/kg; s.c. n=7) or SAFit2 (20 mg/kg; s.c.; n=7) 
at 09.00h and 17.00h on the day of blood sampling. For SAFit1 experiments, rats were treated 
with either vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in 0.09% saline; 2 ml/kg; s.c. 
n=9) or SAFit1 (20 mg/kg; s.c.; n=3) at 09.00h, 14.00h and 19.00h on the day of blood 
sampling. Note that this experiment protocol differed from the SAFit2 experiment only in the 









Figure 5.1. Experimental schedule for the acute SAFit2 and SAFit1 treatment in female rats.   
 
5.2.2. Experiment 11: Effect of sub-chronic SAFit2 treatment on CORT ultradian rhythm 
and stress-induced CORT secretion in female rats  
For SAFit2 experiments rats were treated with either vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in 0.09% sterile saline; 2 ml/kg; s.c., n=7) or SAFit2 (20 mg/kg; s.c.; n=6) 








Figure 5.2. Experimental schedule for the sub-chronic SAFit2 treatment in female rats.   
 
For all three SAFit1 and SAFit2 experiments, ABS for measurement of basal CORT was 
conducted from 07.00h on day 1, or day 5, until 07.00h the following day. At 07.00h of day 6, 
all rats were subject to noise stress (10 min, 96dB, white noise) and blood sampling collection 
continued for one more hour. Immediately after the sampling had stopped at 08.00h the rats 
were euthanized using pentobarbitone injection in the i.v. cannula followed by decapitation 
with a guillotine. The brains were dissected to isolate specific areas, and, along with the 
anterior pituitary gland and adrenal gland, were snap-frozen on dry ice to be used for further 
gene expression analysis.  
Due to time restraints, for the SAFit1 experiment, the data from the vehicle group was 
pooled with the vehicle group from the acute SAFit2 female experiment for all data analysis. 
The analysis for the SAFit2-treated rats was only compared to the respective vehicle-treated 
animals, not with the pooled vehicle-treated animals.  
 
5.2.3. Experiment 12: Expression of FKBP5, GR and MR in the brain and anterior pituitary 
gland of intact male and female rats 
Female and male Sprague-Dawley of 8 weeks old were euthanized in the AM (08.00h-
09.00h) or PM (16.30h-17.30h) using isoflurane. Brains and anterior pituitary gland were 
dissected and snap-frozen on dry ice and further processed for gene expression analysis. The 









5.3.1. The effect of acute SAFit2 treatment on basal CORT concentrations and ultradian 
rhythms in adult female rats 
In this experiment, the same protocol was followed as for the acute SAFit2 ABS 
experiment in male rats. Seven vehicle-treated rats and seven SAFit2-treated rats were all 
subject to ABS every 10 minutes for 24 hours on the same day as treatment. The mean 24-h 
CORT profiles are shown in figure 5.3 (A) along with the individual representative profile (B-
E). 
To allow for a quantitative comparison of the CORT parameters, the individual 24-hour 
CORT profiles were analysed using PULSAR. The means for each parameter are shown in figure 
5.4. An unpaired t-test revealed no significant effect of treatment on any of the parameters 
tested, including mean CORT (t(11)=-0.66, P=0.522), max CORT (t(11)=0.91, P=0.385),  
baseline CORT (t(11)=-0.95, P=0.358), number of pulses (t(11)=1.78, P=0.103), pulse 
amplitude (t(11)=0.12, P=0.905), pulse height (t(11)=-0.03, P=0.976), pulse length (t(11)=-
1.27, P=0.227), pulse area (t(11)=-1.23, P=0.242), IPI (t(11)=-1.14, P=0.275), pulse frequency 











Figure 5.3. The effect of acute SAFit2 treatment on ultradian CORT secretion in female rats.  
Mean + SEM (A) CORT concentrations, and representative individual profiles (B-E) from female 
adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; 
s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=7) or at 09.00h, and 17.00h. Blood samples were 
collected via a cannula implanted in the right jugular vein every 10 min for 24-h using an 
automated blood sampling system. Plasma corticosterone was measured by 







Figure 5.4. The effect of acute SAFit2 treatment on PULSAR parameters in female rats.  Mean 
+ SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated with 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; n=5) or SAFit1 (20 
mg/kg, s.c.; n=7) at 09.00h, and 17.00h. Amp=amplitude, IPI=inter-pulse interval, AUC= area 
under the curve. Amp=amplitude, IPI= inter-pulse interval, AUC= area under the curve.  
 
These data are in contrast with the data showing an effect of acute SAFit2 in male rats, 
with significantly lower maximum CORT concentrations. This highlights an important 
difference in the regulation of basal HPA axis activity in males and females following the 
inhibition of FKBP51. Nevertheless, a higher dose of, or prolonged treatment with SAFit2 may 






5.3.2. The effect of SAFit1 treatment on basal CORT concentrations and ultradian rhythms 
in adult female rats 
To further investigate the effect of FKBP51 inhibition in female rats and the role of 
FKBP51 in HPA axis sexual dimorphism, SAFit1 was administered acutely in female rats and 
the effect on basal HPA axis activity was investigated. Since there was no effect of acute SAFit2 
administration on basal CORT concentrations or the ultradian pulsatile pattern, it would be 
interesting to investigate whether a peripheral-only FKPBP51 inhibition would have different 
effects. As already mentioned, the use of SAFit1 allows the distinguishing between central 
and peripheral mechanisms, and to investigate what effect may occur when peripheral-only 
FKBP51 inhibition is achieved. Furthermore, as acute SAFit1 administration in male rats 
(chapter 3) did not have any effects on basal CORT concentration or CORT pulsatility, this 
experiment allowed the comparison of a potential sex difference in the peripheral regulation 
of CORT secretion.  
The same sampling protocol was followed as for the acute female SAFit2 ABS 
experiment, and the acute male SAFit2 and SAFit1 ABS experiments, and the animals were 
treated at 09.00h, 14.00h, and 19.00h on the same day as sampling.  
Twenty-four-hour sampling profiles of CORT concentrations were obtained for three 
vehicle-treated and five SAFit1-treated animals and the mean average CORT concentration 
was calculated for each time point. Individual representatives and the resultant mean profiles 
are shown in fig 5.5. Due to technical problems with the sampling procedure (i.e. lack of 
cannula patency), and time limitations, full 24-h CORT profiles from only three vehicle-treated 
rats were obtained, and therefore the data was pooled with the vehicle-treated rats from the 
female acute SAFit2 experiment. Although this is not ideal due to difference in treatment 
frequency and timings, and different batches of animals, an unpaired t-test of the two vehicle-
treated groups did not reveal any significant differences for any of the PULSAR parameters, 
suggesting that the two vehicle-treated groups are comparable.  
All the individual 24-hour profiles were analysed with PULSAR and the means for each 
parameter are shown in figure 5.6. Further, an unpaired t-test revealed a significant effect of 
treatment on mean CORT (t(10)=2.48, P=0.033), AUC basal (t(10)=2.89, P=0.016) and AUC 




(t(10)=2.05, P=0.067) and pulse height (t(10)=1.95, P=0.080), with all parameters decreased 
in the SAFit1-treated rats compared to vehicle-treated rats. There was no effect of treatment 
on max CORT (t(10)=1.00, P=0.340), baseline CORT (t(10)=0.91, P=0.379), number of pulses 
(t(10)=-0.26, P=0.795), pulse length (t(10)=0.034, P=0.974), pulse area (t(10)=0.27, P=0.790), 




















Figure 5.5. The effect of acute SAFit1 treatment on ultradian CORT secretion in female rats.  
Mean + SEM (A) CORT concentrations, and representative individual profiles (B-E) from female 
adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; 
s.c.; n=3+6) or SAFit1 (20 mg/kg, s.c.; n=4) or at 09.00h, 14.00h, and 19.00h. Blood samples 
were collected via a cannula implanted in the right jugular vein every 10 min for 24-h using an 
automated blood sampling system. Plasma corticosterone was measured by 





Figure 5.6. The effect of acute SAFit1 treatment on PULSAR parameters in female rats. Mean 
+ SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated with 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3+6) or SAFit1 
(20 mg/kg, s.c.; n=4) at 09.00h, and 17.00h. Amp=amplitude, IPI=inter-pulse interval, AUC= 
area under the curve. Amp=amplitude, IPI= inter-pulse interval, AUC= area under the curve. 
*P<0.05 compared to vehicle-treated rats, with unpaired t-test. 
 
5.3.3. The effect of acute SAFit2 and SAFit1 treatment on post-stress CORT concentrations 
in adult female rats  
Following 24-h blood sampling and treatment with SAFit2 or SAFit1, the rats were 
subjected to noise stress and blood sampling continued for 60 minutes following the noise 
stress (see schematic figure 5.1).  
The mean + SEM CORT concentration at each time point was calculated for each group 
as shown in figure 5.7. In the SAFit2 experiment (figure 5.7 A), repeated measures ANOVA 




interaction between time and treatment (F(2.1,24.8)=2.0, P=0.146), and only a trend toward 
a significant effect of the treatment was found (F(1,12)=4.193, P=0.063).  Further, post hoc 
analysis revealed a significant increase in stress-induced CORT in vehicle-treated rats at the 
10 (P<0.0001), 20 (P<0.0001), and 30 (P<0.0001) minute time points, compared to vehicle-
treated rats at the 0 minute time point. A significant increase in stress-induced CORT in SAFit2-
treated rats was also observed at the 10 (P<0.0001), 20 (P<0.0001), and 30 (P<0.0001) minute 
time points, compared to SAFit2-treated rats at the 0 minute time point. There was no 
difference between the baseline CORT at the 0 minute time point between vehicle-treated 
rats and SAFit2-treated rats. 
These data suggest there is no difference in stress-induced CORT secretion in SAFit2-
treated rats compared to vehicle-treated rats.  
In the SAFit1 experiment (figure 5.7 B), repeated measures ANOVA analysis showed a 
significant effect of time (F(2.5,32.2)=45.7, P=<0.00001), a significant interaction between 
time and treatment (F(2.5,32.2)=4.9, P=0.009), and a significant effect of treatment 
(F(1,13)=9.003, P=0.01). Further, post hoc analysis revealed a significant increase in stress-
induced CORT in vehicle-treated rats at the 10 (P<0.0001), 20 (P<0.0001), and 30 (P<0.0001) 
minutes time points, compared to vehicle-treated rats at the 0 minute time point.   In 
comparison, no significant increase in stress-induced CORT in SAFit1-treated rats was 
observed at any time points. Plasma CORT concentrations were significantly lower in the 
SAFit1-treated rats at the 10 minutes (P=0.005), 20 minutes (P=0.001) and 30 minutes 
(P=0.005) time points compared to vehicle-treated rats at respective time points. There was 
no difference between the baseline CORT at the 0 minute time point between vehicle-treated 
rats and SAFit2-treated rats. 
These data indicate that, compared to vehicle-treated rats, acute SAFit1 treatment in 





Figure 5.7. The effect of acute SAFit2 and SAFit1 treatment on stress-induced CORT secretion 
in female rats.   (A) Mean + SEM corticosterone levels during noise stress (96dB, 10 minutes, 
white noise, 07.00h) from female adult rats treated with vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=7) at 09.00h, 
and 17.00h on the day prior to the noise stress. (B) Mean + SEM corticosterone levels during a 
noise stress (96dB, 10 minutes, white noise, 07.00h) from female adult rats treated with 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3+7) or SAFit1 
(20 mg/kg, s.c.; n=4) at 09.00h, 14.00h, and 19.00h on the day prior to the noise stress. Blood 
samples were taken every 10 minutes from a cannula implanted in the right jugular vein and 
CORT concentrations measured with CORT RIA. The grey bar indicates noise stress. *P<0.05; 
compared to rats treated with vehicle, with Tukey’s post hoc test. #P<0.05; compared to 
respective time 0, with Tukey’s post hoc test. 
 
5.3.4. The effect of sub-chronic SAFit2 treatment on basal CORT concentrations and 
ultradian rhythms in adult female rats 
Six vehicle-treated rats and six SAFit2-treated rats were treated for 5 consecutive days 
and on the fifth day they were all subject to ABS every 10 minutes for 24 hours. The blood 
samples were assayed for CORT concentrations and the mean was calculated for each time 
point for both groups. The resultant average 24-h profiles are shown in figure 5.8 (A) along 




All the individual 24-hour profiles were analysed with PULSAR and the means for each 
parameter are shown in figure 5.9. Further, an unpaired t-test revealed a significant effect of 
treatment on mean CORT (t(11)=2.96, P=0.013), max CORT (t(11)=3.50, P=0.005), baseline 
CORT (t(11)=2.68, P=0.021), pulse amplitude (t(11)=3.58, P=0.004), pulse height (t(11)=4.00, 
P=0.002), pulse area (t(11)=2.36, P=0.038), AUC basal (t(11)=2.11, P=0.048), AUC total 
(t(11)=2.31, P=0.046). There was a trend of effect on the pulse length (t(11)=1.91, P=0.081) 
and the IPI (t(11)=1.87, P=0.088). All these parameters were decreased in the SAFit2-treated 
female rats. There were no significant effects on the number of pulses (t(11)=-1.61, P=0.136), 


















Figure 5.8. The effect of sub-chronic SAFit2 treatment on ultradian CORT secretion in female 
rats.  Mean + SEM (A) CORT concentrations, and representative individual profiles (B-E) from 
female adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 
2 ml/kg; s.c.; n=6) or SAFit2 (20 mg/kg, s.c.; n=7) or at 09.00h, and 17.00h for five consecutive 
days. Blood samples were collected via a cannula implanted in the right jugular vein every 10 
min for 24-h using an automated blood sampling system on the fifth day. Plasma 







Figure 5.9. The effect of sub-chronic SAFit2 treatment on PULSAR parameters in female rats. 
Mean + SEM CORT parameters calculated using PULSAR from 24-hour profiles of rats treated 
with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.;  n=6) or SAFit1 
(20 mg/kg, s.c.; n=7) at 09.00h, and 17.00h. Amp=amplitude, IPI=inter-pulse interval, AUC= 
area under the curve. Amp=amplitude, IPI= inter-pulse interval, AUC= area under the curve. 
*P<0.05 compared to vehicle-treated rats, with unpaired t-test. 
 
5.3.5. The effect of sub-chronic SAFit2 treatment on post-stress CORT concentrations in 
adult female rats  
Following sub-chronic treatment with SAFit2 in male rats, the post-noise CORT 
concentrations were significantly lower in the SAFit2 group. Therefore, it was of interest to 
investigate whether the sub-chronic treatment with SAFit2 would have the same inhibitory 




Following 24-h blood sampling and treatment with SAFit2 or vehicle, the rats were 
subjected to noise stress and blood sampling continued for 60 minutes after the noise stress 
(see schematic figure 5.2).  
The mean + SEM CORT concentration at each time point was calculated for each group 
as shown in figure 5.8. Repeated measures analysis revealed a significant effect of time 
(F(3.3,26.1)= 55.3,P=<0.00001), no significant interaction between time and treatment 
(F(3.3,26.1)=0.4, P=0.752), and no significant effect of treatment (F(1,8)=0.624,P=0.448). 
Further, post hoc analysis revealed a significant increase in stress-induced CORT in vehicle-
treated rats at the 10 (P<0.0001), and 20 (P<0.0001) minute time points, compared to vehicle-
treated rats at the 0 minute time point.   A significant increase in stress-induced CORT in 
SAFit2-treated rats was also observed at the 10 (P<0.0001), 20 (P<0.0001), and 30 (P=0.019) 
minute time points, compared to SAFit2-treated rats at the 0 minute time point. There were 
no difference between the baseline CORT at the 0 minute time point, or any of the other time- 
points, between vehicle-treated rats and SAFit2-treated rats. 
The results of this experiment indicate that repeated sub-chronic administration of 










Figure 5.10. The effect of sub-chronic SAFit2 treatment on stress-induced CORT secretion in 
female rats. Mean + SEM corticosterone levels during a noise stress (96dB, 10 minutes, white 
noise, 07.00h) from female adult rats treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% 
Tween 80 in saline; 2 ml/kg; s.c.; n=6) or SAFit2 (20 mg/kg, s.c.; n=6) at 09.00h, and 17.00h 
for five consecutive days. Blood samples were taken every 10 minutes from a cannula 
implanted in the right jugular vein and CORT concentrations measured with CORT RIA. The 
grey bar indicates noise stress. #P<0.05; compared to respective time 0, with Tukey’s post hoc 
test. 
 
Numerous rodent studies have shown a sexual dimorphism in the CORT response to 
stress. Indeed, several studies have shown a higher response in female rats when exposed to 
stressors including forced running, foot shock, immunological stressors, immobilisation, 
alcohol administration, ether, noise stress and a novel environment (231). Comparing the 
data from the female sub-chronic SAFit2 experiment with the male sub-chronic SAFit2 
experiment, the vehicle-treated females do not have higher post-stress CORT concentrations. 
That is surprising however these are different experiments on different litters, and the CORT 
concentrations were measured in different CORT RIAs, thus cannot be directly compared. It 
is, however, interesting to note the difference between the sub-chronic SAFit2 effects on the 
stress-response in male and female rats. Following acute SAFit2 treatment in female rats, 




SAFit2-treated females this was abolished and there was no difference in stress-induced CORT 
compared to the vehicle-treated groups. In contrast, in the acutely SAFit2-treated males, 
there was also a small decrease in stress-induced CORT, however, this was further lowered in 
the sub-chronically treated SAFit2 males. Hence, this further supports the hypothesis that 
SAFit2 has opposite actions centrally and peripherally in female rats, with a decrease of GC-
mediated negative feedback centrally, and an increase in GC-mediated negative feedback 
peripherally.   
 
5.3.6. Stress-induced gene expression in the hypothalamus and anterior pituitary gland 
following acute SAFit2 or SAFit1 treatment. 
In both experiments, the rats were sacrificed immediately following the collection of 
the last blood sample, 60 minutes subsequent the noise stress. Tissues were dissected and 
extracted for RT-qPCR analysis for gene expression in the hypothalamus and anterior pituitary 
gland. As described in the sampling experiment section, due to time constraints only three 
vehicle-treated rats from the SAFit1 experiment were obtained and therefore the data from 
these rats were pooled with the data from the vehicle-treated rats from the SAFit2 
experiment.  
The effects of SAFit2 and SAFit1 treatment on HPA axis activity in the hypothalamus 
were investigated by quantifying the expression of the GR and MR, and CRH, AVP, and c-Fos. 
The c-Fos expression is a marker of general neuronal excitability, with an increased expression 
suggesting an increased neuronal firing. To evaluate whether either compound had any effect 
on GR transcriptional activity, the expression of several GR-inducible genes, including FKBP5, 
GILZ, PER1, and SGK1 was also investigated.  
 
5.3.6.1. Hypothalamus 
The relative expression of GR, MR, CRH, AVP, and c-Fos mRNA in the hypothalamus 
following the noise stress in the acute female SAFit2 experiment are shown in figure 5.11 A. 




mRNA (t(13)=0.43, P=0.672), CRH mRNA (t(13)=1.37, P=0.193), AVP mRNA (t(13)=-0.07, 
P=0.944), or on c-Fos mRNA (t(13)=-0.25, P=0.810).  
Figure 5.11 B shows the expression of the same genes in the hypothalamus from the 
acute female SAFit1 experiment. A lower expression of CRH mRNA (t(12)=2.73, P=0.018) was 
observed in the SAFit1-treated rats compared to vehicle-treated rats. There was no effect of 
treatment on GR mRNA (t(12)=1.61, P=0.134), MR mRNA (t(12)=1.61, P=0.132), AVP (t(12)=-
1.38, P=0.193), or on c-Fos mRNA (t(12)=1.15, P=0.270), as shown by an unpaired t-test.  
The GR-inducible genes FKBP5, GILZ, PER1, and SGK1 mRNA in the hypothalamus 
following the noise stress in the acute female SAFit2 experiment are shown in figure 5.11 C. 
There was no effect of treatment on FKBP5 mRNA (t(13)=-0.95, P=0.359), GILZ mRNA 
(t(13)=1.03, P=0.320), PER1 mRNA (t(13)=-0.25, P=0.580), or on SGK1 mRNA (t(13)=0.16, 
P=0.359), as revealed by an unpaired t-test.  
For the acute female SAFit1 experiment, the expression of the same GR-inducible 
genes in the hypothalamus following noise stress are shown in figure 5.11 D. An unpaired t-
test revealed a trend for an effect of treatment on FKBP5 mRNA (t(12)=-1.86, P=0.087), with 
higher expression in the SAFit1-treated rats compared to vehicle-treated rats. There was no 
effect of treatment on GILZ mRNA (t(12)=0.50, P=0.626), PER1 mRNA (t(12)=0.72, P=0.486), 





Figure 5.11. The effect of acute SAFit2 and SAFit1 treatment on stress-induced gene 
expression in the hypothalamus of female rats. Mean + SEM of GR, MR, CRH, AVP, and c-Fos 
mRNA in the hypothalamus of female rats treated acutely with vehicle (VEH: 4% Ethanol; 5% 
PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=7) (A) and 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3+7) or SAFit1 
(20 mg/kg, s.c.; n=4)(B). Mean + SEM of FKBP5, GILZ, PER1, and SGK1 mRNA in the 
hypothalamus of female rats treated acutely with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% 
Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=7) (C) and vehicle (VEH: 4% 
Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3+7) or SAFit1 (20 mg/kg, s.c.; 
n=4)(D). *P<0.05 compared to vehicle, with unpaired t-test.   
 
5.3.6.2. Anterior pituitary gland 
In the anterior pituitary gland, the expression of GR, MR, CRH, AVP, and c-Fos mRNA 




Unpaired t-tests revealed a significant effect of treatment on POMC mRNA (t(13)=2.49, 
P=0.027), with lower expression in the SAFit2 group. There was no effect of treatment on GR 
mRNA (t(13)=0.06, P=0.950), MR mRNA (t(13)=0.27, P=0.786), or on c-Fos mRNA (t(13)=-1.75, 
P=0.103).  
The relative expression of GR, MR, CRH, AVP, and c-Fos mRNA in the anterior pituitary 
gland following noise stress in the acute female SAFit1 experiment are shown in figure 5.12 
B. There was no effect of treatment on GR mRNA (t(12)=-0.75, P=0.467), MR (t(12)=-1.32, 
P=0.211), POMC (t(12)=-0.39, P=0.721), or on c-Fos mRNA (t(12)=-1.24, P=0.239), as revealed 
by unpaired t-tests.  
Figure 5.12 C shows the expression of FKBP5, GILZ, PER1, and SGK1 mRNA in the 
anterior pituitary gland following noise stress in the acute female SAFit2 experiment. 
Unpaired t-tests revealed no effect of treatment on either of the genes: FKBP5 mRNA (t(13)=-
0.07, P=0.944), GILZ mRNA (t(13)=0.58, P=0.572), PER1 mRNA (t(13)=0.52, P=0.359), or on 
SGK1 mRNA (t(13)=-1.05, P=0.313).  
Further, for the acute SAFit1-treated female rats the relative expression of FKBP5, 
GILZ, PER1, and SGK1 mRNA in the anterior pituitary gland following the noise stress are 
shown in figure 5.12 D. An unpaired t-test revealed a significant effect of treatment on FKBP5 
mRNA (t(12)=-2.96, P=0.012), with higher expression in the SAFit1-treated rats compared to 
vehicle-treated rats. There was a trend for an effect of treatment on SGK1 mRNA (t(12)=1.95, 
P=0.074), with decreased expression in the SAFit1-treated rats compared to vehicle-treated 
rats. There was no effect of treatment on GILZ mRNA (t(12)=-1.65, P=0.125), or on PER1 mRNA 






Figure 5.12. The effect of acute SAFit2 and SAFit1 treatment on stress-induced gene 
expression in the anterior pituitary gland of female rats. Mean + SEM of GR, MR, CRH, AVP, 
and c-Fos mRNA in the anterior pituitary gland of female rats treated acutely with vehicle 
(VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, 
s.c.; n=7) (A) and vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; 
n=3+7) or SAFit1 (20 mg/kg, s.c.; n=4)(B). Mean + SEM of FKBP5, GILZ, PER1, and SGK1 mRNA 
in the anterior pituitary gland of female rats treated acutely with vehicle (VEH: 4% Ethanol; 
5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=7) or SAFit2 (20 mg/kg, s.c.; n=7) (C) and 
vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=3+7) or SAFit1 
(20 mg/kg, s.c.; n=4)(D). *P<0.05 compared to vehicle, with unpaired t-test.   
 
These data indicate an effect of the acute SAFit2 treatment on POMC mRNA, with 




might increase negative feedback at the level of the pituitary gland in female rats by reducing 
POMC mRNA expression and decreased ACTH synthesis and secretion.   
Furthermore, these results indicate that there is a pituitary gland-specific induction of 
FKBP5 in the acute SAFit1 group following noise stress. This indicates either increased 
transcriptional GR activity or compensation for reduced FKBP51 activity by enhancing FKBP5 
mRNA production. Nevertheless, it is plausible to speculate that SAFit1 affects negative 
feedback in the pituitary gland to reduce CORT concentrations. There was no effect on FKBP5 
mRNA in the anterior pituitary gland following acute SAFit2 treatment, suggesting that the 
two SAFit compounds have different effects on the regulation of this gene. This is consistent 
with the lower basal and stress-induced CORT concentration observed in the SAFit1 group but 
not in the SAFit2 group.  
 
5.3.7. Stress-induced gene expression in the hypothalamus and anterior pituitary gland 
following sub-chronic SAFit2 treatment 
To compare the effect of acute SAFit2 treatment with sub-chronic SAFit2 treatment 
on HPA axis activity in the hypothalamus and anterior pituitary gland in females, the 
expression of GR, MR, CRH, AVP, and c-Fos was quantified. The c-Fos expression is a marker 
of general neuronal excitability, with an increased expression indicating increased neuronal 
firing (378). To evaluate whether either compound had any effect of GR transcriptional 
activity, expression of some GR-inducible genes, including FKBP5, GILZ, PER1, and SGK1 was 
also investigated. 
Figure 5.13 A represents the expression of GR, MR, CRH, AVP, and c-Fos mRNA in the 
hypothalamus following the noise stress in the sub-chronic female SAFit2 experiment. An 
unpaired t-test revealed no effect of treatment on GR mRNA (t(14)=-0.81, P=0.434), MR 
mRNA (t(14)=-0.29, P=0.775), CRH mRNA (t(14)=1.04, P=0.315), AVP mRNA (t(14)=0.15, 
P=0.882), or on c-Fos mRNA (t(14)=0.87, P=0.487).  
Furthermore, the relative expression of FKBP5, GILZ, PER1, and SGK1 mRNA in the 
hypothalamus for the same experiment are shown in figure 5.13 B. There was no effect of 




mRNA (t(14)=0.186, P=0.855), or on SGK1 mRNA (t(14)=0.37, P=0.717) as revealed by 
unpaired t-test.  
For the anterior pituitary gland, the relative expression of GR, MR, CRH, AVP, and c-
Fos mRNA in the hypothalamus following noise stress in the sub-chronic female SAFit2 
experiment are shown in figure 5.13 C. An unpaired t-test revealed no effect of treatment on 
GR mRNA (t(14)=0.47, P=0.640), MR mRNA (t(14)=0.34, P=0.735), POMC mRNA (t(14)=-1.55, 
P=0.141), or on c-Fos mRNA (t(14)=0.99, P=0.337).  
Lastly, figure 5.13 D shows the expression of the GR-inducible genes:  FKBP5, GILZ, 
PER1, and SGK1, in the anterior pituitary gland for the same experiment. There was a 
significantly higher expression of PER1 (t(14)=-2.26, P=0.040) in the SAFit2-treated rat 
compared to vehicle-treated rats. There was no effect of treatment on FKBP5 mRNA 






Figure 5.13. The effect of sub-chronic SAFit2 treatment on stress-induced gene expression in 
the hypothalamus and anterior pituitary gland of female rats. Mean + SEM of GR, MR, CRH, 
AVP, and c-Fos mRNA in the hypothalamus (A) and anterior pituitary gland (C) of female rats 
treated with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=6) 
or SAFit2 (20 mg/kg, s.c.; n=6)  for 5 consecutive days. Mean + SEM of FKBP5, GILZ, PER1, and 
SGK1 mRNA in the hypothalamus (B) and anterior pituitary gland (D) of female rats treated 
with vehicle (VEH: 4% Ethanol; 5% PEG300; 5% Tween 80 in saline; 2 ml/kg; s.c.; n=6) or SAFit2 






In summary, there are no changes in gene expression at 60 minutes post noise stress 
in the hypothalamus following sub-chronic SAFit2 treatment. In contrast, an increase of PER1 
in the anterior pituitary gland was observed in the SAFit2-treated rats compared to the 
vehicle-treated rats. This suggests an increase in GR transcriptional activity only in the 
pituitary gland following stress in sub-chronic SAFit2-treated females.  
 
5.3.8. Sexual dimorphism in the expression of GR, MR, and FKBP51 
For this study, the aim was to investigate whether the sexual dimorphism in the effect 
of SAFit1 and Safit2 on HPA axis activity may be due to differential expression of the GR, MR 
or FKBP51 in male and female rats. The expression of these genes was quantified in the brains 
and anterior pituitary gland of adult, untreated intact male and female rats, sacrificed either 
in the morning or the afternoon. This experimental design allowed for the investigation of not 
only the sex differences in gene expression but also the circadian expression of GR, MR and 
FKBP5, and if that expression differs in males and females. In addition to the anterior pituitary 
gland, other brain areas were investigated, including the hippocampus, hypothalamus, and 
prefrontal cortex, as these are all known to project to the PVN and to regulate HPA axis 
activity (21).  
 
Hippocampus 
The expression of hippocampal FKBP5, GR, and MR is shown in figure 5.14. Two-way 
ANOVA for FKBP5 gene expression in the hippocampus showed that there was an overall 
effect of time (F(1,24)=6.311, P=0.021), but no effect of sex (F(1,24)=0.065, P=0.801), nor any 
interaction (F(1,24)=0.824, P=0.375). Further post hoc analysis revealed no significant 
differences between the groups. From this it can be deduced that there was a difference in 
the expression of FKBP5 in the hippocampus in the morning and evening, however, the 
expression level was similar in both sexes.  
With regard to hippocampal GR expression there was no significant effect of time 
(F(1,24)=2.738, P=0.114), and no significant effect of sex (F(1,24)=0.614, P=0.442), however 
there was a significant interaction (F(1,24)=5.777, P=0.026). Further post hoc analysis 
revealed a significant difference in GR expression between AM and PM in the female rats 




This suggests that in the hippocampus there is a circadian rhythm of GR expression with lower 
levels in the evening in females but not in males. The hippocampus generally has a net 
inhibitory input to the HPA axis, and the deletion of hippocampal GR in the mouse leads to 
increased CORT levels in the morning (390). Thus in females perhaps lower GR expression in 
the evening, compared to the morning, contributes to a bigger difference in circadian CORT 
fluctuations compared to male rats.  
There was no difference in MR expression in the hippocampus in either of the groups 
as demonstrated by no effect of time (F(1,24)=2.781, P=0.111), sex (F(1,24)=0.170, P=0.684) 
and no interaction (F(1,24)=0.002, P=0.969), suggesting that MR expression in the 
hippocampus are similarly expressed in both sexes. Previously it has been found in male rats 
that MR mRNA expression in all hippocampus subfields has a circadian pattern with higher 
levels in the morning, a trough at around 15.00 and then the expression increases to levels 
similar to the morning (360). This is consistent with the findings in the present study, as the 
PM time point is around 17.00h and, therefore, the MR mRNA levels may have risen again 











Figure 5.14. Expression of FKBP5, GR, and MR in the hippocampus of male and female rats. 
Mean + SEM of FKBP5, GR, and MR mRNA in the hippocampus, in male AM (n=6), male PM 
(n=6), female AM (n=6), and female PM (n=6). Animals were euthanized in the AM (08.30h to 
09.30h) or the PM (16.30h to 17.30h) and tissues snap-frozen on dry ice. #P<0.05 compared 
to female AM. *P<0.05 effect of time.  
 
Hypothalamus 
Given the role of PVN CRH and AVP in the regulation of the HPA axis the expression of 
FKBP5, GR, and MR in the hypothalamus was investigated (figure 5.15). Two-way ANOVA for 
FKBP5 expression in the hypothalamus revealed an overall effect of time (F(1,24)=8.588, 
P=0.008), however, there was no effect of sex (F(1,24)=0.593, P=0.450), and no significant 
interactions (F(1,24)=1.531, P=0.230). Post hoc analysis revealed significantly higher 
expression in the female PM compared to female AM (P=0.037), but this difference was not 
observed in the males. This indicates that in females there may be a circadian difference in 
the FKBP5 mRNA expression in the hypothalamus, with higher expression in the evening, 
while in the males the expression may be flattened. Higher levels of FKBP5 could potentially 
contribute to the higher CORT concentrations seen in female rats, by decreasing GR activity 
and hence reducing negative feedback.  
Further, there was no effect of time on hypothalamic GR expression (F(1,24)=0.686, 




P=0.287). Similarly, for hypothalamic MR expression there was no effect of time 
(F(1,24)=0.106, P=0.748), no effect of sex (F(1,24)=0.461, P=0.505), and no interaction 
(F(1,24)=1.659, P=0.212). These results suggest that the underlying sex differences in the HPA 





Figure 5.15. Expression of FKBP5, GR, and MR in the hypothalamus of male and female rats. 
Mean + SEM of FKBP5, GR, and MR mRNA in the hypothalamus, in male AM (n=6), male PM 
(n=6), female AM (n=6), and female PM (n=6). Animals were euthanized in the AM (08.30h to 
09.30h) or the PM (16.30h to 17.30h) and tissues snap-frozen on dry ice. #P<0.05 compared 
to female AM.  
 
Anterior pituitary gland 
As suggested by the data reported here, the effects of SAFit1 and SAFit2 are 
presumably mainly due to an effect of the compounds on the anterior pituitary gland, 
supporting the general idea that the GR activity in the pituitary gland is important for 
regulation of basal CORT concentrations. It was therefore of interest to elucidate whether the 
expression of FKBP5, MR, and GR in the anterior pituitary gland was different in female rats 




is shown in figure 5.16. Two-way ANOVA for anterior pituitary gland FKBP5 expression 
revealed no effect of time (F(1,24)=2.514, P=0.129), however there was a significant effect of 
sex (F(1,24)=4.688, P=0.043), but not an interaction (F(1,24)=0.273, P=0.607). The post hoc 
analysis did reveal a trend towards an effect of lower FKBP5 in the female rats in the PM 
group, compared to the male rats in the PM group (P=0.072). Similarly, results for anterior 
pituitary gland GR mRNA expression showed no effect of time (F(1,24)=1.553, P=0.417), an 
overall effect of sex (F(1,24)=4.443, P=0.048), and no interaction (F(1,24)=2.008, P=0.172). 
The post hoc test failed to reveal any significant difference for the specific groups, however, 
there was a trend for lower GR expression in females PM compared to males PM (P=0.070). 
For anterior pituitary gland MR mRNA expression there was no effect of time (F(1,24)=0.916, 
P=0.350), however an overall significant effect of sex (F(1,24)=7.154, P=0.015), and no 
interaction (F(1,24)=0.750, P=0.397). The post hoc analysis revealed significantly lower MR 
mRNA in the female rats in the PM group compared to male rats in the PM group (P=0.021).   
It is somewhat surprising that the expression of FKBP5 is lower overall in the females 
compared to males at the time points investigated, as lower FKBP5 would be expected to be 
accompanied by increased GR translocation and activity and increased CORT-mediated 
negative feedback. However, the anterior pituitary gland GR mRNA expression is also lower 
in the females compared to the males which would potentially cause lower GR activity. It is 
plausible that the lower FKBP5 expression is to compensate for the lower GR expression. 
Interestingly it has been found that ovariectomized female rats have higher anterior pituitary 
gland GR and MR mRNA expression compared to ovariectomized females given oestrogen 
replacement (391).  This suggests that oestrogen in females is involved in the regulation of 
GR and MR mRNA expression in the anterior pituitary gland. This is also consistent with the 
data showing higher levels of anterior pituitary gland GR and MR mRNA in males with no 
oestrogen, similar to the ovariectomized females. This is also consistent with several studies 
demonstrating that oestrogen increases HPA axis activity and testosterone has an inhibitory 
effect on the HPA axis (reviewed in (231)) and ovariectomised female rats have basal CORT 
concentrations similar to sham males, while castrated males display basal CORT levels similar 








Figure 5.16. Expression of FKBP5, GR, and MR in the anterior pituitary gland of male and 
female rats. Mean + SEM of FKBP5, GR, and MR mRNA in the anterior pituitary gland, in male 
AM (n=6), male PM (n=6), female AM (n=6), and female PM (n=6). Animals were euthanized 
in the AM (08.30h to 09.30h) or the PM (16.30h to 17.30h) and tissues snap-frozen on dry ice. 
*P<0.05 effect of sex.  $P<0.05, compared to males PM.  
 
Prefrontal cortex 
The prefrontal cortex and more specifically the medial prefrontal cortex, which is the 
limbic region of the prefrontal cortex, is activated following a stressor as demonstrated by 
enhanced c-Fos and glucose utilisation (50, 51). Lesion of the medial prefrontal cortex in male 
rats does not affect the basal AM or PM CORT or ACTH concentrations although the CORT and 
ACTH concentrations following restraint stress are significantly elevated (54, 55). These 
studies indicate a specific effect of the MpFC in the regulation of the stress response but not 
basal HPA axis activity. These effects are at least partly mediated by  GR, as knockdown of the 
GR in either the infralimbic region or the prelimbic region of the MpFC causes 
hyperresponsiveness to stressful stimuli (392). Further, MR is also expressed in the prefrontal 
cortex and is downregulated in patients with bipolar disorder (393), implicating pre-
frontocortical MR in influencing HPA axis activity. Given the role of both prefrontocortical GR 




(figure 5.17). Two-way ANOVA showed no effect of time (F(1,24)=0.564, P=0.461) or of sex 
(F(1,24)=1.023, P=0.324) and no interaction (F(1,24)=0.005, P=0.944). These data suggest that 
sex differences in the stress response are not likely to be due to differences in prefrontal 
cortex expression of the GR or MR, or FKBP51 at the time points investigated. However, it 
cannot be ruled out that there is a difference in FKBP5, GR and MR expression within specific 
regions of the prefrontal cortex or at different time points.  
 
 
Figure 5.17. Expression of FKBP5, GR, and MR in the prefrontal cortex of male and female 
rats. Mean + SEM of FKBP5, GR, and MR mRNA in the prefrontal cortex, in male AM (n=6), 
male PM (n=6), female AM (n=6), and female PM (n=6). Animals were euthanized in the AM 
(08.30h to 09.30h) or the PM (16.30h to 17.30h) and tissues snap-frozen on dry ice.  
 
In summary, data from this experiment highlights a sex difference in expression of GR, 
MR, and FKBP5 in the anterior pituitary gland, with overall lower expression of all three genes 
in females. Lower GR in the anterior pituitary gland might cause reduced negative feedback 
and may perhaps contribute to overall higher CORT concentrations in female rats. Although 
the expression of FKBP5 is also lower, this could counteract the lower expression of GR, 
however, it could also render FKBP51-inhibition less effective as there is less FKBP51 available 




in castrated males compared to sham males. In contrast, an increase in GR mRNA expression 
was observed in ovariectomized females compared to sham females (239, 240).   
 
5.4. Discussion   
In this chapter, data has been presented demonstrating a strong effect of acute SAFit1 
treatment in female rats on HPA axis activity, with lower basal and stress-induced CORT 
concentrations.  
As already mentioned, numerous studies indicate sexual dimorphism in HPA axis 
activity, both in basal and in stress-induced CORT secretion. There is inconclusive evidence 
indicating whether this dimorphism is central and/or peripheral and if it involves GR, MR, and 
FKBP51. One study measured basal CORT concentrations during a 24-h period in sham males, 
castrated males, sham females, and castrated females, and found that castrated males 
showed similar CORT profiles to sham females and vice versa (239). Further, these effects 
were abolished by administering testosterone or oestrogen (240). Furthermore, the same 
effects were seen on the post-stress CORT concentrations following noise stress and LPS 
injections (immune stress). This suggests that sex steroids directly affect the HPA axis activity 
and that these effects regulate both basal and stress-induced CORT secretion (239, 240).  
As mentioned in the general introduction, female 51KO mice have significantly lower 
concentrations of both basal and post-stress CORT (343), suggesting that a decrease in, or a 
complete knock out of FKBP51 alters HPA axis activity in female mice. In the present study, 
there was no overall difference in hypothalamic FKBP5 or GR mRNA expression in females and 
males, although the females had a stronger circadian difference in hypothalamic FKBP5 
expression. Further, the acute SAFit1 and SAFit2 studies in male rats showed an effect of 
SAFit2 in the brain and anterior pituitary gland and only in the anterior pituitary gland for 
SAFit1. Given the lower expression of both FKBP51 and GR in females in the anterior pituitary 
gland, it is plausible to expect a reduced effect of the SAFit2 in females as there is lower 
anterior pituitary gland FKBP51 expression already and there is lower expression of anterior 
pituitary gland GR to be activated and induce negative feedback. Acute administration of 
SAFit1 in male rats did not alter either basal or stress-induced CORT concentrations. Although 




ACTH and CORT response, suggesting that both SAFit2 and SAFit1 have an effect on the 
pituitary gland.  
In chapter 3 the effects of both SAFit2 and SAFit1 on CORT secretion following an ACTH 
challenge in male rats were discussed. The results indicated that neither SAFit compounds 
have a direct effect on ACTH-induced CORT secretion from the adrenal glands. Unfortunately, 
due to time constraints, the same experiment could not be performed in female rats, 
although that would potentially have produced interesting findings. It is therefore not known 
whether SAFit2 and SAFit1 can affect the adrenal glands directly in the female rat. In addition, 
the brain permeability studies were performed in male mice, and hence SAFit1 may have a 
different brain permeability in rats and especially female rats.  
In addition to lipid solubility, numerous other factors dictate the brain permeability of 
a molecule, including charge, tertiary structure, and protein binding (394). However, the main 
factor determining brain permeability is size, and it has been described that the cut-off point 
for molecules is around 400-600 kDa, although it has been proposed that few molecules over 
500 kDa reach the brain by simple diffusion (395). The molecular weight of SAFit2 and SAFit1 
is 803 kDa and 747 kDa, respectively (349).   
Uptake transporters function to transport essential nutrients to the brain such as 
glucose, vitamin B6 and vitamin B12, and other substances, for example, L-DOPA and caffeine, 
are transported into the brain by a saturable transport system (396). The rate of diffusion of 
a saturable transport system can be up to 10 times higher than transmembrane diffusion 
(397).  
On the other hand, the P-glycoprotein belongs to the family of ABC transporters and 
is a blood-to-brain efflux pump which can limit the amount of drug available in the brain (398). 
The P-glycoprotein and other ABC transporters are a major problem in the development of 
central nervous system drugs (399).  
It is currently not known how SAFit2 enters and remains in the brain and why SAFit1 
does not. SAFit2, due to its size, presumably enters the brain by active transport. Although 
peptides and proteins over 600kDa have been known to cross the BBB by transmembrane 




molecular weight of 7800kDa is the largest substance known to have crossed the BBB (400) 
hence it is indeed plausible that SAFit2 does not require active transport across the BBB.  
In addition, SAFit2 is also likely to be actively transported out of the brain with 
differences between males and females. Furthermore, the plasma to brain ratio studies were 
performed in male mice (347) and it is not known how these parameters compare in rats. 
However, experiments to elucidate this are currently being planned. The current hypothesis 
is that SAFit1 has less membrane permeability and increased brain efflux.  
The results from the acute SAFit2 ABS experiment in females indicate no effect on 
basal CORT secretion. SAFit2 and SAFit1 both act peripherally and only differ in BBB 
permeability and half-life. Hence, as SAFit1 decreases basal CORT by actions in the periphery, 
the central FKBP51-inhibition elicited by SAFit2 must have an opposing effect on the 
peripheral FKBP51-inhibition. Thus, it is plausible that central FKBP51-inhibition in female rats 
increases CRH release from the PVN. SAFit2 administration would then cause increased CRH 
secretion to the pituitary gland from central FKBP51 inhibition but decreased ACTH and CORT 
secretion. This would counteract the increase in CRH and result in unchanged CORT secretion, 
as seen in the female SAFit2 ABS study.  
A study using global FKBP51 knock-out (51KO) female mice measured basal CORT 
concentrations and revealed lower CORT in the 51KO female (343). However, besides any 
species-related difference, these data are representative of only one time point of basal CORT 
and are from mice, which differ from the rat in various aspects of physiology. To my 
knowledge, there are no other findings of differential activity of FKBP51 in male and female 
rats and it is an area that would be interesting to investigate further.  
The data in this chapter are in contrast to the results from the same experiment 
performed in males, where there was no difference between SAFit1- and vehicle-treated rats. 
In the females, however, there was no effect of acute SAFit2 on basal CORT secretion and 
only a small decrease in stress-induced CORT. Furthermore, the sub-chronic administration 
of SAFit2 caused a decreased in basal CORT but had no effect on stress-induced CORT. In 
addition, females treated acutely with SAFit1 had increased expression of FKBP5 mRNA 
following exposure to noise-stress, compared to vehicle-treated rats, while there was no 




following sub-chronic SAFit2 was seen in the anterior pituitary gland of the female rats. These 
data suggest that in females, central inhibition of FKBP51 may counteract the effect of 
peripheral FKBP51-inhibition. This would explain the lower CORT secretion following the 
acute administration of SAFit1 but not of SAFit2. However, sub-chronic SAFit2 decreased basal 
CORT concentrations significantly. Perhaps a prolonged treatment with SAFit2 would cause 
the peripheral effects to be stronger than the central effects. This is also consistent with an 
increase in the GR-inducible PER1 mRNA expression in SAFit2-treated animals following sub-
chronic treatment.   
 With regards to the effect of SAFit2 and SAFit1 on the stress-induced CORT in 
these three different experiments, further investigation will help unravel the mechanisms 
underlying the role of FKBP51 and GR in the regulation of stress-induced negative feedback. 
However, the data from the experiments described in this chapter indicate a strong effect of 
acute SAFit1 administration on stress-induced CORT secretion, presumably due to enhanced 
negative feedback at the level of the pituitary gland. These data suggest that peripheral-only 
FKBP51 inhibition, compared to global FKBP51 inhibition, has stronger effects in reducing 
stress-induced CORT secretion in female rats. Because the half-life of SAFit1 is shorter than 
SAFit2 (2.5 versus 9 hours), there should not be any active SAFit1 at the time of the noise 
stress as this is 12 hours after the last dose of SAFit1. Although this is perhaps an experimental 
limitation it can be used to deduce the mechanism of how SAFit1 reduces stress-induced 
CORT. Hence the effects of SAFit1 on stress-induced CORT would be effects sustained from 
the administration at 19.00h the day before the noise stress. Therefore, it is plausible that the 
effects on stress-induced CORT by SAFit1 are due to genomic actions, presumably in the 
pituitary gland, rather than rapid, non-genomic actions.   
 Neither acute nor sub-chronic SAFit2 treatment affected stress-induced CORT.  Sub-
chronic SAFit2 treatment in females causes a reduction in basal CORT but had no effect on 
stress-induced CORT. This suggests that prolonged SAFit2 treatment enhances the pituitary 
gland effects of SAFit2 enough to overpower the central effects of SAFit2. Interestingly, it has 
been shown that in OVX female rats, DEX suppresses peak diurnal and stress-induced CORT 
increase. However, when OVX females were administered oestrogen replacement, the 
diurnal CORT concentrations increased and the suppression of diurnal CORT by DEX was 




peak of CORT. Moreover, the same study showed that oestrogen replacement in the OVX 
females significantly increased stress-induced CORT, and the DEX suppression of stress-
induced CORT was abolished. Importantly these changes in CORT were accompanied by 
similar changes in ACTH concentrations (401) indicating that they are not due to increased 
activity of the adrenal gland, but rather to changes in negative feedback regulation. The same 
study showed that activation of ER alpha (ERα) in the PVN increased the diurnal HPA axis 
activity, and it was sufficient to abolish the suppressive effects of DEX during the diurnal peak 
in CORT. Furthermore, activation of ERα in the PVN diminished DEX suppression and results 
in ACTH and CORT concentrations similar to those of vehicle-treated female rats (401). Thus, 
these data suggest that oestradiol impairs GC negative feedback during the diurnal peak of 
CORT and following stress-induced CORT and that this effect is mediated by activation of ER-
α in PVN neurons. It has been shown that FKBP51 is involved in TTC9A-mediated suppression 
of ER-α activity (402). Thus, FKBP51 inhibition may cause a reduced suppression of ER-α 
activity and, if this occurs in the PVN, decreased GC negative feedback. It is tempting to 
speculate that this could explain why SAFit2 has opposing effects in the central and 
peripheral, however, further investigation is required.  
The female rats used in the experiments described in this chapter were not checked 
for the stage of their oestrous cycle. It has been shown that female rats have increased basal 
CORT during the proestrus stage of the oestrus cycle compared to the oestrus and metestrus 
stage of the cycle (232).  Moreover, the same study showed that the basal CORT 
concentrations were similar in male rats and female rats in the oestrus stage, and the CORT 
concentrations were only higher in female rats compared to male rats when they were in the 
metestrus, proestrus, and diestrus  (232). Hence the oestrus cycle stage could influence the 
results of an experiment involving the HPA axis activity. Previous studies using freely cycling 
female and male Sprague-Dawley rats found that both basal and stress-induced HPA axis 
activity was significantly different between the two sexes despite not controlling for cycle 
stage (239, 240).  Hence when comparing sexual dimorphic effects of HPA axis activity it 
appears that controlling for oestrus cycle in the females might not be necessary. However, in 
this chapter vehicle-treated female rats were compared to SAFit2- or SAFit1-treated female 
rats and thus if the females were in different stages this would influence the HPA axis activity. 




synchronize their oestrus cycle by excreting pheromones (403), it has also been reported that 
this is not the case (404), and the reports seem to be mixed. Nevertheless, it is possible that 
the females used in the studies in this chapter were in different stages of the oestrus cycle 
and it would have been useful to control for this.  
Other limitations include using PCR to quantify the gene expression, as discussed 
previously, this does not give an anatomical representation. A more suitable approach would 
have been ISH or RNA scope, and to include additional time points to investigate the gene 
expression following stress in more depth. However, as there was limited availability of the 





















Chapter 6: Pilot studies for rat models of dysregulated HPA axis  
 
6.1. Introduction 
In the previous chapters, the results from experiments that focused on the effects of 
FKBP51-inhibition under normal conditions, in healthy, naïve rats have been described. 
However, the potential for using FKBP51-inhibition as a therapeutic tool for psychiatric 
illnesses in humans will involve using it in patients with a dysregulated HPA axis. Studies in 
primates show that increased FKBP51 expression is accompanied by GC resistance (321, 322). 
Further, in humans, it is indeed suggested that patients with MDD have increased FKBP51 
levels (405-407). Overexpression of FKBP51 in the BLA in mice leads to increased anxiety-like 
behaviour, which can be mitigated by systemic administration of the FKBP51-inhibitor SAFit2 
(340). Although these studies demonstrate that overexpression of FKBP51 is linked to 
increased HPA axis activity, no studies to date have investigated whether central FKB51 
overexpression has any effect on the HPA axis ultradian pulse dynamics during 24 hours in 
the rat. This is an important question that would translate these findings into the clinic, as it 
has been shown that patients with unipolar depression have increased pulse amplitude and 
overall increased cortisol secretion compared to normal subjects (295, 296).  
Furthermore, given the wide range of actions of GCs, including in the central nervous 
system, the immune system, and in metabolic processes, alterations of basal HPA axis 
concentrations and pulsatility can influence the susceptibility and severity of various diseases.  
In this regard, the Lewis rat strain has been extensively studied for its increased 
susceptibility to numerous inflammatory conditions including experimentally induced 
arthritis (408-411) and encephalomyelitis (412, 413). In contrast, the histocompatible and 
closely related Fischer rat strain does not develop these conditions (409-411). The reason 
behind the differential responsiveness to immune stress in these two rat strains is linked to 
their differences in HPA axis activity. The Lewis rat shows a reduced HPA axis response to 
various stressors including physical (414, 415), psychological (416, 417), and immune 
stressors (411, 415, 417) compared to the Fischer rat. Thus it is suggested that the reduced 
HPA axis activity in the Lewis rat, and thus lower levels of CORT, is not able to reduce the 




and Lewis rats indicated similar CORT pulse height in the two strains, but an increased number 
of pulses throughout the 24-hours in the Fischer rats, resulting in higher mean basal CORT 
and, importantly, a lack of CORT circadian rhythm was observed (418).  
To date, there have been no ABS studies characterising full 24-h CORT profiles and 
ultradian pulsatile dynamics of male Fischer and Lewis rats. Studies using hand sampling for 
CORT concentrations have showed increased morning and evening HPA axis activity in male 
Fischer rats compared to both Sprague-Dawley and Lewis rats. Furthermore, Lewis rats have 
significantly decreased CORT compared to both Sprague-Dawley and Fischer rats in the 
evening (419). Furthermore, FKBP51 expression in the Fischer and Lewis rats in the anterior 
pituitary gland and hypothalamus is currently unknown. It is an intriguing hypothesis that 
higher FKBP51 expression in these two areas may contribute to the increased HPA axis activity 
observed in Fisher rats.  
The studies described in this chapter aim to investigate two potential rat models for 
hyperactive, or dysregulated, HPA axis activity. The first model is a virus-induced 
overexpression of FKBP51 (FKBP51 OE) in the PVN in male naïve Sprague-Dawley rats. The 
aim was to use this rat model to further elucidate whether FKBP51 regulates basal HPA axis 
activity. The second model is the male Fischer rat which has already been shown to exhibit 
increased CORT concentrations compared to Sprague-Dawley and Lewis rats, however, the 
ultradian CORT dynamics in this strain are unknown. Therefore, the aim was to characterise 
the ultradian CORT dynamics in this strain, as well as investigate if the increased HPA axis 
activity observed in male Fisher rats is due to changes in FKBP51 expression, compared to the 
Lewis rats.  
 
6.2. Methods  
6.2.1. Experiment 13: The effects of AAV-mediated overexpression of FKBP51 in the rat 
PVN on CORT ultradian rhythms and stress-induced CORT secretion.  
It has been shown that FKBP5 expression is upregulated following acute stress (420), 
and that overexpression of FKBP5 in the amygdala induces anxiogenic behaviour in mice 
(340). The aim of this experiment was, therefore, to use the same overexpression protocol as 




6.2.1.1. Viral overexpression of FKBP51 
Viral overexpression was performed using an adeno-associated bicistronic AAV1/2 
vector (GeneDetect) as previously described (421). The vector contained a CAGHA-tagged-
FKBP51-WPRE-BGH-polyA expression cassette that contained the coding sequence of human 
FKBP51 NCBI CCDS ID CCDS4808.1. For the control group, the same vector constructs without 
expression of FKBP51 (CAG-Null/Empty-WPRE-BGH-polyA) was used. Virus production, 
amplification, and purification were performed by GeneDetect with no restriction enzymes 
used. Rats were anaesthetized with isoflurane and bilaterally injected with AAV.FKBP51 or 
AAV.null as described below.  
 
6.2.1.2. Bilateral PVN injection of AAV.FKBP5  
Rats were anaesthetised using isoflurane mixed with oxygen, as described for 
cannulation surgery in section 2.4. Once total anaesthesia was achieved, the dorsal side of 
the head, between the ears, was shaved using an electric shaver.  The rats were fixed in a 
stereotaxic frame with a mask for isoflurane delivery fitted to the frame. The shaved part of 
the head was sterilised with chlorhexidine. Using a scalpel, a small incision was made on the 
dorsal side of the head (approximately 1 cm) and the skin dissected to expose the skull. The 
scalpel was used to scrape the membrane off the skull to expose the bone surface and so that 
the Bregma could be located. Bregma level was identified using the stereotaxic frame and the 
following coordinates were used for the intra-PVN injection: Bregma -1.8 anteroposterior 
(AP), +/- 0.4 lateral (lat), -8.0 dorsoventral (DV). Two small burr holes were drilled through the 
skull, and a 10 ul, 25-G Hamilton syringe was used to deliver bilaterally 500 nl of 1.3x1012 
genomic particles of AAV.FKBP51 or AAV.null using a Harvard automatic infusion pump over 
a 5 min period per site. The infusion was set to 100nl per minute and the needle was left in 
for an additional 1 minute before it was slowly withdrawn.  
The skin was sutured, and wound powder applied. The rats were single-housed and 
allowed to recover on heat-pads. The rats were kept single-housed until the sutures had 
healed (5-7 days). After three weeks all rats were subjected to jugular vein cannulation as 




any potential weight changes. Automated-blood sampling was conducted 5 days after the 
jugular vein cannulation.  
Automated-blood sampling for measurement of basal CORT was conducted from 
07.00h on day 1, until 07.00h the following day. At 07.00h of day 2, all rats were subject to 
noise stress (10 min, 96dB, white noise) and blood sampling collection continued for 60 
minutes following the onset of the noise stress. Immediately after the sampling had stopped 
at 08.00h the rats were euthanized using pentobarbitone injection in the i.v. cannula, 
followed by decapitation with a guillotine. Whole brains were snap-frozen and then stored in 
-80°C.  
 
6.2.1.3. Cryostat sectioning and in situ hybridisation  
Frozen brains were fixed with poly freezer tissue medium (Tissue Tek O.C.T 
Compound, Sakura Finetek, Staufen Germany) and sectioned using a cryostat microtome at 
18 µm. Brains were cut in the coronal plane through the following brain regions of interest: 
PVN; VMH; ARC; ventral hippocampus (VH) and NTS. Brain sections were then thaw mounted 
on Super Frost Plus slides (Menzel GmbH, Braunschweig, Germany) and stored at -20°C until 
further use. 
In situ hybridization was performed using 35S labelled ribonucleotide probes for 
FKBP51 (forward primer: 5’CCTTGATTTCAAAGGTGAGGA; reverse primer: 5’ 
CAGGCGTTATCCGTAGAATCA) as previously described (343). The FKBP5 Exon 9 was cloned in 
a pCRII-TOPO vector and the circular probe had a final concentration of 1512 ng/µl. The 
primers used for the linearisation were: Sense: pCRII-TOPO-T7-SISH 5’-
GAATTGTAATACGACTCACTATAGGGCGAA-3’, Antisense: pCRII-TOPO-Sp6-SISH 5’-
CCAAGCTATTTAGGTGACACTATAGAATAC-3’.  
 
In brief, after mixing gently by tapping the reaction tube, samples were quickly 
centrifuged and incubated at 37°C for 3 hours. After 1 h, another 0.5 µl of RNA polymerase 
was added. Unbound DNA was subsequently digested by adding 2 µl of RNAse-free DNAse I 




purification of the riboprobe, the Qiagen RNeasy Kit (Qiagen, Hilden, Germany) was used 
according to the manufacturer’s protocol. The concentration of the label was measured in 2 
ml of Scintillation Solution in a scintillation counter.   
Prepared sections were fixed in 4 % paraformaldehyde, acetylated in 0.25 % acetic 
anhydride in 0.1 triethanolamine/HCL and subsequently dehydrated in increasing 
concentrations of ethanol (60 %, 75 %, 95 %, 100 %, Chloroform, 100 %). The antisense cRNA 
riboprobes were transcribed from a linearised plasmid.  
Tissue sections were saturated with 100 µl of hybridisation buffer containing 3-7 x 106 
CPM 35S labelled riboprobe. Brain sections were incubated overnight at 55°C. The following 
day, sections were rinsed in 4 X SSC (standard saline citrate), subsequently treated with RNAse 
A (10mg/mL) and washed in increasingly stringent SSC solutions (2x, 1x, 0.5x) at room 
temperature. Sections were then washed in 0.1 x SSC for 2 x 30 minutes at 64°C and 
dehydrated through increasing concentrations of ethanol. Slides were exposed to Kodak 
Biomax MR Films (Eastman Kodak Co., Rochester, NY) and developed after at least one week 
of exposure. Note that the cryostat sectioning and the ISH were performed by Lea-Maria Brix, 
Max Planck Institute of Psychiatry, Germany.  
 
6.2.2. Experiment 14: Characterisation of FKBP5 mRNA expression in the hypothalamus 
and anterior pituitary gland of male Fischer and Lewis rats.  
  Male Fischer and Lewis rats were subject to jugular vein cannulation (see general 
methods, section 2.4) and allowed to recover for five days. Automated-blood sampling for 
measurement of basal CORT was conducted from 07.00h on day 1, until 07.00h the following 
day to establish CORT secretion profiles. These rats were then used for the gene expression 
analysis, along with the rats that had lost cannula patency and could not be used for ABS.  
For the gene expression analysis, the rats were euthanized using pentobarbitone 
injection in the i.v. cannula, followed by decapitation with a guillotine. The brains were 
dissected, to isolate specific areas, and, along with the anterior pituitary gland, were snap-
frozen on dry ice to be used for further gene expression analysis. All were euthanized either 




6.3. Results  
6.3.1. Effects of AAV-mediated overexpression of FKBP51 in the rat PVN on CORT ultradian 
rhythms and stress-induced CORT secretion.  
 Previous studies in mice have shown that overexpression of FKBP51 in the BLA induces 
anxiety-like behaviour as shown by decreased entries to the open arm in the elevated plus 
maze and decreased time struggling in the forced swim test (340). In this study, the same viral 
construct was used to attempt bilateral overexpression of FKBP51 in the PVN of male rats. 
The hypothesis was that increased FKBP51 in the PVN would decrease GR activity and hence 
decrease GC negative feedback resulting in increased circulating CORT concentrations. The 
CORT concentrations were measured using ABS for 24 hours of basal HPA axis activity and 
during noise stress.  
 In-situ hybridisation indeed revealed overexpression of FKBP51 in the AAV.FKBP5 rats, 
however, the location appeared to be in the paraventricular nucleus thalami (PVT) of the 








 Figure 6.1. Confirmation of FKBP5 overexpression following bilateral PVN injection of 
AAV.null or AAV.FKBP51 in male rats.  In situ hybridisation of FKBP5 expression in two 
representative rats with AAV.null (A, B) and AAV.FKBP51 (C, D) bilateral PVN injection. (A) and 
(C) shows the FKBP5 expression at the level of the PVN in five 18 micron slices, and (B) and (D) 
at the level of the hippocampus in five 18 micron slices. The cryostat sectioning started at AP-
1.0 and 2 series of each 8 slides, per each 5 brain slices were cut. The AAV.FKBP51 rats showed 
increased FKBP5 expression in the thalamus. The cryostat sectioning and in situ hybridization 
were performed by Lea-Maria Brix, Institute of Psychiatry, Max Planck Institute of Psychiatry, 
Germany.  
 
Although 12 rats per group received intra-cranial injections, six AAV.null and six 
AAV.FKBP5 rats maintained cannula patency and could be connected to the sampling system. 
Furthermore, one AAV.FKBP5 animal showed no overexpression and was hence excluded. 
Rats were all subjected to ABS every 10 minutes for 24 hours. The blood samples were 
assayed for CORT concentrations and the mean was calculated for each time point for both 
groups. The resultant average 24-h profiles are shown in figure 6.2 (A) along with the 
individual representative profile (B-E). All the individual 24-hour profiles were analysed with 




unpaired t-tests revealed a significant increase in the number of pulses (t(8)=-2.93, P=0.019), 
and the pulse frequency (t(8)=-2.93, P=0.019), in the AAV.FKBP51 rats, and a significant 
decrease in pulse length (t(8)=2.45, P=0.043), pulse area (t(8)=2.61, P=0.031), and pulse IPI 
(t(8)=2.75, 0.025), in the AAV.FKBP51 rats compared to AAV.null rats. There was no significant 
effect on mean CORT (t(8)=1.53, P=0.164), max CORT (t(8)=--0.28, P=0.785), basal CORT 
(t(8)=1.47, P=0.177), pulse amplitude (t(8)=0.62, P=0.558), pulse height (t(8)=1.01, P=0.323), 
















Figure 6.2. The effect of central FKBP5 overexpression on ultradian CORT secretion in male 
rats. Mean + SEM (A) CORT concentrations, and representative individual profiles from male 
adult rats with bilateral PVN injection of AAV.null (B, C; n=6) or AAV.FKBP51 (D, E; n=6) 4 weeks 
prior to the experiment. Blood samples were collected via a cannula implanted in the right 
jugular vein every 10 min for 24-h using an ABS. Plasma corticosterone was measured by RIA. 
Grey bar indicates light off (19:00-05:00h). In-situ hybridisation showed the injection site was 






Figure 6.3. The effect of FKBP5 overexpression on PULSAR parameters in male rats. Mean + 
SEM (A) CORT concentrations, and representative individual profiles from male adult rats with 
bilateral PVN injection of AAV.null (n=5) or AAV.FKBP51 (n=6). *P<0.05 compared to AAV.null 
rats, with unpaired t-test. Amp=amplitude, IPI= inter-pulse interval, AUC= area under the 
curve.  
 
These results suggest that the AAV.FKBP51 construct previously used successfully in 
mice (340) does indeed induce FKBP51 overexpression in rats too. However, histological 
analysis of the rat brains showed that the injection site targeted the thalamus, PVT to be 
precise, rather than the PVN. Interestingly, the data above indicate that increased FKBP51 
expression in the thalamus of male rats can affect CORT ultradian pulsatility. The AAV.FKBP51 
rats had an increased number of CORT pulses, (AAV.FKBP51 25.8 ±1.77; AAV.null: 19.8 ±1.01) 
compared to AAV.null-treated rats. Further, both the pulse length and the IPI were lower in 
the AAV.FKBP51 rats compared to AAV.null rats. This suggests that overexpression of FKBP51 




concentrations. This is interesting as it suggests that thalamic GR signalling can affect CORT 
ultradian rhythm dynamics. 
To investigate the effect of thalamic FKBP51 overexpression on the CORT response to 
stress, following 24-h blood sampling the rats were subjected to noise stress and blood 
sampling continued for 60 minutes following the noise stress (figure 6.4). Repeated measures 
analysis showed an overall significant effect of time (F(1.463, 14.633)=15.730, P=0.001), 
however no significant interaction between time and treatment (F(1.463, 14.633)=2.340, 
P=0.603), but a significant effect of treatment (F(1,9)=4.544, P=0.020). Further, post hoc 
analysis revealed a significant increase in stress-induced CORT in AAV.null rats at the 10 
minutes (P<0.0001), 20 minute (P=0.001), and at the 30 minutes (P=0.005) time point after 
the noise onset, compared to AAV.null rats at the 0 minute time point. In comparison a 
significant increase in stress-induced CORT in the AAV.FKBP51 rats were only observed at the 
10 minute time point (P=0.018), compared to AAV.FKBP51-treated rats at the 0 minute time 
point. Moreover, there was a significant difference between the AAV.FKBP51 and the 
AAV.null rats at the 10 minute time point (P=0.005). There was no difference between the 









Figure 6.4. The effect of FKBP5 overexpression on stress-induced CORT in male rats. Mean + 
SEM corticosterone levels during noise stress (96dB, 10 minutes, white noise, 07.00h) from 
male adult rats with bilateral PVN injection of AAV.null (n=6) or AAV.FKBP5 (n=7) 4 weeks prior 
to the experiment. Blood samples were taken every 10 minutes from a cannula implanted in 
the right jugular vein and CORT concentrations measured with CORT RIA. The time indicates 
the time after the noise stress, which was performed at 0 minutes.  *P<0.05, compared to 
AAV.null rats with Tukey’s post hoc test. #P<0.05, compared to respective time 0, with Tukey’s 
post hoc test.  
 
These data suggest a trend for overall decreased CORT and a significantly shorter CORT 
response to noise stress in the AAV.FKBP51 rats compared to AAV.null rats.  
 
6.3.2. Experiment 14: Characterisation of CORT ultradian rhythms, and FKBP5 mRNA 
expression in the hypothalamus and anterior pituitary gland, in male Fischer and 
Lewis rats.  
Four Lewis and three Fischer male rats were all subject to ABS every 10 minutes for 24 
hours and complete profiles were obtained for three Lewis and two Fischer rats. The blood 




point for both groups. The resultant average 24-h profiles are shown in figure 6.5 (A) and two 
individual profiles (B-E) from each group are represented.  
All the individual 24-hour profiles were analysed with the PULSAR algorithm and the 
means for each parameter are shown in figure 6.6. However, due to the low number of rats 
in each group, it was not possible to perform a statistical analysis of the PULSAR data. The 
mean CORT, max CORT, pulse amplitude, pulse height, pulse length, pulse area, AUC basal, 
and AUC total were all lower in the Lewis rats compared to the Fischer rats. It should be noted 
that these are observations are only based on the mean in each group and not statistics. 
Nevertheless, these results are the first to show the full 24-hour CORT profiles of male Fischer 




















Figure 6.5. 24-hour basal CORT profiles of male Fischer and Lewis rats. Mean + SEM CORT 
(A) and individual profiles from male adult Lewis (B, C; n=3) and Fischer (D, E; n=2) rats. Blood 
samples were collected via a cannula implanted in the right jugular vein every 10 min for 24-







Figure 6.6. PULSAR parameters of male Fischer and Lewis rats. Mean + SEM and mean CORT 
parameters calculated using PULSAR from 24-hour profiles of male adult Lewis (n=3) and 
Fischer (n=2) rats. Amp=amplitude, IPI= inter-pulse interval, AUC= area under the curve. Note 
that as there are only two Fischer rats there are no error bars for that group.  
 
It is currently unknown why these histocompatibility strains have such different CORT 
profiles. Given the pivotal role of FKBP51 in regulating GR and hence GC negative feedback, it 
is plausible to speculate that these differences in CORT may be due to differential expression 
of FKBP51 or GR. Therefore, FKBP5 and GR mRNA was quantified in the hypothalamus and 
anterior pituitary gland of Fischer and Lewis rats at two time points in the AM or PM. The 
relative expression of FKBP5 and GR mRNA in the hypothalamus in male Lewis and Fisher rats 
are shown in figure 6.7. For hypothalamic FKBP5 mRNA, a two-way ANOVA revealed an overall 
significant effect of time (F(1, 14)=8.973, P=0.013), however no significant effect of strain (F(1, 
14)=0.032, P=0.861), and no significant interaction (F(1, 14)=1.588, P=0.236). Further, post 
hoc analysis revealed a significant increase in FKBP5 mRNA in Lewis PM rats (P=0.037) 




significant effect of time (F(1, 14)=0.009, P=0.925), no significant effect of strain (F(1, 
14)=1.367, P=0.269), and no significant interaction (F(1, 14)=1.550, P=0.242). Thus, these data 
indicate that in the hypothalamus there is a circadian variation in FKBP5 mRNA expression in 
the Lewis rats, with higher expression in the PM compared to AM, whereas there is no 




Figure 6.7. Expression of FKBP5 and GR in the hypothalamus of male Fischer and Lewis rats. 
Mean + SEM FKBP5 (A) and GR (B) mRNA in the hypothalamus of male Lewis euthanized in the 
AM (n=4) or PM (n=4) and Fischer rats euthanized in the AM (n=3) or PM (n=3). *P<0.05, effect 
of time, analysed by post hoc multiple comparisons with Tukey’s post hoc test.  
 
The relative expression of FKBP5 and GR mRNA in the anterior pituitary gland in male 
Lewis and Fisher rats are shown in figure 6.8. For anterior pituitary gland FKBP5 mRNA, a two-
way ANOVA revealed an overall significant effect of time (F(1, 14)=62.062, P=0.00001), a 
significant effect of strain (F(1, 14)=38.946, P=0.0001),   and a significant interaction (F(1, 
14)=7.087, P=0.02). Further, post hoc analysis revealed a significant increase in FKBP5 mRNA 
in Lewis PM rats (P=0.012) compared to Lewis AM rats, and a significant increase in FKBP5 
mRNA in Fischer PM rats (P=0.0002) compared to Fischer AM rats. In addition, there was a 
significant increase in FKBP5 mRNA in Fischer PM (P=0.0004) compared to Fischer AM. For 
anterior pituitary gland GR mRNA, two-way ANOVA revealed an overall significant effect of 




however no significant interaction (F(1, 14)=1.550, P=0.242). Further, post hoc analysis 
revealed a significant increase in FKBP5 mRNA in Lewis PM rats (P=0.031) compared to Lewis 
AM rats, and only a trend for higher levels of FKBP5 mRNA in Fischer PM rats (P=0.092) 
compared to Fischer AM rats. Furthermore, there was a significantly higher levels of FKBP5 
mRNA in Fischer AM (P=0.030) compared to Lewis AM.   
 
 
Figure 6.8. Expression of FKBP5 and GR in the anterior pituitary gland of male Fischer and 
Lewis rats. Mean + SEM FKBP5 (A) and GR (B) mRNA in the anterior pituitary gland of male 
Lewis euthanized in the AM (n=4) or PM (n=4) and Fischer rats euthanized in the AM (n=3) or 
PM (n=3). *P<0.05, effect of time, analysed by post hoc multiple comparisons with Tukey’s 
test. $P<0.05, effect of strain, analysed by post hoc multiple comparisons with Tukey’s post 
hoc test. 
  
These data indeed demonstrate differential expression of both FKBP5 and GR in the 
anterior pituitary gland in Lewis and Fischer rats. The most noticeable finding is the increased 








6.4. Discussion  
This chapter contains preliminary data from two rat models of dysregulated HPA axis 
activity suggesting that these rats could potentially be used to further investigate the role of 
FKBP51 in the regulation of HPA axis activity and CORT ultradian rhythm. 
 
6.4.1. FKBP51 overexpression 
 Little is known about the role of FKBP51 in the thalamus, and only a few studies have 
investigated the role of the thalamus in regulating HPA axis activity. Studies have shown that 
some areas of the thalamus, including the lateral parvocellular region of the subparafascicular 
nucleus and the posterior intralaminar nucleus, project directly to CRH-containing neurones 
in the PVN (361). In particular, these thalamic regions seem to be sensitive to auditory stress 
(361) such as the noise stress used in the present study. Other studies have shown that in the 
rat the PVT has strong projections to the CeA, BLA, and BNST (22-24), areas that are implicated 
in the regulation of HPA axis activity (149). Thus, the thalamus has indeed been shown to have 
a role in HPA axis regulation.  
 Interestingly, in the above study, there was a strong effect on CORT pulsatility 
following thalamic FKBP51 overexpression, with increased pulse frequency in the AAV.FKBP51 
rats compared to AAV.null rats. According to the mathematical model of ultradian CORT 
pulsatility developed by Walker and colleagues, an increase in CRH drive causes an increase 
in ultradian CORT pulse frequency (132). Overexpression of FKBP51 in the BLA, using the same 
construct as in the present study, showed an increase in anxiety-like behaviour in mice (340) 
and this is not surprising, as the amygdala has an excitatory effect on HPA axis activity (149). 
How the FKBP51 is involved in this thalamus-mediated change in HPA axis pulsatility is yet to 
be unravelled. Lesion of the medial geniculate nucleus of the thalamus auditory system has 
been shown to block CORT secretion following audiogenic stress in rats (422). In the present 
study stress-induced CORT following noise stress was lower in the AAV.FKBP51 rats suggesting 
that FKBP51 overexpression and the potential reduction in nuclear GR in the thalamus is 





6.4.2. Fisher and Lewis rats 
 The 24-hour CORT profiles of the Lewis and Fischer male adult rats differ from the 
previously published female Lewis and Fischer CORT profiles. Female Fisher rats exhibit 
increased CORT pulse amplitude throughout the 24-hour and hence lack a circadian variation 
in mean CORT (418). In contrast, the male Fischer rats in the present study showed a circadian 
variation in CORT pulse amplitude, however, the overall CORT concentrations were higher 
compared to the male Lewis rats. Observations from the PULSAR analysis suggests the 
increased CORT in the Fischer rats is due to increased pulse amplitude and pulse height. This 
increase in CORT in the male Fischer rats, compared to Lewis rats, is consistent with previous 
reports (419). The results from the gene expression analysis suggest that the higher CORT 
concentrations in the Fischer rats, compared to Lewis rats, is at least partly due to higher 
expression of FKBP51 in the Fischer rats. The Fischer rats had significantly higher FKBP51 
mRNA expression in the PM group compared to Lewis rats in the PM group. It is plausible that 
this causes decreased GR transcriptional activity, decreased GC negative feedback, and a 
subsequent increase in CORT. The increased GR mRNA in the Fischer AM compared to Lewis 
AM, might mitigate these effects in the morning and could explain why there is a circadian 
variation in CORT. In light of the data showing sexual dimorphism in the effects of SAFit1 and 
SAFit2, it would be interesting to determine the expression profiles of FKBP51 and GR in 
female Fischer and Lewis rats. Perhaps female Fischer rats have no circadian variation in the 
GR expression and hence why there is no circadian variation in CORT concentrations.  
 In this chapter, data has been presented from two novel rat models of dysregulated 
HPA axis function, which could both be useful for further characterisation of the involvement 
of the FKBP51 in HPA axis regulation and novel therapeutics. For example, it would be 
interesting to characterise the potential effects of SAFit2 and SAFit1 in Fischer and Lewis rats 
and to investigate whether this would mitigate the increased FKBP51 expression in the Fischer 
rats. In addition, it would be of interest to investigate whether SAFit2 would counteract the 
overexpression of FKBP5 in the PVT. As the viral vector of FKBP5 overexpression used in this 
study did indeed work, it will also be interesting to characterise the effect of FKBP5 





Chapter 7: General Discussion  
 
7.1. Introductory statement  
Although a vast amount of research is being done to further elucidate the molecular 
mechanisms responsible for psychiatric disorders such as major depression, bipolar 
disorder, schizophrenia, and anxiety disorders (71, 137), those mechanisms are not fully 
understood. However, it has been shown that a dysfunctional HPA axis activity is often 
present in patients with psychiatric disorders. This can, in turn, lead to a failure to terminate 
the cortisol response to stress, thus creating stress-hypersensitivity. Studies have found 
that this HPA axis dysfunction is partly due to a decreased activity of the GR (71), which 
results in an inadequate GC negative feedback response and increased cortisol 
concentrations (137).   
What causes this dysfunction of the GR? Recent studies found that certain variants of 
SNPs in the gene encoding for FKBP51 (FKBP5) is correlated with hyperactivity of the HPA 
axis in depressed patients and with the effectiveness of antidepressant treatment in these 
patients (334). Because of its role in regulating GC negative feedback via modulation of GR 
activity, the general hypothesis is that increased expression of FKBP51 will cause a decrease 
in transcriptional GR activity, followed by decreased GC negative feedback and an increase 
in circulating GC. This led to the intriguing hypothesis that inhibition of FKBP51 could 
represent a valid therapeutic tool to treat depression associated with HPA axis 
hyperactivity. For many years, the development of a selective FKBP51-antagonist has been 
hindered by the structural similarity between FKBP51 and FKBP52. A recent breakthrough 
came when highly specific FKBP51-antagonists, SAFit1 and SAFit2, were developed by 
Professor Felix Hausch at the Max Plank Institute of Psychiatry in Munich (347). Since then, 
SAFit1 and SAFit2 have been experimentally used in mice to characterise the effects of 
FKBP51-inhibition on HPA axis activity (347), as well as its effect on anxiety-like behaviour 
(340), metabolism and pain (351, 423). Within this thesis, the effects of SAFit2 and SAFit1, 
on basal and stress-induced CORT secretion, in both male and female rats have been 
investigated. The results of the experiments have extended our previous knowledge on the 




regulating the HPA axis and have further elucidated the sexual dimorphism in HPA axis 
activity.  
 
7.2. Summary of aims and findings 
 
Table 7.1. Summary of the main findings from the SAFit2 and SAFit1 experiments. HY= 
hypothalamus, PIT= anterior pituitary gland.  
 SAFit2 
















Basal CORT ↓ ↓↓ - ↓ - ↓ ↓ 
Stress CORT ↓ ↓↓ - ↓ - - ↓ 
GR inducible 
gene expression 
- ↑ HY - - - ↑ PIT ↑ PIT 
 
The general aim of this project was to characterise the role of the GR chaperone 
protein FKBP51 in the regulation of HPA axis activity and corticosterone ultradian rhythm in 
the rat. The overall hypothesis was that by inhibiting FKBP51, GR activity will be altered, and 
this will have profound effects on GC negative feedback. The most important finding of this 
research is that treatment with the central and peripheral FKBP51-inhibitor SAFit2 for five 
consecutive days caused a reduction in basal CORT secretion in both male (figure 4.2) and 
female rats (figure 5.3), whereas a reduction in stress-induced CORT was observed only in 
male rats (figure 4.6) and not in the female rats (figure 5.7). Furthermore, treatment with the 
peripheral-only FKBP51 inhibitor, SAFit1 caused changes in ultradian pulse dynamics in male 
rats (figure 4.5). The molecular mechanisms underlying the observed effects are yet to be 
elucidated however following prolonged SAFit2 treatment a significant increase in GR-
inducible genes was observed in the hypothalamus in male rats (figure 4.7), and in the 
anterior pituitary gland in female rats (figure 5.13). The summary of the main effect following 
SAFit2 and SAFit1 administration in male and female rats are shown in table 7.1. The data 
produced by this work will help elucidate the role of the GR chaperone, FKBP51, in the 




In this chapter the results will be discussed in relation to the following aims: 
Aim 1. To elucidate the effects of SAFit2 and SAFit1 treatment on the HPA axis activity in male 
rats. 
Aim 2. To elucidate the effects of SAFit2 and SAFit1 treatment on the HPA axis activity in 
female rats. 
Aim 3. To elucidate the molecular mechanisms underlying the effects of SAFit2 and SAFit1 on 
the HPA axis activity described in aim 1 and 2. 
 
7.3. Effects of SAFit2 and SAFit1 treatment on the HPA axis activity in male rats 
The first aim of the project was to characterise the effects of two FKBP51-inhibitors, 
SAFit2 and SAFit1, on basal and stress-induced CORT concentrations, and on the ultradian 
rhythm of CORT secretion in male rats. The hypothesis was that by inhibiting the activity of 
FKBP51, SAFit2, and SAFit1 would enhance GR nuclear translocation and therefore affect its 
transcriptional activity. This would subsequently enhance GC negative feedback and 
ultimately reduce CORT secretion. Since SAFit2 can block FKBP51 expression both peripherally 
and centrally, whereas SAFit1 affects only peripheral FKBP51, the hypothesis was that the 
effects of these two compounds would be different. Indeed, the results demonstrate a 
reduction in both maximum CORT, and stress-induced CORT secretion following acute SAFit2 
administration in male rats (figure 3.3 and 3.6). In contrast, there was no effect on either basal 
or stress-induced CORT following acute SAFit1 administration in male rats.   
Within this same aim, the effects of prolonged exposure to SAFit2 and SAFit1 on basal 
and stress-induced CORT in male rats was investigated. The FKBP51 inhibitors have been 
suggested to represent a novel therapeutic tool for the treatment of mental illnesses linked 
to a dysregulated HPA axis activity. Therefore, the sub-chronic administration of SAFit2 and 
SAFit1 was performed to better understand the effects of prolonged treatment with an 
FKBP51 inhibitor. Following sub-chronic treatment with SAFit2 or SAFit1, both inhibitors 
significantly lowered stress-induced CORT concentrations in male rats (figure 4.2 and 4.4). 
This contrasts with the results from the acute studies where only the SAFit2 caused lower 




pituitary gland GR-mediated negative feedback may not be sufficient to reduce stress-
induced CORT, however, when rats are exposed to the prolonged enhancement of pituitary 
gland-mediated GC negative feedback, these changes can lead to reduced stress-induced 
CORT secretion.  
Further, the data show that sub-chronic SAFit1 treatment alters the ultradian rhythm 
of CORT secretion in male rats. By analysing the 24-hour CORT profiles with the PULSAR 
algorithm the data revealed that in the male SAFit1 group the number of pulses increased and 
both the pulse length and IPI were shorter, which resulted in a smaller pulse area (figure 4.5). 
In contrast, sub-chronic SAFit2 administration resulted in lower maximum and mean CORT 
concentration, pulse amplitude and height, and CORT 24-h AUC, but no effects on the 
dynamic of CORT pulses (i.e. pulse length and IPI) were found (figure 4.3). Thus, the data 
suggest that prolonged peripheral-only inhibition of FKBP51 alters ultradian CORT pulsatility 
dynamics in male rats, while central and peripheral inhibition reduces the pulse height and 
subsequently the mean and max CORT concentrations, with no effects on the dynamic of the 
CORT pulses.  
 Finally, the aim was to characterise at what level of the HPA axis SAFit2 and SAFit1 are 
acting. In other words, to investigate how the central and peripheral regulation differs and 
what effects this produces to obtain a better understanding of how the HPA axis is regulated 
by FKBP51. Indeed, determining if SAFit2 and SAFit1 are causing their effects at the level of 
the hypothalamus or other brain areas (SAFit2 only), at the level of the pituitary gland, or in 
the adrenal gland directly, could help characterise the mechanism of FKBP51 involvement in 
the GC negative feedback. To investigate the effects of the FKBP51 antagonists at the three 
different levels of the HPA axis, the following three models were used to activate HPA axis 
activity, pituitary-adrenal gland activity and/or adrenal gland CORT secretion, respectively: i) 
noise stress, ii) CRH injection, iii) ACTH injection (chapter 3). Performing these experiments 
allowed for determining whether there was any difference in the responses to each 
stimulation model, and hence if the SAFit2 and SAFit1 affected any specific level of the HPA 
axis.  
Following the CRH injection, both SAFit2- and SAFit1-treated rats had lower ACTH 
secretion compared to the vehicle-treated rats (figure 3.9).  The CORT concentrations 




compared to vehicle-treated rats (figure 3.10). Thus, suggesting that both SAFit2 and SAFit1 
reduce the CORT response following a CRH injection by reducing ACTH secretion. 
Furthermore, neither SAFit2 nor SAFit1 had any effect on ACTH-induced CORT secretion 
(figure 3.11), indicating that there is no direct effect of SAFit2 or SAFit1 on the adrenal glands. 
These experiments indicate that lower CORT concentrations following CRH administration in 
both the SAFit2 and the SAFit1 group are due to lower ACTH secretion from the anterior 
pituitary gland.  
 
7.3.1. Effects of SAFit2 and SAFit1 treatment on basal and stress-induced corticosterone 
secretion in male rats 
Acute SAFit2 administration decreased max CORT concentrations under basal 
conditions while there was no effect of acute SAFit1 administration. Furthermore, the CRH 
and ACTH injection experiments (chapter 3), as mentioned above, suggest both SAFit2 and 
SAFit1 are acting in the anterior pituitary gland to reduce ACTH secretion. However, only 
acute SAFit2 treatment results in lower stress-induced CORT, whilst there was no effect of 
acute SAFit1 treatment (figure 3.6).  
Therefore, as both SAFit2 and SAFit1 are active in the anterior pituitary gland, this 
suggests that SAFit2 must have additional effects elsewhere to produce the observed 
decrease in CORT that was not seen in the SAFit1-treated rats. As SAFit2 should cross the BBB, 
it is plausible that SAFit2 is, in addition to the pituitary gland, also acts centrally to reduce CRH 
secretion following a stressor. However, if SAFit1 reduces the ACTH and subsequent CORT 
response to exogenous CRH, why is there no reduction in CORT following stimulation with 
endogenous CRH, such as that induced by noise stress? The CORT concentrations following 
the noise stress were approximately two-fold higher than following exogenous CRH 
stimulation. As only SAFit2 caused a reduction in stress-induced CORT concentrations, it is 
plausible that when the rats are exposed to higher concentrations of CRH, a central 
enhancement in negative feedback is required to lower the stress-response. Enhanced 
negative feedback at a central level would reduce CRH concentrations. In contrast, enhanced 
negative feedback in the pituitary gland would not affect CRH concentrations, and thus in the 




sufficient to reduce ACTH and subsequent CORT secretion. To investigate whether SAfit2 
directly affects CRH synthesis/secretion, it would have been interesting to administer SAFit2, 
expose the rats to noise stress, terminate the rats at different time points and perform in situ 
hybridisation for CRH mRNA and/or hnRNA levels in the PVN, and POMC in the anterior 
pituitary gland.  
It is known that rapid, GC-induced negative feedback is induced both centrally, for 
example in the PVN, hippocampus, and amygdala, and also in the pituitary gland (357). In the 
hypothalamus, this rapid negative feedback is thought to depend on endocannabinoid 
signalling involving the CB1 (143). For example, CB1 knock out mice display a greater stress-
response to the forced swim test and tail suspension test (424, 425). When GCs are 
administered systemically, the HPA axis activity is rapidly reduced (172, 426). To determine 
whether this rapid negative feedback is occurring in the PVN, Evanson and colleagues 
performed stereotaxic injections of GCs bilaterally in the PVN. The result indeed indicated a 
rapid suppression of HPA axis activity following an acute stressor (143). Furthermore, this 
rapid negative feedback was also observed in rats injected with DEX conjugated to BSA, and 
hence unable to cross the plasma membrane (143). Thus, these data suggest that rapid 
negative feedback in the PVN is dependent on a putative membrane-associated GR and 
endocannabinoid signalling.  
Nevertheless, the anterior pituitary gland has also been implicated in the rapid, stress-
induced GC negative feedback mechanism (427, 428). For example, HPA activation by CRH 
injection is attenuated by pre-treatment with GCs, and this is GR-mediated (428, 429). Indeed, 
Cole and colleagues showed that the CORT response to a CRH challenge was completely 
abolished when the rats were pre-treated with DEX. However, DEX pre-treatment had no 
effect when the rats were subject to an ACTH-challenge (428), indicating the rapid, GC-
induced negative feedback occurred in the anterior pituitary gland and was GR-mediated. 
Furthermore, human studies have shown that prednisolone (a GR agonist treatment caused 
reduced ACTH and cortisol concentrations following CRH stimulation, and these effects were 
observed within 30 minutes of CRH administration (429).  Similarly, in the rat, the 
administration of methylprednisolone induces a rapid suppression of CORT secretion both in 




The noise stress used in the acute and sub-chronic experiments was performed at 
07.00h when the HPA axis activity in rats is low (see for example figure 3.2) and there was no 
visible difference in basal CORT concentrations before the noise stress between vehicle and 
SAFit1- or SAFit2-treated rats. Therefore, if the SAFit2- or SAFit1-treated rats show a blunted 
CORT response to the noise stress this is not attributed to a difference in the basal CORT 
concentrations before the noise, but rather an enhancement in the rapid GC negative 
feedback in response to the stress. As GC-mediated rapid negative feedback in the PVN, 
hippocampus, and amygdala have shown to be GR-dependent (357), perhaps the inhibition 
of FKBP51 can regulate this rapid negative feedback. Therefore, it is reasonable to suggest 
that acute SAFit2 treatment enhances rapid GC-induced negative feedback centrally. The 
exact mechanism is beyond the scope of this thesis, however this putative membrane-
associated GR shares homology with the intracellular GR (431) and it is therefore likely to bind 
FKBP51. The FKBP51 impairs ligand (CORT) binding to the GR (432) and thus FKBP51 inhibition 
by SAFit2 could enhance CORT-mediated activation of the putative membrane-associated GR 
and therefore enhance rapid, endocannabinoid-mediated GC negative feedback in the PVN. 
In the sub-chronic studies, SAFit2-treated male rats showed decreased mean and 
maximum CORT, and stress-induced CORT, compared to the vehicle-treated rats (figure 4.3 
and 4.6). As suggested above, the reduction in basal and stress-induced CORT following both 
acute and sub-chronic SAFit2 treatment may be due to enhanced GC negative feedback in the 
PVN, or other brain areas involved in regulating the HPA axis such as the hippocampus or 
amygdala. 
 Rapid negative feedback does not only occur centrally but also at the level of the 
anterior pituitary gland. In the corticotrophs of the anterior pituitary gland, CRH stimulates 
the increase in bursts and frequency of action potentials (200) which in turn increases 
intracellular calcium and vesicle-mediated release of ACTH (201, 202). This increase in burst-
type firing is dependent on the activity of BK channels (200, 204) suggesting that the BK 
channels are required for ACTH release. It has been shown in vitro that CORT reduces both 
spontaneous and CRH-mediated burst-type firing and that this is BK channel-dependent (433). 
The exact mechanism is not yet clear, however, it has been suggested that CORT is involved 
in BK channel deactivation by phosphorylation (206, 207). Furthermore, it has been shown 




activated intracellular GR (434, 435). In addition to this, it has been demonstrated that the 
protein ANXA1 is involved in the regulation of ACTH secretion from the corticotropic cells, 
and this involves reorganisation of the actin cytoskeleton (208). This has been proposed to be 
dependent on the GR activation and a subsequent kinase cascade (209). It has been shown 
that the stress-induced effects of GCs on ACTH and CORT inhibition can me mimicked by 
intracerebroventricular (i.c.v.) injections of human recombinant ANXA1 (hrANXA1) in vivo. It 
is suggested that ANXA1 inhibits ACTH release from the pituitary gland by inhibiting the 
exocytosis of ACTH (208). This process is dependent on GR activity in the folliculostellate cells, 
where GC initiates GR activation, which in turn activates a kinase cascade, and ANXA1 
translocates to the plasma membrane where it can be secreted to nearby corticotrophs (209). 
It is not yet clear if FKBP51 inhibition would have any effect on this process, however, it has 
been shown that when FKBP51 is bound to the GR-Hsp complex this reduces the affinity of 
the receptor complex for CORT (315, 316). Thus, SAFit2 and SAFit1 may inhibit FKBP51 bound 
to GR, which allows CORT to bind and activate GR to allow for the kinase cascade and ANXA1 
secretion to inhibit ACTH. Although these are only speculations it would be interesting to test 
this experimentally.    
Thus, there are several different mechanisms by which a change in GR activity can 
affect ACTH secretion from corticotrophs in the anterior pituitary gland. FKBP51 regulates GR 
translocation to the nucleus (72) and hence the transcriptional activity of GR. Besides, FKBP51 
also regulates the steroid affinity of GR, as when FKBP51 is bound to the receptor complex 
the affinity for GCs is reduced (436). Furthermore, FKBP51 has also been shown to regulate 
the activity of several kinases such as AKT (366) and GSK3B (328), both of which regulate GR 
activity (367). Inhibition of FKBP51 in the anterior pituitary gland by SAFit2 or SAFit1 may, 
therefore, decrease ACTH release in various ways following stress-induced increases in CORT 
secretion.  
Why is the reduced stress-induced CORT not seen in the acute SAFit1 experiment? It 
is clear from the data that prolonged treatment is required to observe a significant effect of 
SAFit1 on HPA axis activity. Similar results were observed in the SAFit2 experiments, where 
the reduction in stress-induced CORT was further enhanced with sub-chronic SAFit2-
treatment in males compared to the acute SAFit2-treatment (figure 3.6 and figure 4.6). In the 




compared to the acute treatment experiment (compare figure 3.2 with figure 4.2). Thus, this 
suggests that prolonged treatment with the SAFit2 or SAFit1 augments (SAFit2) or induces 
(SAFit1) their effects on HPA axis activity. In comparison, a previous study using a GR 
antagonist, Org34850, measured the 24-hour CORT secretion in adult male rats (352).  
Whereas acute treatment did not affect either basal or stress-induced CORT secretion, 5 days 
of consecutive treatment with Org34850 resulted in overall increased basal CORT 
concentrations (353). Moreover, there was no effect of sub-chronic Org348540 treatment on 
stress-induced CORT secretion following noise stress (353). Org34850 occupies GR in the 
hypothalamus, frontal cortex, and pituitary gland but fails to occupy GR in the hippocampus, 
amygdala, and neocortex (437). The effects on basal CORT secretion of SAFit2 and Org34850 
are somewhat opposite, which is consistent with the fact that SAFit2 should enhance GR 
activity and Org34850 reduces GR activity.  It is unclear why Org34850 does not have any 
effect on stress-induced CORT, however, a separate mechanism may regulate stress-induced 
GC-negative feedback, compared to basal GC-negative feedback. SAFit2 administration did, 
however, affect the stress-induced CORT response. The SAFit2 is presumably active in several 
brain areas, and perhaps has more widespread effects than Org34850.  
 
7.3.2. Effects of SAFit2 and SAFit1 on gene expression in male rats  
In the hypothalamus, there was a trend of increased c-Fos mRNA expression following 
noise stress in the sub-chronic SAFit2 group (figure 4.7 A), and significantly decreased c-Fos 
mRNA expression in the sub-chronic SAFit1 group compared to the respective vehicle-treated 
group (figure 4.7 B). As c-Fos is a marker of cellular activity (378), this suggests that SAFit2 
increases and SAFit1 decreases hypothalamic neuronal activity in response to stress. It has 
been shown that c-Fos expression is induced following audiogenic stress in most of the 
hypothalamic nuclei including the PVN (361). Since the sub-chronic SAFit2 treatment lowered 
the stress response, it could be expected that the c-Fos expression would also be lower, 
however, the results indicated a trend towards higher c-Fos expression compared to vehicle-
treated rats. In contrast, in the sub-chronic SAFit1 group, where there was also a lower stress-
response, the c-Fos expression was significantly lower. From this, it can be deduced that 
measuring c-Fos expression in whole hypothalamic extract, and quantifying the expression by 




suitable technique would be, for example, ISH or immunocytochemistry for Fos protein which 
would give an anatomical quantification of c-Fos/Fos expression. For example, one study 
investigated c-Fos expression in various brain areas following 30 minutes of constant noise 
stress (361). The rats were euthanised immediately following the noise stress and ISH used to 
investigate the induction of c-Fos in the brain (422). The group found that a robust increase 
in c-Fos mRNA was observed following acute noise stress in the majority of the brain, 
including the cortex, hypothalamus, thalamus, and hippocampus (422). Perhaps a more 
robust change in c-Fos expression would have been present if more time points and a 
different technique such as ISH had been used.  
Interestingly, in the males, an increase in GR-responsive genes expression was only 
seen following sub-chronic treatment with SAFit2. In the hypothalamus of SAFit2-treated rats, 
both GILZ and SGK1 mRNA expression were significantly higher compared to vehicle-treated 
rats (figure 4.7 C). This is particularly interesting as the stress-induced CORT concentrations 
were significantly lower in the sub-chronic SAFit2-treated rats, and hence the activation of GR 
by CORT is lower than in the vehicle-treated rats. This suggests that sub-chronic treatment 
with SAFit2 does induce enhanced GR transcriptional activity, which in turn either enhances 
the activity of nuclear GR or increases the translocation of GR to the nucleus. There was no 
increase in GR-inducible genes in the sub-chronic SAFit1-treated males, which is consistent 
with SAFit1 not being active centrally.  
Furthermore, in the anterior pituitary gland of the sub-chronically treated animals, 
there was no increased expression of GR-inducible genes in the SAFit2-treated male rats 
compared to the vehicle-treated male rats (figure 4.8 C). Similarly, no increase in GR-inducible 
genes was observed in the sub-chronic SAFit1-treated male rats (figure 4.8 D). Results from 
the CRH-injection study showed that both SAFit2 and SAFit1 act in the anterior pituitary gland 
to reduce ACTH concentrations following CRH stimulation. The lack of induction of GR-
inducible genes in the anterior pituitary gland in both the SAFit2- and SAFit1-treated males 
suggest that the effect may be non-genomic. As mentioned (see sections 1.5, 1.6.1, 1.7.1) 
there are various non-genomic actions of GR, some of which are directly related to the 
negative feedback mechanisms in the anterior pituitary gland including GC-mediated effects 




Another study investigated the induction of gene expression of various genes in the 
dentate gyrus, the CA regions, and in the ventral hippocampus following FST for 15 minutes 
in 25°C water. The rats were sacrificed immediately following the FST, or 30, 60, or 180 
minutes following the onset of the FST (355). The study found that FKBP5 mRNA was only 
increased at 180 minutes post-stress, while both SGK1 and PER1 mRNA were both increased 
at 60 minutes post-stress. Moreover, the same study measured the hnRNA expression of the 
same genes and found a robust increase in SGK1 and PER1 hnRNA at the 30 minute time point, 
and at the 60 minute time point for FKBP5 hnRNA (354). This study highlights the importance 
of measuring gene expression at multiple time points post-stress. An increased number of 
time points would have been ideal, but this was not feasible due to a limited amount of SAFit2 
and SAFit1 available. 
 
7.3.3. Acute versus sub-chronic effects of SAFit2 and SAFit1 in male rats  
 Acute treatment with SAFit2 caused a decrease only in max CORT and, following the 
sub-chronic SAFit2 treatment, the overall 24-hour CORT secretion was decreased due to 
lower CORT pulse amplitude (figure 3.3 and figure 4.3).  In comparison, acute SAFit1 
treatment did not have any effects on basal CORT, and sub-chronic SAFit1 treatment did not 
affect the amplitude of the CORT pulses but did increase their frequency (figure 3.5 and 4.5). 
This suggests that acute treatment with SAFit1 is not sufficient to exert any effects on basal 
HPA axis activity, effects are however observed following sub-chronic treatment. This is 
consistent with the SAFit2 studies: longer treatment renders a greater effect. This is also 
consistent with previous studies using a GR antagonist, where prolonged treatment had a 
greater effect on HPA axis activity (353, 437).   
Importantly, sub-chronic treatment with SAFit1, in contrast to SAFit2, does alter the 
dynamics of ultradian CORT pulses, without affecting the overall CORT concentration (figure 







7.3.4. Changes in pulsatility following sub-chronic SAFit1 treatment in male rats  
Walker and colleagues (131, 132) have described a mathematical model of CORT 
regulation that suggests CORT pulses are independent of the CRH pattern but are governed 
by a feed-back/feed forward dynamic within the pituitary-adrenal gland system (figure 1.3). 
Therefore, when the CRH drive is low, as observed in the rat under basal conditions, CORT 
secretion is within a ‘pulsatile’ region. In contrast, when the CRH drive is higher, for example 
following stress, CORT secretion is in the ‘constant’ region and the CORT pulsatility is 
governed by the pituitary-adrenal gland system and by the frequency of CRH forcing (CRH 
drive). This indicates that when CRH concentrations are within a physiological range even 
constant CRH infusion will generate a pulsatile ACTH and CORT response. Indeed, this was 
demonstrated by Walker and colleagues in vivo by infusing rats with three different doses of 
CRH at a constant pattern and measuring the CORT output (131). At lower physiological doses 
of constant CRH, the subsequent CORT response was pulsatile. Moreover, this pulsatile 
response was similar to that of rats with endogenously regulated CRH secretion. When the 
rats were exposed to a higher dose of constant CRH the CORT response was also constant 
(131).  
This model of pituitary-adrenal gland regulation of ultradian pulsatility is consistent 
with the changes in pulse dynamics following sub-chronic SAFit1 treatment (figure 4.5). The 
SAFit1 is only active peripherally and exerts HPA axis effects by interfering with the negative 
feedback in the pituitary gland. Hence, there are no changes to the central regulation of CRH 
secretion. There has been a longstanding notion that CORT pulsatility is under hypothalamic 
regulation, like other pulsatile hormones such as LH and GH, whose pulsatility depends on 
their respective hypothalamic release factor (125-127). However, in rats CRH has a pulse 
frequency of 3 pulses per hour (114), compared to approximately 1 pulse per hour for ACTH 
and CORT (102), hence there is a mismatch between the hypothalamic release of CRH and 
ACTH and subsequent CORT release. The fact that SAFit1 alters pulse frequency is a novel 
finding, and further evidence for the model of a pituitary-adrenal gland feed-
forward/feedback loop of CORT pulsatility.  
Furthermore, the mechanism behind this model of CORT pulsatility is dependent on 
ACTH-mediated positive feedforward drive from the pituitary gland, which acts on the adrenal 




to regulate ACTH release. The resultant pulsatile dynamic is due to the time delay in the 
adrenal gland de novo synthesis of CORT, and in the negative feedback, regulation to inhibit 
ACTH release from the pituitary gland. Pulsatile ACTH release, and the subsequent pulsatile 
pattern of CORT, has been well established in the rat (111, 131, 133, 134) and humans (109). 
As shown in chapter 3, SAFit1 enhances the GC negative feedback in the anterior pituitary 
gland, and this would increase the rate of the negative feedback loop to the adrenal glands, 
as well as reduce the ACTH secretion, and result in shorter CORT pulses and less overall CORT. 
This is indeed observed following sub-chronic SAFit1 treatment. However, SAFit2 also 
enhances the negative feedback in the anterior pituitary gland, as shown in the CRH 
experiment (figure 3.9 and figure 3.10), but under basal conditions, does not affect the 
number of pulses, the pulse length, or the IPI (figure 4.3). The data in this thesis are not 
sufficient to explain the mechanisms underlying the effects of SAFit1 on the CORT pulsatile 
dynamics. However, mathematical modelling studies of the system that will take into account 
the activity of FKBP5 and its inhibition are on-going. Results from these mathematical 
modelling studies will certainly help elucidate the role of FKBP5 in regulating ultradian pulse 
dynamics and will allow predictions on how the system responds to perturbation on GR and 
FKBP5 signalling, in a region- and time-dependent manner. 
 
7.4. Effects of SAFit2 and SAFit1 treatment on the HPA axis activity in female rats  
The second aim was to determine the effects of acute and prolonged administration 
of SAFit2 and SAFit1 on basal and stress-induced CORT secretion in female adult rats, and 
investigate whether these effects differ from the effects seen in male rats and if so, to attempt 
to elucidate the mechanisms underlying these differences. This aim was driven by the well-
known sexual dimorphism in the HPA axis activity in both humans and rats (reviewed in (231) 
– section 1.9). This HPA axis dimorphism is characterised by increased basal and stress-
induced CORT concentrations in female rats (231). Whereas in humans the results are more 
varied, women show an increased stress-response to certain stressors including social 
interaction and rejection (262), and pharmacological stressors (260). Interestingly, one study 
showed that women have reduced GC-mediated negative feedback compared to men when 




Hence, this difference in HPA axis regulation is characterised by different sensitivity to 
certain stressors in men and women. It is indeed suggested that dysfunctional GC-mediated 
negative feedback, and thus an inability to terminate a stress response adequately, is present 
in patients with certain mood disorders such as depression (71, 270, 438, 439). Although the 
molecular basis for the sex differences in HPA axis activity is not fully understood, studies in 
both humans and rodents suggest that females have decreased GC negative feedback. For 
example, the DEX-CRH test results in higher CORT concentrations in women (270, 307), and 
female rats have lower expression of GR in the PVN compared to males (239). It is plausible 
that similar mechanisms contribute to the higher prevalence of mental disorders in women 
(440).  
In addition to the well-characterised sex differences in basal and stress-induced CORT 
secretion in rodents, it has been shown that female rats have increased serum CBG (up to 2.5 
fold) compared to male rats (287), and CBG is positively regulated by oestrogen (441). This 
implies that free, biologically active CORT could be similar, or even lower in female rats. It is 
therefore plausible that in female rodents the higher levels of CBG compensate for higher 
CORT concentrations. This was investigated by measuring intrahippocampal ultradian 
rhythms of CORT in male and female rats in basal conditions and following stress (119, 442). 
Because CBG is not present in the brain this measured the free, active, CORT. The studies 
found similar concentrations, and similar circadian and ultradian pulses of hippocampal CORT 
in male and female rats (119, 442).  
In this thesis, it was determined whether there were any effects of acute treatment 
with SAFit2 or SAFit1 on basal and stress-induced CORT. Unfortunately, due to limited SAFit1 
availability and time constraints, it was not possible to characterise the effects of sub-chronic 
SAFit1 treatment in female rats. Furthermore, the expression of GR, MR, and FKBP5 in the 
hippocampus, hypothalamus, prefrontal cortex, and the anterior pituitary gland, in male and 
female control rats, in basal conditions both in the morning (9 AM) and in the evening (5 PM) 
was determined. The hypothesis was that, if the expression profile of those genes is different 
in males and females, this difference could contribute to any potential differences in the 
effects of SAFit2 or SAFit1 in male and female rats. 
Acute SAFit2 administration in female rats did not affect the basal 24-hour CORT 




contrast, acute SAFit1 administration significantly decreased both basal (figure 5.5) and 
stress-induced (5.7 B) CORT concentrations in female rats. The decrease in basal CORT was 
evidenced by decreased mean CORT and CORT AUC. Gene expression analysis following the 
noise stress did not reveal any effect of the SAFit2 treatment on any of the genes quantified 
(figure 5.11 A, C, and figure 5.12 A, C). In contrast, acute SAFit1 treatment significantly 
increased FKBP5 mRNA in the anterior pituitary gland (figure 5.12 C).  
Sub-chronic administration of SAFit2 in female rats significantly decreased basal CORT 
concentrations (figure 5.8), however, there was no difference in stress-induced CORT 
concentrations compared to vehicle-treated rats (figure 5.10). The reduction in basal CORT 
was due to significantly lower pulse height, pulse amplitude, and pulse area, and therefore 
lower mean, maximum and baseline CORT. The gene expression analysis following noise 
stress revealed an increase in PER1, a GR-inducible gene, in the anterior pituitary gland in 
female rats treated sub-chronically with SAFit2 (figure 5.13 D).  
The results from the gene expression quantification in untreated male and female rats 
showed that the major differences were in the anterior pituitary gland, where the overall 
expression of GR, MR, and FKBP5 was significantly lower in the females compared to males 
(figure 5.14). Seale and colleagues compared the expression of GR mRNA in the PVN in sham 
male, sham female, castrated males, and ovariectomised female (239). The study found that 
sham females had lower PVN GR mRNA compared to sham males, and castrated males have 
decreased GR mRNA compared to sham males. Further, ovariectomised females had 
increased GR mRNA compared to sham females (239). Although they did not investigate 
potential changes in GR mRNA in the pituitary gland, the study did show that sex steroids can 
influence GR expression. In the studies performed in chapter 5 of this thesis, there was no 
difference in GR mRNA between males and females in the hypothalamus, however, this might 
be because the whole hypothalamus was used, rather than isolated PVN. Overall, the results 
are consistent with the present study, where females have lower expression of GR mRNA 
compared to males. The same group performed a second study where the castrated and 
ovariectomised male and female rats were treated with respective sex steroids (240). The 
results indicated that when castrated males are treated with testosterone the GR mRNA in 
the PVN returns to similar levels as in sham males (240). Similarly, ovariectomised female rats 




rats (240). Overall, this suggests that testosterone induces GR expression, and oestrogen 
inhibits GR expression, presumably via the AR and the ER, respectively. Although it is not yet 
known how sex steroids can influence the expression of GR and although, to my knowledge, 
no ARE or ERE has been discovered on the GR promoter, further research in this area might 
reveal a mechanism. Besides, CRH-neurons located in the PVN express ER-β  (443) and it is 
thought that oestradiol-mediated activation increases CRH expression (444).  
Mechanisms may have evolved to compensate for the higher CORT concentrations 
observed in female rats and mice (231). This might include the increased CBG in female rats 
as mentioned above (287). On the other hand, lower expression of GR and FKBP5 mRNA in 
the anterior pituitary gland of female rats compared to male rats was observed in the studies 
in chapter 5 (figure 5.14), and lower GR mRNA expression in females in the anterior pituitary 
gland has been observed in other studies (239), as mentioned. A lower expression of GR in 
the PVN and anterior pituitary gland might contribute to a decreased GC-mediated negative 
feedback in female rats. As the FKBP5 mRNA expression is also lower in the anterior pituitary 
gland of the female rats in the present study, perhaps this is to mitigate the effects of reduced 
GR availability. Although beyond the scope of this thesis it would be interesting to further 
characterise the expression of FKBP51 and GR in the pituitary gland and brain under various 
physiological conditions.  
 
7.4.1. Effects of SAFit2 and SAFit1 treatment on basal and stress-induced CORT secretion 
in female rats  
 As SAFit2 has the same chemical characteristics as SAFit1, except that it can cross the 
BBB, SAFit2 should also be active peripherally. Indeed, in male rats, acute SAFit2 treatment 
result in lower ACTH, and subsequent CORT secretion, thus indicating that SAFit2 is active in 
the pituitary gland. Hence, as acute SAFit1 treatment in females result in significantly lower 
CORT concentrations, one would expect SAFit2 to also cause lower basal CORT, as the SAFit2 
is also present and should be active in the periphery, similar to SAFit1. Moreover, SAFit2 
should be active centrally in the females if it is assumed that SAFit2 can cross the BBB in 
females. The sub-chronic SAFit2 experiment in females suggests that the peripheral effects of 




induced CORT is not affected. The mechanism behind this is not clear, however as discussed 
in section 5.4, it may involve the ER-α in the PVN.  Perhaps the stress-mediated increase in 
CRH during the stress response further enhances this centrally mediated decrease in negative 
feedback, and the peripheral actions of SAFit2 are not sufficient to diminish this. Intra-cranial 
injection of SAFit2 in female rats could be performed to further elucidate this.  
Another interesting observation in the female studies was that acute SAFit2 does not 
affect stress-induced CORT secretion, however, SAFit1 significantly reduces stress-induced 
CORT secretion. This suggests that the stress-induced rapid negative feedback can be 
enhanced by inhibition of FKPB51 in the pituitary gland. There are several mechanisms by 
which this might occur, as discussed above. Compared to the male SAFit1 experiments there 
was no effect of acute SAFit1 on stress-induced CORT, however, a decrease was seen 
following sub-chronic SAFit1 treatment. Perhaps stress-induced rapid negative feedback is 
regulated to a greater part in the pituitary gland in females and therefore lower CORT 
concentrations are observed after acute treatment with SAFit1. If the stress-induced CORT is 
regulated to a greater part centrally in males then that could explain why prolonged 
treatment of SAFit1, and hence a build-up of the SAFit1 to render a stronger effect, is required 
to see an effect on the stress-induced CORT. Furthermore, as shown in chapter five (figure 
5.14), untreated females have a lower basal expression of both GR and FKBP5 mRNA in the 
pituitary gland, compared to control males. Thus, the same dose of SAFit1 could be more 
effective in females due to less FKBP51 available.  
 
7.4.2. Sex differences in SAFit2 and SAFit1 effects  
The results reported in this thesis highlight several sex differences in FKBP51-
mediated regulation of GC negative feedback under both basal conditions and subsequent 
stress.  Even though both males and females responded to the SAFit2 and SAFit1 treatments, 
and there were several similarities in the response, several important differences were 
observed. The first remarkable difference was the effect on stress-induced CORT following 
sub-chronic treatment. In males, the stress-induced CORT was significantly decreased, 
whereas in females there was no effect of the SAFit2 treatment on stress-induced CORT 




meditated activation of ERα in the PVN (401). More stress-related sex differences became 
apparent following acute SAFit1 treatment. In females, this caused a significant decrease in 
stress-induced CORT (figure 5.7), whereas in males there was no effect (figure 3.6). In 
comparison, acute SAFit2 treatment caused a significant decrease in stress-induced CORT in 
males (figure 3.6) whereas there was no effect in females (figure 5.7). Thus, acute 
administration of SAFit2 was effective in reducing stress-induced CORT secretion in males 
only, whilst SAFit1 was effective in reducing stress-induced CORT secretion in females only. 
In males, the lack of a decrease in stress-induced CORT following SAFit1 treatment, compared 
to a reduction in stress-induced CORT following SAFit2 suggests a central regulation of the 
stress-mediated negative feedback. However, sub-chronic SAFit1 treatment caused a 
reduction in stress-induced CORT in male rats. This indicates that the rapid GC negative 
feedback following stress is mediated by both central and pituitary gland mechanisms in male 
rats.  
Previous studies have revealed that micro-infusion of CORT into the PVN, 1 hour or 
immediately before a stressor, inhibits ACTH secretion (143, 445). This suggests that the 
decrease in ACTH is due to decreased CRH stimulation. The decrease in CRH could be because 
of direct inhibition of the CRH neurons which, in turn, inhibits CRH secretion, or due to an 
indirect effect, such as the induction of retrograde endocannabinoid signalling which in turn 
regulates CRH neuron synaptic transmission (357). Another study investigated the effects of 
administering CORT at different time points before the onset of a stressor (446). Thus, this 
allows for a comparison of the negative feedback effects when the stress coincides with 
CORT’s rapid rising phase (30 seconds before stress), high plateau phase (15 minutes before 
stress), and restored basal phase (60 minutes before stress). Administration of CORT at all 
three time points result in significantly lower ACTH secretion following restraint stress, and 
this reduction in ACTH was fully present at 5 minutes post-stress (446). In comparison, CORT 
administration 5 minutes post-onset of the restraint stress did not affect ACTH secretion. 
These results indicate that CORT administration as close as 30 seconds before a stressor 
significantly reduces stress-induced CORT secretion, thus suggesting that these effects may 
occur by non-genomic CORT actions (446). Moreover, the same study demonstrated that the 
effects of fast feedback lasted at least 15 minutes once initiated. This is consistent with the 




191). Furthermore, it was found that CRH hnRNA at 30 minutes post-stress was significantly 
decreased in rats receiving the 30-second CORT pre-treatment (446). This suggests that CORT-
mediated GR activation also has rapid negative feedback actions to reduce CRH gene 
expression. The same study showed that the CORT treatment 5 minutes post-stress did not 
affect the stress-mediated increase in CRH hnRNA expression, but suppressed POMC hnRNA 
expression at the same time point (446). This indicates that resistance in stress-induced fast 
feedback is at the level of the PVN.  
Numerous studies have reported GC-mediated rapid negative feedback in the 
pituitary gland as well (136, 200, 208) and have proposed several possible mechanisms, 
including changes in the cells electrophysiological properties (200), alterations to the actin 
cytoskeleton (208) and ligand-dependent membrane association of the GR (136). Deng and 
colleagues showed that CORT mediated ACTH suppression occurred rapidly but was short-
lasting (approximately 5 minutes). The sustained effects of negative feedback seen in vivo 
following CORT administration (446) indicate that the stress-induced rapid negative feedback 
may not be mediated solely by corticotrophs and further supports a central regulation of the 
stress-induced negative feedback. Furthermore, in the in vivo experiment where sustained 
negative feedback was seen, to activate the negative feedback response a dose of CORT that 
is equivalent to stress-induced plasma levels of CORT (~400 ng/ml) was used. In contrast, 
Deng and colleagues used CORT concentrations equivalent to physiological concentrations of 
CORT (136). Thus, these studies indicate a central regulation of the stress-induced CORT 
negative feedback.  
As discussed above, in comparison to male rats, central FKBP51-inhibition in female 
rats seem to counteract the pituitary gland effects of FKBP51-inhibition. As stress-induced 
CORT was significantly suppressed following acute SAFit1 treatment, and if we assume that 
SAFit2 has the same effects as SAFit1 on pituitary gland negative feedback, this infers that 
SAFit2 treatment increases CRH release. The CRH-mediated ACTH release is then reduced 
from the enhanced negative feedback in the pituitary gland by SAFit2. The same mechanism 
would explain the lack of stress-induced CORT in sub-chronic SAFit2-treated rats. The stress-
induced CORT decreased following sub-chronic SAFit1 treatment in male rats, and following 
acute SAFit1 treatment in female rats, if the SAFit1 does not have central effects? A stressor 




including the hippocampus, amygdala, and the PVN directly (21). This, in turn, initiates the 
release of CRH from the PVN and an increase in ACTH and CORT secretion follows. The 
increased CORT secretion activates negative feedback by the mechanisms explained above. 
Thus, in the SAFit2-treated male rats, FKBP51-inhibition in the brain should enhance GR 
activity and this central negative feedback should ultimately reduce CRH release, and 
therefore decrease ACTH release. In addition, SAFit2 also enhances the negative feedback at 
the level of the pituitary gland, which further reduces ACTH release from the pituitary gland.  
In contrast, in the SAFit1-treated rats, there is no enhanced negative feedback in the 
brain, hence the CRH that reaches the pituitary gland will be the same as in the vehicle-treated 
rats. However, in the pituitary gland, the SAFit1 enhances GC negative feedback, thus should 
reduce ACTH and CORT release, although to a lesser extent than in the SAFit2-treated rats. 
This is consistent with the result from the sub-chronic experiments in males, where the 
reduction of stress-induced CORT was more pronounced in the SAFit2-treated rats than in the 
SAFit1-treated rats. This is also consistent with the acute SAFit2 and SAFit2 experiments in 
males, where a small decrease in post-stress CORT was observed in SAFit2-treated rats, 
however, no decrease was seen in the SAFit1-treated rats. Thus the effect of acute SAFit1 was 
not sufficient to decrease stress-induced CORT, however, the effects of SAFit1 were enhanced 
when given for a prolonged time in line with studies of acute versus sub-chronic GR 
antagonists (383, 437).  
Another striking difference between the males and females was the effect of acute 
SAFit1 treatment on basal HPA axis activity. In females, there was a significant decrease in 
mean CORT secretion in SAFit1-treated rats (figure 5.6), while in males there was no effect of 
SAFit1 treatment on the 24-hour basal CORT concentrations (figure 3.5). As there is lower 
expression of FKBP51 in the anterior pituitary gland in the control female rats compared to 
control male rats (figure 5.16), it is plausible that SAFit1 has a stronger effect in female rats 
because the SAFit1 can inhibit more of the available FKBP51.  Furthermore, the gene 
expression profiles in the sub-chronic SAFit2-treated males and females differed. In the males, 
there was an increase in GR-inducible genes GILZ and SGK1 in the hypothalamus (figure 4.7 
C), while in the females there was an increase in the GR-inducible gene PER1 in the anterior 
pituitary gland (figure 5.13 D). This indicates increased GR transcriptional activity in the 




occurred in the anterior pituitary gland in the SAFit2-treated female rats. This is consistent 
with the hypothesis of no enhanced central negative feedback following SAFit2 treatment in 
females. It is also consistent with an increased stress-induced negative feedback in the 
pituitary gland following SAFit2 or SAFit1 treatment in females, while in males the enhanced 
central negative feedback seems to play a bigger role. It should be noted that the increase in 
these GR-inducible genes is occurring despite the reduced CORT in the SAFit2- or SAFit1-
treated rats, suggesting an even stronger effect on GR transcriptional activation. 
In summary, there are sex differences in the regulation of FKBP51-mediated GR 
activation in regards to GC negative feedback in male and female rats, with a stronger effect 
on negative feedback in the pituitary gland in females. Furthermore, it is plausible that 
FKBP51 inhibition, via ERα, increases CRH release in SAFit2-treated females. This data 
highlights the complexity of HPA axis regulation and the difference between males and 
females.  The reason why females and males have differentially regulated HPA axis responses 
is a pivotal question, yet to be fully understood. In humans, women are more susceptible to 
social rejection than are men (262) and perhaps this is because in our ancestors, women 
possibly relied on protection from other humans when breastfeeding their offspring, although 
this is only a hypothesis.  
Studies have shown that the prevalence of any mental health disorder is higher in 
women than in men (440), and twice as many women are diagnosed with anxiety compared 
to men (447). Increased awareness of HPA axis sexual dimorphisms will help elucidate the 
underlying mechanisms of disorders with altered HPA axis activity and differences in men and 
women. Further research is needed to fully understand how the regulation of HPA axis activity 
differs in males and females. In addition, this will have profound clinical implications with the 
potential to develop a gender-specific treatment for not only psychiatric disorders but also 
for synthetic GC treatment.  For example, if women have decreased GR-mediated negative 
feedback compared to men, can this be counteracted by administering a GR agonist? Or, if 
men have increased levels of FKBP5 mRNA (as seen in male rats – section 5.3.8), can this be 
targeted by administering an FKBP51-inhibitor? Although these are only speculations, the 
clinical implications of elucidating the HPA axis sexual dimorphism are many and the data 





7.5. Molecular mechanisms underlying the effects of SAFit2 and SAFit1. 
The third aim was to investigate the molecular mechanism underlying the effects of 
SAFit2 and SAFit1 on HPA axis activity that were observed in basal and stress conditions. This 
aim was based on the hypothesis that FKBP51 inhibition increases nuclear GR, and hence 
could increase transcriptional active GR. This would, in turn, include GR-mediated activation 
of GC negative feedback ultimately to reduce circulating CORT concentrations. To test this 
hypothesis, animals were treated with SAFit2, SAFit1, or vehicle, and then injected with either 
CORT (0.3 mg/kg, s.c.) or saline. The results indicated no major effect of SAFit2 or SAFit1 on 
sub-cellular localisation or activation of GR or MR (figure 3.14 and 3.15). An interesting 
observation made was that in the hippocampus, membrane-associated MR was observed, 
while in the anterior pituitary gland no MR was present in the cell membrane fraction.  
Although the distribution of MR is not the focus of this thesis, this is a novel finding and would 
be worth looking into further.  
Furthermore, to determine whether there was an induction of GR-inducible genes, 
and hence increased GR transcriptional activity, the gene expression of various GR-inducible 
genes was measured following noise stress in all the acute and sub-chronic SAFit2 and SAFit1 
sampling experiments, as described above. In summary, there was an induction of GR-
inducible genes in the hypothalamus of sub-chronic SAFit2 males (figure 4.7 C), and the 
anterior pituitary gland of sub-chronic SAFit2 females (figure 5.13 D). For the acute studies, 
an increase in FKBP5, which is also GR-inducible (325, 326), was observed in the anterior 
pituitary gland in SAFit1-treated female rats (figure 5.12 D) but not in the SAFit1-treated male 
rats (figure 3.16 D).  Hence, an increase in GR transcriptionally activity is observed following 
SAFit2 treatment in the hypothalamus of male rats, and the anterior pituitary gland of female 
rats. An increase in GR transcriptionally activity is observed in female rats in the anterior 
pituitary gland following acute SAFit1 treatment. The time points for the gene expression 
quantification was 60 minutes following noise stress, suggesting that GR translocates and 
enhances gene expression before 60 minutes. It is plausible that the timing of the sub-cellular 
localisation experiment contributed to the lack of effects seen.    
The fact that there is no induction of the GR-regulated genes in the hypothalamus of 
the SAFit2-treated female rats (figure 5.11 A, C, and figure 5.13 A, B) further supports the 




expression in the anterior pituitary of the sub-chronically SAFit2-treated females (figure 5.13 
D) indicates SAFit2 indeed causes enhanced negative feedback in the pituitary gland. 
Furthermore, there is a clear induction of the GR-inducible genes in the hypothalamus of the 
sub-chronically SAFit2-treated males, however, there is no effect in the pituitary gland, also 
consistent with the ABS studies and noise stress experiment. Unfortunately, the translocation 
study did not reveal the molecular mechanism behind these effects. The gene expression 
analysis suggests that the effects of SAFit2 are due, at least partly, to genomic actions. In 
contrast, the results suggest that the effects of SAFit1, at least in male rats, are due to non-
genomic effects.  
In conclusion, these data further support the evidence for a centrally regulated stress-
induced CORT negative feedback. Moreover, it is plausible that the ultradian pulsatility is at 
least partly regulated by non-genomic GR activity, as there was no induction of GR-inducible 
genes in the anterior pituitary gland following SAFit2 or SAFit1 treatment.  
 
7.6. Future studies  
To further elucidate the effects of SAFit1 treatment in females, it would be interesting 
to perform sub-chronic SAFit1 treatment in female rats. It is plausible that the decrease in 
basal and stress-induced CORT would be further enhanced. Moreover, it would be interesting 
to investigate gene expression following noise stress in such an experiment. In the acute 
SAFit1-treated female rats an increase in the GR-inducible FKBP5 mRNA following noise stress 
was observed in the anterior pituitary gland, suggesting increased GR transcriptional activity. 
It would be interesting to investigate whether prolonged SAFit1 treatment in females would 
increase the expression of other GR-inducible genes. In addition, performing similar CRH and 
ACTH experiments to those in chapter 3 in female rats would help further elucidate the 
observed sex differences in the central and peripheral effects of SAFit2 and SAFit1 on GC 
negative feedback. Furthermore, using ChIP on brain tissue to further investigate the effect 
of SAFit2 and SAFit1 on GR-DNA interactions could be a better way of detecting alterations in 
transcriptional activity, rather than the translocation experiment I performed. Similarly, using 




anatomical representation of the potential changes in gene expression and could, for 
example, show differences in gene expression between subregions of the hypothalamus.  
The molecular mechanisms underlying the effects of SAFit2 and SAFit1 are yet to be 
fully elucidated. The translocation study (section 3.3.7) did not reveal any effects on GR 
translocation or phosphorylation following SAFit2 or SAFit1. Perhaps performing the same 
study with a higher dose of CORT, and at different time points for tissue collection, would 
reveal potential differences. The gene expression quantification following the noise stress 
does indeed suggest an increase in GR transcriptional activity. Performing the western 
immunoblotting to examine intracellular receptor translocation following sub-chronic 
treatment of SAFit2 or SAFit1 could reveal a stronger effect of the putative enhanced GR 
translocation. Furthermore, a more comprehensive gene expression analysis at the diurnal 
peak, following SAFit2 and SAFit1, could help elucidate any potential basal differences in gene 
expression.  
The potential for FKBP51-inhibitors as therapeutics for disorders with a dysregulated 
HPA axis activity, such as depression, is promising. In the present study, SAFit2 and SAFit1 
were tested in healthy male and female rats and the next step would be to perform similar 
studies in rats with a disrupted HPA axis. For example, rats exposed to chronic mild stress 
(CMS) have been shown to comprise a translational model of depression as indicated by the 
rat depression-like behavioural phenotype (448). Thus, administering SAFit2 and SAFit1 in a 
rat model of depression will help determine how the FKBP51-inhibition will affect a 
dysregulated HPA axis. For such studies, it might be advantageous to use an alternative to the 
subcutaneous administration of the SAFit2 and SAFit1, as the infection risk with the 
subcutaneous cannula increases with prolonged use. Other studies using SAFit2 in mice have 
explored a gel formulation, with good results (350, 351, 423). The SAFit2 was combined with 
a vesicular phospholipid gel (VPG) as a carrier, and it was shown that this results in stable 
plasma and brain concentrations of SAFit2 (351, 423).  
To investigate the potential for FKBP51 as therapeutics for disorders involving HPA 
axis dysregulation, it is important to establish first a rat model with a hyperactive HPA axis 
and overexpression of FKBP51. Naturally occurring FKBP51 overexpression is present in 
squirrel monkeys, as described in the introduction (322, 331, 332), and FKBP51 




model for naturally occurring or induced overexpression of FKBP51 in the rat. Therefore, I 
decided to investigate the potential for two new rat models of dysregulated HPA axis activity, 
the Fischer rat, and induced overexpression of FKBP51.  
 
7.7. Pilot studies of dysregulated HPA axis activity 
In chapter 6 it was demonstrated that male Fischer rats have increased FKBP51 
expression in the anterior pituitary gland, compared to the histocompatible Lewis rats (figure 
6.8). This is an important discovery, as it implicates the Fischer rats as a potential model for 
studying dysregulated HPA axis activity. Further, increased FKBP51 expression in humans has 
been linked to depression (407) and hence the Fischer rat model could be translational to 
humans. Characterising the potential effects of SAFit2 and SAFit1 on Fischer and Lewis rats 
can provide further insight into the involvement of FKBP51 and GR in HPA axis regulation.  
 In chapter 6 the effects of FKBP5 overexpression in the PVT of the thalamus were also 
discussed. Very little is known regarding the role of the thalamus in the regulation of the HPA 
axis activity, and even less is known regarding the involvement of FKBP51 in this regulation. 
The results from the study indicate that increased GR activity in the PVT alters ultradian CORT 
pulsatility resulting in enhanced pulse frequency, and reduced stress-induced CORT. These 
findings will provide new insight to further research into the involvement of the thalamus in 
HPA axis regulation.  
 
7.8. Limitations of studies 
The main limitation of the studies presented in this thesis was the availability of SAFit2 
and SAFit1, which were not commercially produced (when these experiments were 
conducted) and had to be synthesised on request. It would have been useful to perform 
similar studies with GR agonists, as although this would not elucidate the effect of FKBP51, it 
would give further insight in HPA axis regulation by GR. For example, one could administer GR 
agonists centrally and peripherally, peripherally only, or intra-cranially, and then perform ABS 
studies to evaluate the effects on basal and stress-induced CORT. Furthermore, it would have 




effects of these, although due to limited availability of the SAFit2, and time limitations this 
was not possible.  
The translocation experiment had limitations in that the technique used was not 
highly sensitive in quantifying the expression of GR. The experiment was also limited to one 
time point of tissue harvesting following the CORT injection, and this was based on previous 
studies (359). The CORT concentrations following the CORT injection were lower in this 
experiment than previously published (359) and perhaps even though the pre-administration 
of SAFit2 or SAFit1 could alter the dynamic of the GR translocation the effects would have 
been evident had a higher CORT dose been given, or if more time points had been 
investigated. It should also be noted that it appears some of the adrenalectomies were only 
partial as CORT concentrations were detected in the vehicle-saline group.  Chromatin 
immunoprecipitation can be used for investigating DNA binding activity (380) and would have 
been a suitable option for the translocation study.  
 The surgical techniques were well-established within the group however patency of 
the cannulas is a common issue in cannulated animals and could perhaps be further improved. 
This issue was also further complicated by the limited availability of the SAFit2 and SAFit1 as 
I could not cannulate ‘spare’ rats to use in case some lost the cannula patency. This was 
especially apparent during the sub-chronic studies where large amounts of the SAFit 
compounds were required. Because of the quantities required, spare rats could not be treated 
and used if any of the SAFit-treated rats lost the cannula patency.  
 The Fischer and Lewis study had limitations in that due to the animal numbers being 
low and it was not possible to perform statistical analysis on the PULSAR data. This was mainly 
due to difficulties with the cannulation surgery and the ABS. As the Fischer rats were smaller 
in size than Sprague-Dawley rats this made successful cannulation more difficult due to 
smaller jugular veins.  
 The overexpression study had limitations because it was the first time this AAV-
mediated overexpression had been done in rats hence we had no reference point for volume, 
time for full expression, etc. In addition, this study was particularly complicated as the rats 




unsuccessful in targeting the PVN, this led to a discovery of a strong involvement of FKBP51-
mediated thalamic input to regulate HPA axis activity.  
As previously mentioned, the stress-induced gene expression data from the ABS 
experiments have limitations in that only one time-point was investigated, as all rats were 
killed 60 to 90 minutes following the noise stress.  Although, previous studies have shown 
that some of the genes investigated are indeed significantly induced at 60 minutes post-stress 
(13, 355).  
Rats that were implanted with jugular vein cannula were injected with pentobarbital 
before rapid decapitation (less than 30 seconds). In some experiments where rats were not 
cannulated, rats were killed quickly by isoflurane exposure (less than 15 seconds) before rapid 
decapitation. Work from our group and others has shown that this procedure does not induce 
an increase in ACTH or CORT (132, 355).  
 
7.9. Clinical implications and perspective 
A vast number of studies have focused on elucidating the molecular mechanisms 
underlying the dysregulation of HPA axis activity observed in various psychiatric disorders 
such as major depression, bipolar disorder, schizophrenia, and anxiety disorders (71, 137). It 
is suggested that hyperactivity of the HPA axis in these disorders results from a failure to 
terminate the cortisol response to stress, thus creating stress-hypersensitivity. This 
mechanism is thought to be as a result of a dysfunctional GR activity (71), rendering an 
inadequate GC negative feedback response (137).   
 Recent interest in the GR chaperone, FKBP51, was sparked when Binder and 
colleagues published data suggesting a strong link between polymorphism in the gene 
encoding FKBP51, and the response to antidepressants (334). This led to an intriguing 
hypothesis that FKBP51 is implicated in the dysregulation of GC negative feedback seen in 
patients with psychiatric disorders (137). Most studies hypothesise that depressed patients 
have increased FKBP51 levels (339, 407, 449) which causes GR resistance (450).   
 The results from the experiments in this thesis have shown that central and peripheral 




in decreased basal CORT concentrations in both sexes, and decreased stress-induced CORT in 
male rats. Administration of the peripheral-only FKBP51-inhibitor, SAFit1, for five consecutive 
days resulted in a change in ultradian CORT pulsatility. This is consistent with the hypothesis 
of a pituitary-adrenal gland feed-forward/feedback pulse generator. This work has taken 
important steps in further unravelling the complexity of HPA axis regulation and will be useful 
for future studies exploring the use of FKBP51-inhibitors as a treatment for psychiatric 
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